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Abstract
Dystroglycan is a heterodimeric transmembrane glycoprotein protein of a  and 
(3 subunits that links the exti’acellular matrix to the cytoskeleton. Recent data tend to 
suggest that the role of dystroglycan in non-muscle cells is for cell adhesion, and 
cytoskeleton reorganisation signalling. To study the relationship between dysti'oglycan 
signalling and ERK signalling in focal adhesions, an YFP-ERK construct was expressed 
in REF52 cells. YFP-ERK was expressed with ERK activity and formed adhesion-like 
structures in the REF52 cells, however, no ERK activity was detected in the adhesion­
like structures in the REF52 cells. To determine the function of dystroglycan for 
adhesion or cytoskeleton organisation in non-muscle cells, a GFP-tagged full-length 
dysti'oglycan (a[3DG-GFP) or its deletion mutants was expressed in REF52 cells. 
Expression of a(3DG-GFP markedly altered cell phenotype on a laminin or fibronectin 
substrate, resulting in the induction of actin-rich filopodia. The p-dystroglycan 
cytoplasmic domain is determined as the mediator for the dystroglycan-dependent 
filopodia formation mediated partly by integrin signalling. The dysti'oglycan deletion 
mutants lacking a-dystroglycan failed to target to the plasma membrane. Expression of 
an alkaline phosphate-tagged p-dystroglycan cytoplasmic domain construct (AP-cP), 
which targeted the p-dystroglycan cytoplasmic domain to the membrane without the a- 
dystroglycan, was sufficient to induce the filopodia phenotype, indicating that with the 
proper membrane localisation, P-dystroglycan can regulate filopodia formation 
independently of a-dystioglycan. However, a-dystroglycan might be necessaiy for P- 
dystroglycan to target to the plasma membrane. These distinct morphologies strongly 
implied that P-dystroglycan mediates Cdc42 regulated cytoskeleton reorganisation. By 
cotiansfecting dominant negative Cdc42 (Cdc42N17) or constitutively activated Cdc42 
(V12Cdc42) constructs with aPDG-GFP or the mutants, Cdc42 was determined to be a 
mediator for dystroglycan-dependent filopodia formation. Therefore a signalling cycle 
of dystroglycan-Cdc42-PAK-ezrin-dysti'oglycan is identified. With this signalling cycle, 
dystroglycan plays a role in inducing actin filopodia formation and, at the same time, 
might also inhibit focal adhesion and stress fibre formation.
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Chapter 1 
Introduction
1.1 Background
Dystroglycan is a transmembrane heterodimer complex of a  and (3 subunits that links 
the extracellulai' matrix to the cytoskeleton and was originally isolated from skeletal 
muscle as a component of the dystrophin-glycoprotein complex (DGC) (Ibraghimov- 
Beskrovnaya, et a l, 1992). DGC has been determined to be disrupted or missing as a 
cause of Duchenne muscular dystrophy (DMD) (Aiahata et al, 1988). The DGC in 
skeletal muscle is expressed throughout the sarcolemma. The membrane presented DGC 
has been shown to interact with the extracellulai' matrix (ECM) and associate with 
dystrophin, which directly associates with the actin cytoskeleton. In addition to 
dystroglycan, the DGC comprises saicoglycans, saicospan, syntrophins, caveolin, and 
dystrobrevin. Thus, by interacting with ECM proteins and dystrophin, the DGC forms a 
physical linkage between ECM and cytoskeleton (Ervasti and Campbell, 1991).
Dystroglycan is central to the DGC and has been shown to directly interact with ECM 
proteins and dystrophin. In muscle cells, dystroglycan binds to the extracellular proteins 
laminin 1 and laminin2 and anchors to dystrophin, which associates with actin in the 
cytoskeleton, forming a physical link between the cytoskeleton and extracellular matrix 
of the membrane (Fig 1,1, A) (Ervasti and Campbell, 1991; Ervasti and Campbell,
1993). The dramatic reduction of dystroglycan in patients affected by DMD and in 
dystrophin deficient mdx mice (Sicinski et al, 1989) supports the hypothesis that the 
dysti’ophin-dystroglycan complex may play a structural role in maintaining the stability 
of the sai'colemmal membrane (Ervasti, et al, 1990; Menke and Jockush, 1991; Ervasti 
and Campbell, 1993).
Beyond muscle cells, dystroglycan has been shown to be expressed in many non-muscle 
tissues and cell types, indicating that functions of dystroglycan are not restricted to 
muscle tissues (Fig 1.1 B). However, instead of full-length dystrophin, alternative 
products from the dystrophin locus containing the dystroglycan interaction domain are 
found to be expressed in non-muscle cells and associate with dystroglycan (James et al, 
1996). These include products of the same gene by using alternative promoters and
related proteins encoded by different genes (reviewed in Sadoulate-Puccio and Kunkel, 
1996). Utrophin is the most closely related to dystrophin, and associates with a complex 
similar to that in DGC in most of the non-muscle cells (James, et al., 1996), and also at 
neuromuscular junctions (NMJ) in muscle (Mastumura et a l, 1992). Loss-of-function 
studies have clearly shown that dystroglycan is required for branching epithelial 
moiphogenesis (Durbeej et al, 1995), neuronal development (Tian et a l, 1996; 
Mastumura et a l, 1997), embryonic basement membrane (Reichert’s membrane) 
formation (Williamson et al, 1997) and neuromuscular junction formation (Gee et al,
1994). Interestingly, these cellular or developmental events are all adhesion-mediated. 
This suggests that in non-muscle tissues, dystroglycan performs a function in receiving 
adhesion-mediated signals, and regulating cell proliferation and survival signalling.
Dystroglycan has been shown to colocalise with focal adhesion structural proteins, 
indicating dystroglycan might be involved in the assembly of focal adhesions (Belkin 
and Smalheiser, 1996). The transmembrane portion of dystroglycan has been shown to 
associate with dystrophin homologues linking to the actin cytoskeleton, and has been 
shown to associate with the SH3 domain of the Grb2 adaptor protein (Jung et al, 1995). 
This implies that both actin cytoskeleton organisation and activation of Grb2-mediated 
signalling might be in response to the expression of dystroglycan. Additionally, it has 
been shown that a tyrosine residue in the PPPY motif in the C-terminal tail of (3- 
dystroglycan is phosphorylated in an adhesion-dependent manner. This tyrosine 
phosphorylation in the PPPY motif can regulate the binding affinity of dystroglycan to 
dystrophin/utrophin (James et al, 2000) or the recruitment of some SH2 domain 
containing proteins, including Src, Fyn, Csk, Nek and SCH (Sotgia et al, 2001), which 
are involved in integrin dependent focal adhesion signalling. Thus, dystroglycan seems 
to be a transmembrane laminin receptor that plays a role in regulating focal adhesion 
signalling and cytoskeleton reorganisation. The adhesion role of a-dystroglycan binding 
to the ligands in non-muscle cells has been described (reviewed in Durbeej et al, 1995) 
whereas the signalling role of p-dystroglycan has remained unclear. This study is to 
investigate the function of dystroglycan, especially P-dystroglycan, in mediating 
adhesion signalling and regulating actin cytoskeleton organisation in non-muscle cells.
Figure 1.1 Schematic representation of the arrangement of dystrophin glvcoprotein 
complex (DGC) of muscle cells and dystroglycan of non-muscle cells
In skeletal muscle (A), the dystrophin-glycoprotein complex (DGC), in addition to 
dystrophin, contains the dystroglyeans a  and P, the sarcoglycans, sarcospan, syntrophin 
and dystrobrevin. Neuronal NO synthase (NOs) is associated with syntrophin. 
Dystrophin in the DGC associates with transmembrane dystroglycan and F-actin 
cytoskeleton via its C-terminal and its N-terminal, respectively. Dystroglycan, which 
interacts with extracellular matrix laminin and agrin (not shown), and associates with 
dystrophin, is considered crucial in maintaining the stability of muscle cells. 
Dystroglycan is expressed in non-muscle cells as well. In non-muscle cells (B), 
dystroglycan interacts with laminin and associates with utrophin or other dystrophin 
isoforms, completing the linkage between extracellular matrix and actin cytoskeleton.
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1.2 Structure of dystroglycan
Dystroglycan contains a  and |3 subunits, a-dysli'oglycan is a highly glycosylated 
peripheral membrane protein and (3-dystroglycan is membrane spanning protein. A 
highly conserved gene encoding a -  and j3- dysti'oglycan has been found in several 
vertebrate species (Henry and Campbell, 1996). The dystroglycan gene, DAGl, 
comprises two exons, which are transcribed into a single inRNA product for a- and 
p-dystroglycan (Ibraghimov-Beski'ovnaya et ai, 1993). a- and p- dysti'oglycan 
encoded by a single mRNA is translated into a single dystroglycan precursor. The 
dystroglycan precursor undergoes proteolytic cleavage at amino acid residue 653 and, 
posttranslational glycosylation to generate mature a- and p- dysti'oglycan subunits 
(Ibraghimov-Beskrovnaya et a l, 1992). Both O-linked and N-linked glycosylation are 
found in dyshoglycan. The mechanism of the proteolytic cleavage of dystroglycan is 
still unclear. However, it has been identified that neither the O-linked nor the N-linked 
glycosylation affects the proteolytic cleavage of dystroglycan (Holt et ai, 2000). The 
primaiy structure of oc/p dystroglycan precursor, and mature a  and p dystroglycan are 
shown in figure 1.2A and B. The a- and p-dystroglycan presented on the plasma 
membrane is shown in figure 1.3.
1.2.1 a-Dystroglycaii
A 28 amino acid signal sequence (SS) is present at the N-terminal of the ot/p 
dystroglycan precursor, allowing the precursor to insert the ER membrane system. The 
sequence of mature a-dysti'oglycan starts from amino acid 29. a-dysti’oglycan contains 
both N-linked and O-linked caibohydrates. The sialylated O-linked oligosacchai'ides of 
a-dystroglycan are concentrated at the region between amino residues 315 and 484 
(Durbeej, et al, 1998). Studies of a-dystroglycan structures using rotaiy shadowed 
electron microscopy suggested a-dysti'oglycan has a dumbbell-like sti’ucture; two 
globular domains connected by a rod-like mucin domain in the central region (Fig 1.2 
C; left).
Figure 1.2 Processing of the dvstroglvcan propeptide
(Adapted from Winder, 2001)
(A) The product of the DAG 1 gene, a/(3-dystroglycan, is synthesized as a single 895 
amino-acid propeptide with signal sequence (SS), mucin-like region, and a 
transmembrane region (TM). Positions of WW domain interaction motifs PPPY are 
shown. The propeptide is glycosylated with both N-linked ( ^  )and O-linked (mucin­
like) oligo-carbohydrate chains, and is post-translationally cleaved by an unknown 
protease at residue 653 (P) to generate mature a- and P-dysti'oglycan (B). (C) Electron 
microscopy (EM) analysis reveals a  -dystroglycan has a dumbbell shape. Carbohydrate 
side chains are shown schematically as circles for O-linked glycosylation, and branches 
for N-Iinked glycosylation and glycosaminoglycan chains; /5-dystroglycan is shown 
inserted in a lipid bilayer with its C-terminus on the intracellular side. Over 50% of the 
mass of mature a  -and /3 -dystroglycan comprises carbohydrate moieties.
oc/p -dystroglycan propeptide
SS
N
B
Mucin-like
72 KDa
1 1  m  c
28 315 484 
a-dystroglycan
653 751 774 895 
P-dystroglycan
i
26KDa
oooocoococoooocooooc
00000
gg&X)30
mature a-dystroglycan 100-200 kDa mature p-dystroglycan 43 kDa
(Adapted from Winder, 2001)
a  -dystroglycan has been identified as a receptor for laminins (Ervasti and Campbell, 
1991; Ervasti and Campbell, 1993). Laminin is an ECM protein which is abundant in 
basal lamina. All laminins aie heterotrimers composed of individual a,p, and y subunits. 
Laminins assemble into trimers by forming a long coiled-coil interaction in the COOH- 
terminal half of the protein, designated as the long arm. There aie currently five laminin 
alpha chains, three beta chains, and three gamma chains that are found in at least 11 
different heterotiimer combinations in vivo (Miner et a l, 1998). The unique carboxy 
terminal laminin globular* (LG) modules at the C-terminal of laminin bind several cell 
surface integrins. a l  and a2 LG modules, which are present in laminin 1 (a lp ly l)  and 
laminiii2 (a2(31yl), have been shown to bind to a-dystroglycan with very high affinity 
(Andac et al, 1999).
The mucin-like region of a-dystroglycan has been identified as being critical for 
dystroglycan binding to LG modules (Yainada et al, 1996a). The binding mechanism 
between a-dystroglycan mucin-like region and LG domain has recently been studied. 
For example, the a-dystroglycan-laminin interaction is known to be calcium-dependent 
and requires 0-mannosyl-GlcNac glycosylation (Chiba et al, 1997) or sialic acid 
residues (Ervasti et al, 1997) on a-dystroglycan. The Ca^ "^  ions in each of the LG 
module structures, and an extensive positively charged surface surrounded by Ca^ "^  ions, 
are proposed as the site of a-dystroglycan interaction. Furthermore, the binding of 
heparin to the positively chai'ged surface of the LG module can efficiently inhibit the 
interaction with a-dystroglycan (Ervasti and Campbell, 1993). Thus, the mechanism of 
a-dystroglycan binding to LG modules may involve the coordination of the missing 
calcium ligand by negatively charged carbohydrate group of a-dystroglycan mucin-like 
domain and positively charged surface of the LG modules (Tisi et a l, 2000).
In addition to laminin 1 and 2, it has been shown that agi'in (Hoch, 1999), perlecan 
(lozzo, 1998) and biglycan (Bowe et al, 2000) are also the ligands of a-dystroglycan. 
Microbes such as arena viruses and M. leprae (Rambukkana et a l, 1998) have been
shown to recognise a-dystroglycan as an infection receptor (Fig 1.3). However, the 
precise biological functions of these binding to a-dystroglycan remains unclear.
The primary sequence of a-dysti'oglycan predicts a moleculai' mass of 72 KDa; 
however, a-dystroglycan is 156KDa in skeletal muscle (Ervasti and Campbell, 1993), 
140KDa in cardiac muscle (James et al., 1997) and 120KDa in brain and peripheral 
nerves (Yamada et al, 1994). Therefore, a-dystroglycan may undergo significant 
posth'anslational modifications in a tissue-specific manner and these specific 
modifications possibly affect functions of dystroglycan. On the cell surface, a- 
dystroglycan is anchored to the extracellular domain of (3-dystroglycan by a non- 
covalent interaction. The association site of a-dystroglycan recognised by (3- 
dystroglycan has recently been mapped to the amino acid sequence 550-585 (Bozzi et 
al, 2001).
1.2.2 p-Dystroglycan
p-Dystroglycan is a 43KDa transmembrane glycoprotein with an N-terminal 
extracellulai* domain, a transmembrane region and a C-terminal cytoplasmic tail (Fig 1.2 
C; right) (Ibraghimov-Beskrovnaya et a l, 1992). The amino acid sequences of p- 
dystroglycan are strikingly similar between different species. In paiticular, there is a 
100% conservation of the carboxy-terminal dystrophin binding sites and a 93% 
conservation of the central Pro-Tlm rich regions (Brancaccio et a l, 1995). The N~ 
terminal extracellular domain of P-dystroglycan is the glycosylated portion of P- 
dystroglycan. The association region for a-dystroglycan on P-dysti'ogiycan has been 
mapped to amino acid sequence 654-750 (Di Stasio et al, 1999).
p-dystroglycan associates with dystrophin or dystrophin homologues fulfilling the 
connection role of linking the exti*acellular matrix to the F-actin cytoskeleton (Fig 1.3). 
The binding site of dystrophin or dystrophin homologues in p-dystioglycan has been 
localized to a proline-rich region at the extreme C-tenrdnus of the cytoplasmic tail. This 
region contains the proline-rich motif (PPxY or PY motif, where P denotes proline.
Figure 1.3 A representation of g- and B-dvstroglvcan and binding partners 
at the cell surface
(Adapted from Winder, 2001)
The extracellular a-dystroglycan (a) and transmembrane P-dystroglycan (P) are shown 
in blue. Agiin, perlecan and laminin isoforms bind to the a-dystroglycan mucin-like 
region via tlieir laminin G domain (LG) modules. Arenaviruses require a-dystroglycan 
to be glycosylated for binding to occur. Biglycan binds unglycosylated regions of the a- 
dystroglycan N-terminus. Mycobacterium leprae binds a-dystroglycan in a laminin- 
dependent manner. Rapsyn associates with membrane-proximal residues in the P- 
dystroglycan cytoplasmic tail, and Grb2 binds via a SH3-dependent interaction to (3- 
dystroglycan C-terminus tail. Dystrophin or utrophin (or isoforms) bind the C-terminal 
12 amino acids of P-dystroglycan via the WW domain motif PPPY; the utrophin and 
dystrophin N-termini binds to F-actin. Caveolin associates with P-dystroglycan also at 
the PPPY motif.
Arena virus
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(Adapted from Winder, 2001)
Y represents tyrosine, and x denotes any amino acid), which is a consensus site for 
binding dystiophin in muscle cells or utrophin in most of the non-muscle cells (Chen et 
al, 1995). Either dystrophin or utrophin interacts with the cytoplasmic domain of p- 
dystroglycan through a cluster of domains in the C-terminal cystine-rich region of 
dystrophin or utrophin. The cystine-rich region of uh'ophin/dystrophin comprises three 
recognized modules, a WW domain, a pair of EF hands and a ZZ domain (Sudol, 1996). 
The WW domain is a protein-protein interaction domain which resembles SH3 (Src 
Homology) domain. The WW domain is necessary, but not sufficient for binding of 
dystrophin/utrophin to P-dystroglycan (Jung et al, 1995; Suzuki et a l, 1994). The EF 
hands and the ZZ domain play a role in increasing the binding strength of WW domain 
to P-dystroglycan (James et a l, 2000).
Two potential PY motifs are present in the cytoplasmic domain of P-dystroglycan. 
However, except for the C-terminal tail PPPY motif, which is the binding motif of 
dystrophin/utrophin WW domain, no interactions with the other PY motif of p- 
dysti'oglycan have been reported. It has been shown that tyrosine phosphorylation at 
Y892 of the C-terminal tail PPPY motif causes significant reduction of the binding 
affinity of P-dystroglycan to WW domain of dystrophin/utrophin (James et al, 2000), 
suggesting the interaction between dystroglycan and dystrophin/utrophin WW domain 
is regulated by tyrosine phosphorylation of the PPPY motif.
An atomic structure of P-dystroglycan C-terminus PPPY motif and dystrophin/utrophin 
N-terminal WW domain has recently been solved (Huang, et a l, 2000) (Fig 1.4). The 
PPPY motif with its adjacent amino acids, KNMTPYRSPPPYVPP, corresponding to 
880-895 of p-dystroglycan is involved in the binding the WW domain of 
dysti'ophin/utrophin. First, the thi'ee proline residues at the PPPY motif, form a single 
turn of a left-handed poly-proline II helix that is recognised by the WW domain. 
Second, the first two proline residues (residue 889 and 890) in the motif insert into a 
concave hydrophobic surface formed by Tyr 3072 and Trp 3038 in the WW domain are 
stacked against Tyr 3072 and Trp 3080 respectively. The tyrosine residue in PPPY 
motif (Y892) is then located in the hydrophobic pocket formed by lie 3074, Gln3079
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Figure 1.4 Structure of the dvstrophin-B-dvstroglvcan complex
(Huang et al, 2000)
(A) Ribbon diagram showing the overall organization of the dystroglycan binding 
region of dystrophin. The WW domain is colored yellow, the first EF-hand domain 
gieen, the second EF-hand domain blue, and additional helices gold. The P- 
dystroglycan peptide (white) extends across the first EF-hand and the WW domain. 
Elements of secondary structure, the N- and C-termini of the protein, and peptide are 
labeled. (B) Moleculai' surface of the dystrophin p-dystroglycan binding region, colored 
as in (A). Peptide residues Pro 889-Tyr 892 constitute the PPxY motif. Those in the 
PPxY motif form a single turn of polyproline II helix. (C) Detailed view of dystrophin- 
P-dystroglycan recognition. The peptide makes six hydiogen bonds (thin red lines) 
directly to the dystrophin-P dystroglycan binding region, and an additional six through 
bridging water molecules (red spheres).
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(Huang et al., 2000)
and His 3076 of dystrophin (or utrophin) WW domain. The hydroxyl group hydrogen of 
Y892 bonds with His 3076. Additionally, Arg 887 of P-dystroglycan C-terminal tail 
forms a hydi'ogen bond with Trp 3083 in WW domain. Interestingly, beyond the WW 
domain, Arg 887 also foims hydrogen bonds with first EF-hand of dystrophin/utrophin, 
also Pro885 and Tyr886 of P-dystroglycan contact Thr3188 in the EF-hand. This 
additional interaction not only stabilises the binding between P-dystroglycan and 
dystrophin/utrophin, but also provides the P-dystroglycan C-terminal tail with a high 
specificity.
This study helps to explain why the EF hand is necessary for the interaction between 
PPPY motif of P-dystroglycan and WW domain of dystrophin/utrophin. Indeed, the 
other proline rich motif of P-dystroglycan cytoplasmic domain, APLPPPEYPNQS, 
coiTCSponding to residues 824-835 does not bind to the WW domain of 
dystrophin/utrophin. The WW domain present in YAP (YES Kinase Associated protein) 
which binds to PPXY motif cannot recognise the PPPY binding motif at the C-terminal 
tail of P-dystroglycan either (Chen and Sudol, 1995). Tyrosine phosphorylation at 
Tyr892 in P-dystroglycan C-terminal tail PPPY motif disrupts the hydrogen bonded 
formation between Y892 of PPPY and His 3076 of WW, and has been shown to result 
in reduced binding affinity to dysti'ophin/utrophin WW domain (Ilsley et ai, 2000; 
James et al., 2000). These phenomena showed that binding of P-dystroglycan C- 
teiTninal tail PPPY motif with dystrophin/utrophin WW domain is a highly specific but 
dynamic interaction that is responsible for regulation of the connection between P- 
dystroglycan and the actin cytoskeleton.
1.3 Functions of dystroglycan in muscle and non-muscle cells
1.3.1 Function of dystroglycan in muscle cells
1.3.1.1 Role o f dystroglycan in muscular dystrophies
In skeletal muscle, dystroglycan with sarcoglyeans, syntrophins, sarcospan, caveolin, 
and dystrobrevin are expressed thioughout the sarcolemma, forming a large membrane
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protein complex associating with dystrophin called the dystrophin-glycoprotein 
complex (DGC) (Ervasti and Campbell, 1991) (Fig 1.1 A). The DGC links to actin 
filaments, which connect to Z-lines of myofibrils, via dystrophin and forms a physical 
linkage between the saicolemma and myofibrils (reviewed in Spence et al., 2002). In 
this linkage, dystroglycan directly associates with dystrophin and acts as a membrane 
receptor for laminin 1 and 2 and plays a central role in connecting the extracellular 
matrix, actin cytoskeleton and myofibrils in skeletal muscle. The studies of 
dystroglycan started from the investigation into Duchenne musculai' dystrophy (DMD) 
and the milder Becker musculai* dystrophy (BMD). DMD is caused by mutations at 
DMD locus leading to a total lack of dystrophin in muscle cells (Hoffman et al, 1988). 
Interestingly, dystroglycan has been found to be greatly reduced in DMD patients as 
well as in dystrophin deficient mdx mice, revealing that dystroglycan plays an important 
role as well as dystrophin in completing the physical linkage between extracellulai* 
matrix and cytoskeleton, thereby maintaining the stability of skeletal muscle (Sicinski et 
al., 1989). The mutations of dystrophin appear to cause the secondary reduction of 
dystroglycan. However, no primary mutations in dystroglycan have been identified in 
any human disease. Additionally, disruption of DAGl gene in mice results in 
embryonic lethality. Therefore, despite the important role of dystroglycan in linking 
extracellular matrix to cytoskeleton in muscle cells, no direct evidence has been shown 
that primary mutations of dystroglycan can lead to muscular dystrophies. Recently, a 
series of studies suggested that a variety of muscular dystrophies are caused by 
disruption of the interaction between a-dystroglycan and laminin (Table 1.1). In 
Fukuyama congenital muscular dystr'ophy (FCMD), Muscle-eye-brain (MEB) disease, 
and Walker-Warburg Syndrome (WWS) patients, dystroglycan has been found 
expressed as a less glycosylated form. Similar abnormal reduction of dystroglycan in 
glycosylation has been found in myodystrophy {myd} mice as well. Defects in laminin 
a2, which is the ligand of a-dystroglycan, has been found in patients with congenital 
muscular dystrophy (CMD). These studies all support the idea that dystroglycan, or the 
interaction between dystroglycan and its extracellular matrix ligands, plays a very
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Table 1.1 Dvstroglvcan and muscular dystrophies
Disease
Primary
affected Dystroglycan Reference
Duchenne muscular 
dystrophy (DMD)
dystrophin reduced Ervasti et al,  1990
Becker muscular 
Dystrophies (BMD)
dystrophin reduced Hoffman er a/., 1988
Congenital muscular 
dystrophy (CMD)
laminin a2 N.D. Helbling et ah, 1995
Limb Girdle muscular a  sarcoglycan reduced
dystrophy_2D (LGMD-2D)
Roberds et ah, 1993
Limb Girdle muscular ô sarcoglycan
dystrophy_2F (LGMD-2F)
reduced Nigro et ah, 1996
Limb Girdle muscular 
dystrophy 21 (LGMD 21)
homology to 
fukutin
reduced Brockington, et ah, 2001
Muscle- eye-brain disease 
(MEB)
homology to 
fukutin
missing Michele et ah, 2002 
Kano et ah, 2002
Fukuyama congenital 
muscular disease (FCMD)
fukutin missing Michele et ah, 2002 
Hayashi et ah,2001
Walker-Warburg syndrome homology to 
(WWS) o-mannosyltransferase
missing Beltran -Valero De Bernabe
et ah, 2002
N.D. Not determined.
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important role in maintaining the stability of muscle cells. Expression levels of 
dystroglycan have been shown to be reduced in several types of Limb girdle muscular 
dystrophies (LGMDs), including LGMD2C, LGMD2D, LGMD2E, LGMD2F, which 
are defective in expression of sarcoglycans. As mentioned above, dystroglycan 
reduction is also a consequence of loss of function of dystrophin; thus, expression or 
processing of dystroglycan seems to be affected by other members of the DGC. Despite 
playing a central role in forming the ECM-cytoskeleton linkage, dystroglycan might be 
necessary but not sufficient for maintaining the stability of muscle cells.
1.3.1.2 Role o f dystroglycan in neuromuscular junctions
The neuromuscular junction (NMJ) is the contact region between motor neurones and 
the sarcolemma that is responsible for transmitting the electrical stimulus for muscle 
contraction. During the development of the NMJ, acetylcholine receptor (AChR) 
clustering at the motor end plate on the sarcolemma has been shown to be triggered by 
proteins released from the axonal terminal of the motor neuron. The protein agrin has 
been found to be crucial for AChR clustering on the motor end plate (reviewed in 
Burden, 1998). In 1994, agrin was found to be a binding ligand of a-dystroglycan, 
implying that dystroglycan might be the agrin receptor involved in the formation of 
NMJ (Gee et al., 1994). However, subsequent studies revealed that dystroglycan binds 
to inactive muscle agrin isofonns more tightly than to active neuronal agrin isoforms 
(Sugiyama et al, 1994; Campanelli et al, 1994). Additionally, the dystroglycan binding 
domain of agiin is physically separable from the part that induces the AChRs clusters in 
cultured myotubes (Campanelli et al, 1994). Moreover, utrophin knockout mdx mice, 
which also have reduced levels of dystroglycan, still show normal AChR clustering 
during NMJ formation (Deconick, et a l, 1997; Grady et al, 1997). The finding that 
muscle-specific kinase (MuSK) is a target for agrin-mediated signalling diminished the 
role of dystroglycan in clustering AChRs (reviewed in Ruegg and Bixby, 1997). MuSK 
is a receptor tyrosine kinase (RTK) that appears to trigger the agrin-mediated AChR 
clustering (reviewed in Ruegg and Bixby, 1997). Tyrosine phosphorylation of MuSK 
has been shown to be triggered by agrin, but agrin itself is not a ligand that directly 
binds to MuSK (Glass et al, 1996). The interaction between agrin and MuSK is still
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unknown, but it is now clear that binding of agrin to a-dystroglycan is not necessaiy for 
the agrin-mediated aggregation of AChRs. Rapsyn has been identified as an 
intracellular membrane peripheral protein that directly binds to MuSK and is necessary 
for agrin-mediated AChRs clustering (Apel et al, 1997). Interestingly, studies in 
Torpedo californica have shown that rapsyn binds directly to the p-dystroglycan 
juxtamembrane portion (Cartaud et a l, 1998) (Fig 1.3). The physiological role of 
dystroglycan in synapse formation is now still unclear, but it is considered that 
dystroglycan may function more as a structural, rather than signalling component of 
postsynaptic apparatus assembly (reviewed in Durbeej et a l, 1998).
1.3.2 Functions o f dystroglycan in nonmuscle cells
In addition to muscle cells, dystroglycan is also found expressed in many tissues and 
cell types, suggesting that dystroglycan function is not restricted to muscle cells, a- 
dystroglycan in non-muscle cells has been shown to interact with extracellular laminin 
as it does in muscle cells (Ervasti and Campbell, 1993). However, instead of full-length 
dystrophin, various dystrophin isoforms have been identified as the binding proteins 
linking dystroglycan to the actin cytoskeleton, Utrophin, which is the dystrophin 
homologue most related to dystrophin, has been also been shown to be expressed in 
most non-muscle cells where it associates with dystroglycan (James et al., 1996).
1.3.2.1 Role o f  dystroglycan in the central nervous system
In the central nervous system (CNS), dystroglycan is expressed in the brain in many 
different cell types (reviewed in Durbeej, et a l, 1998). For example, in the cerebellum, 
dystroglycan is expressed in Purkinje cells and binds to the laminin a2 chain at the 
glial-vascular* interface, suggesting a role for dystroglycan in maintaining the blood- 
brain barrier (Tian et al., 1996). Histochemical staining showed that dystroglycan in the 
CNS colocalises with utrophin or Dp71 (Schofield et al., 1995; Gorecki, 1995). 
Dystroglycan is also present in the peripheral nervous system (PNS) in Schwann cells. 
It has been shown that a-dystroglycan in PNS is a receptor for both laminirr a2 chain 
and agrin, which are expressed in the surrounding matrix of Schwann cells (Yamada et
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al, 1996b). In the dy mouse that shows a deficiency in laminin a2 chain expression, 
there are myelination defects, implicating dystroglycan in myelinogenesis (Mastumura 
et al, 1997). Both utrophin and Dpi 16 were found to associate with dystroglycan in 
Schwann cells (Love, et al, 1989; Yamada et a l, 1994). Recently, a third member of 
the dystrophin family, dystrophin-related protein 2 (DRP2) has been identified to 
associate with dystroglycan and L-peraxin, which is a PDZ domain containing protein, 
forming a protein complex specific to Schwann cells (Dixon et a l, 1997; Sherman et 
al, 2001). In the absence of peraxin, DRP2 is mislocalised. Disruption of DRP2- 
dystroglycan complex led to hypermyelination and destabilisation of Schwann cells in 
peraxin knockout mice (Sherman et al, 2001). Thus, the dystroglycan-DRP2 complex, 
which associates with extracellular laminin and intracellular peraxin might play a role in 
the termination stage of Schwann cells myelinogenesis (Sherman et a l, 2001).
1.3,2.2 Role o f  dystroglycan in morphogenesis
It has been revealed that dystroglycan is abundant at the basal side of most epithelial 
cells facing the basement membrane in both embryonic and mature tissues (Durbeej et 
al, 1995; reviewed in Durbeej et al, 1998b). In addition, there is dystroglycan 
expression at sites of cell-cell contacts both in vitro and in vivo (Belkin et al, 1996). 
The intracellular bindmg partners of (3-dystroglycan in epithelial cells may include 
utrophin, Dpi 17 and Dp 140 (Durbeej et al, 1997). Antibody perturbation experiments 
have shown that dystroglycan might be required for kidney epithelial morphogenesis 
(Durbeej et a l, 1995). Likewise, antibody perturbation experiments suggest a role for 
dystroglycan in salivary gland morphogenesis (Durbeej, et a l, 1998a). Additionally, 
dystroglycan has been shown to bind to E3 fragment, containing LG domain, of laminin 
1 (Brancaccio et al, 1995), which also has been implicated in branching epithelial 
morphogenesis and basement membrane formation of kidney as well as salivary gland 
(Sorokin et al, 1992; Kadoya et al, 1995). Moreover, the role of dystroglycan in the 
formation of NMJ in muscle development has been described (1.3.1.2). Thus, 
dystroglycan appears to play an important role in the morphogenesis both in epithelial 
cells and muscle tissues.
17
L3.2.3 Early embryonic tissues
The disruption of the dystroglycan gene (DAGl) in mice led to embryonic lethality at 
around day 6.5; the mutant failed to progress beyond the early egg cylinder stage. This 
lethality is due to failure of the formation of Reichert’s membrane, which is an early 
basement membrane produce by extra-embryonic tissues (Williamson et al, 1997). 
Detailed analysis of the embryoid bodies isolated from dystroglycan-deficient animals 
has shown that components of basement membrane, including laminin, perlecan, and 
collagen type IV cannot bind to the surface of dystroglycan-deficient cells (Willamson 
et al, 1997; Henry and Campbell, 1998). These results strongly suggested that 
dystroglycan is necessary for nucleating the assembly of a primary laminin matrix, 
which then serves as a scaffold for the assembly of the remaining components of the 
extracellular matrix. In accordance with this, muscular dystrophies might also be a 
consequence of a failure to assemble the muscle basal lamina properly (Meier and 
Ruegg, 2000).
1.3.2.4 Dystroglycan and adhesion
The evidence that dystroglycan is involved in morphogenesis, myelinogenesis and 
embryogenesis all suggested a role for dystroglycan in adhesion in non-muscle tissues. 
The role of dystroglycan in adhesion became clearer when dystroglycan was identified 
as playing an important role in assembling the extracellular matrix during development. 
The central role of dystroglycan as a linkage between the extracellular matrix and the 
cytoskeleton clearly defines dysti'oglycan as an adhesion molecule. Furthermore, it was 
also shown that utrophin associates with dystroglycan at the cell membrane where it is 
localized to cell-cell (Belkin and Bunidge, 1995a; Belkin and Bunidge, 1995b) and 
cell-matrix adhesion sti'uctures (focal adhesions) (Belkin and Smallheriser, 1996; James 
et a l, 1996). Hence, despite the mechanism of adhesion mediated by dystroglycan 
remaining uncleai*, dystroglycan now is widely considered an adhesion molecule in non­
muscle cells.
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1.4 Signalling role of dystroglycan
In studies of dystroglycan in non-muscle cells, a great deal of emphasis was placed on 
a-dystroglycan and its role in development (reviewed in Durbeej, et al, 1998a). The 
fact that dysti'oglycan interacts with laminin via its carbohydrate moiety has raised the 
possibility that “dystroglycan-activated" signalling could participate in the adhesion 
signalling in non-muscle cells. A signalling role for the DGC has been described in 
muscle cells. Firstly, neuronal nitiic oxide synthase (nNOS) has been identified to 
associate with DGC via a-dystrobrevin. Dystrobrevin associates with dystrophin and 
syntrophins. In DGC, this association affected the recruitment of iiNOS to the 
saicolemma via syntrophin (Grozdanovic et al, 1996), implying that DGC members 
plays a role in regulating nNOS signalling pathways. Secondly, as mentioned above, 
dystroglycan in skeletal muscle could be necessary for the AChR clustering signalling 
in development of NMJ.
More direct evidence of dystroglycan mediating signalling has been shown in the 
studies of p-dystroglycan. The 12kDa C-terminal cytoplasmic domain of p- 
dystroglycan contains more than 20% proline residues, containing four potential SH3 
binding motifs (PxxP) and two WW domain binding motifs (xPPxY), giving it the 
potential to be the signal transduction region of dystroglycan. P-dystroglycan has been 
shown to directly interact with Grb2, an adapter protein involved in signal transduction 
and cytoskeletal organization (Jung et a l, 1995). Grb2 contains SH2 and SH3 domains 
which can interact with proteins containing phosphotyrosine or proline-rich domains. 
The same study also showed that Grb2 interacts with P-dystroglycan via its SH3 domain 
(Fig 1.3). Fractionation of the extracts from bovine brain synaptosomes using a laminin- 
affinity column revealed that in addition to a/p dystroglycan and Grb2, focal adhesion 
kinase (FAK) was also detected in the laminin binding complex. This study showed that 
FAK has no direct association with P-dystroglycan but was co-immunoprecipitated with 
Grb2, suggesting that the adaptor protein Grb2 may mediate FAK-P-dystroglycan 
interaction (Cavaldesi et al, 1999). This finding raised the exciting possibility that P-
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dystroglycan might be able to regulate signalling molecules such as FAK thiough the 
Grb2 adaptor. However, to date, no signalling pathway mediated by p-dystroglycan- 
Grb2-FAK has been reported.
Despite the functions of dystroglycan in non-muscle cells remaining unclear, adhesion- 
dependent dysti'oglycan tyrosine phosphorylation has been demonstrated (James et al, 
2000, Ilsley et al, 2001). The phosphorylation site was determined as Y892 in the P- 
dystroglycan WW domain binding motif, PPPY. In HeLa cells, the tyrosine 
phosphorylation at Y892 of P-dysti'oglycan triggered by adhesion led to the reduction in 
binding affinity of P-dystroglycan to dystrophin/utrophin WW domain, suggesting that 
the interaction between dystroglycan and utrophin/dystrophin WW domain could be 
regulated by adhesion-dependent tyrosine phosphorylation of the p-dystroglycan PPPY 
motif (James et a l, 2000). Characterisation of p-dystroglycan-Grb2 interaction in vitro 
has determined that the 20 amino acid sequence, containing the PPPY motif, at the C- 
terminal tail of P-dystroglycan is responsible for its ability to bind to the N-terminal 
SH3 domain of Grb2. Interestingly, the interaction between dystroglycan PPPY motif 
and Grb2 N-terminal SH3 domain was significantly inhibited in the presence of 
dystrophin, indicating that both dystrophin/utrophin WW domain and Grb2 SH3 domain 
appealed to associate with P-dystroglycan PPPY motif. This implies that a competitive 
regulation of utrophin/dystrophin WW domain or Grb2 SH3 domain binding to P- 
dystroglycan might take place (Russo et a l, 2000).
In addition to WW domain of utrophin/dystrophin and the N-terminal SH3 domain of 
Grb2, caveolin has also been identified to interact with p-dystroglycan. In skeletal 
muscle, caveolin-3 is localized to the sarcolemma, coinciding with dystrophin (McNally 
et a l, 1998). Caveolins aie believed to play a role in the formation of the caveolae. 
Caveolins are small membrane invaginations on the surface of cells that paiticipate in 
membrane trafficking (including endocytosis and pinocytosis). They act as scaffolding 
proteins organizing and concenti'ating caveolin-interacting proteins and lipids in 
caveolae microdomains (reviewed in Schlegel and Lis anti, 2001). The number and size 
of caveolae are abnormal in DMD-patients (McNally et al, 1998). In muscle cells.
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caveolin-3 has been shown to directly interact with nNOS, and binding results in the 
loss of NOS activity (reviewed in Garcia-Cardena et ah, 1997). The association between 
p-dystroglycan and caveolin was mapped in the WW-like domain on caveolin and the 
PPPY motif on P-dystroglycan (Sotgia et al, 2000). While tyrosine phosphorylation at 
Y892 on p-dystroglycan inhibits the binding affinity of the PPPY motif to 
dystrophin/utrophin WW domain, it does not affect the interaction between the PPPY 
and caveolin (Sotgia et al, 2000). However, the binding of dystrophin to P- 
dystioglycan appeai'ed to be interrupted in the presence of caveolin, revealing that 
caveolin also competes for the PPPY motif binding site on p-dystroglycan with WW 
domain (Sotgia et al, 2000). In addition to being triggered by adhesion, the 
phosphorylation of p-dystroglycan at Y892 has been shown to be elevated by a v-Src 
transformed state (Sotgia et al, 2001). Surprisingly, some SH2 containing proteins 
including Fyn, Csk, Nek, SHC, and v-Src itself appeared to be recruited to interact with 
PPPY containing region on P-dystroglycan in response to the tyrosine phosphorylation 
at Y892 (Sotgia et al, 2001). The function of this regulation and recruitment is unclear, 
but these results strongly suggest that P-dystioglycan plays a role as an adhesion 
signalling molecule.
Altogether, the role of dystroglycan in myelinogenesis, morphogenesis and 
embryogenesis, even in maintaining muscle stability could be explained by its role as an 
adhesion molecule. WW domain, caveolin and Grb2 SH3 domain appeared to compete 
for the PPPY binding motif in P-dystroglycan. The adhesion-dependent tyrosine 
phosphorylation at Y892 in PPPY motif of P-dystroglycan seems to play an important 
role in regulating the binding of P-dystroglycan to various signalling molecules. 
Therefore, dystroglycan is doubtless a signalling molecule, a-dystroglycan is 
responsible for recognition and assembly of an extracellular matrix network, while P- 
dysti'oglycan, which provides an anchor for a-dystroglycan, might act as an important 
adhesion signalling mediator. Studies conducted in this thesis aie to investigate the role 
of dystroglycan in cell adhesion signalling.
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1.5 Focal adhesion signalling
1.5.1 Focal adhesions
Evidence has shown that P-dystroglycan might play a role in regulating cell-matrix 
adhesion signalling. Adhesion between a cell and its surrounding extracellular* matrix 
(ECM) controls complex biological processes such as development, wound healing, 
immune response, and tissue function. Adhesion ti’iggers signals regulating cell gi'owth 
and differentiation. Cell attachment to the ECM is primarily mediated by integi*ins, a 
widely expressed family of cell surface adhesion receptors (Hynes, 1992). In addition to 
anchoring cells, integrins transmit signals that direct cell migration, proliferation, and 
differentiation (Ruoslahti and Reed, 1994). After binding to ECM proteins, integrins 
cluster together to form focal adhesions - complexes of intracellular signalling and 
structural proteins. These specialized sites of attachment provide not only a structural 
link between the internal actin cytoskeleton and the ECM but also function as a locus of 
signal transduction activity that control cellular response (reviewed in Jockusch et al, 
1995).
Numerous proteins have been identified in focal adhesions, some of which play a 
predominantly structural role (e.g. a-actinin, talin, vinculin, paxillin) while others are 
involved in signal transduction pathways (e.g. FAK, Src). At the cytoplasmic face of 
focal adhesion sites, bundles of actin filaments (stress fibres; see below) are anchored to 
the cytoplasmic domain of integrins through the multi-molecular complex of junctional 
proteins. Focal adhesion complexes are highly dynamic structures, continuously 
assembling and disassembling in the processes of cells. For example, during cell 
migration, new focal adhesion complexes, containing newly recruited focal adhesion 
structural and signalling proteins, assemble rapidly at the leading edge, and, at the same 
time, disassemble at the retracting tail of the cells (reviewed in Buiridge and 
Chi'zanowska-Wodnicka, 1996). The signalling events that occur with integrin-mediated 
focal adhesion include the phosphorylation of FAK, Src-mediated tyrosine 
phosphorylation of adhesion proteins and stimulation of the mitogen activated protein 
kinase (MAP kinase) cascade.
2 2
Integrins are the important cell-matrix receptors that regulate the assembly of focal 
adhesion complex. Integiins aie a family of heterodimeric transmembrane cell adhesion 
receptors which are of crucial importance in interacting with extracellular matrix 
proteins and promoting a variety of cellular functions such as cell growth, migration, 
proliferation and cytoskeleton reorganization (reviewed in Giancotti and Ruoslahti, 
1999). Each integrin contains a  and P subunits; each subunit has a large extracellular 
domain, a single trans-membrane region and a short cytoplasmic domain (except for P4 
subunit). The differential association of more than 18 a-integrins and 8 p-integiins 
subunits give rise to more than 20 different ot/P-integrin heterodimers (Hynes, 1992; 
Ruoslahti, 1991). Integrin dimers are expressed in specific tissues or cell types and have 
different specificity for extracellular ligands such as laminin or fibronectin. The binding 
affinity of integrins with their ligands can be regulated either by the extracellular factors 
or by intracellular processes so called inside-out signalling (Hughes et al, 1997).
Integrins have been implicated in two major types of activities: adhesion of cells to their 
substrate and transmission of signals from the external environment to the cell interior. 
The aP pairings specify the ligand binding abilities for integrin heterodimers. Large 
ECM proteins such as collagen, laminin, vitronectin, and fibronectin can be recognised 
by integrins. However, some short peptide sequences within the larger proteins, for 
example, RGD (Ai*g-Gly-Asp) sequence found in fibronectin and vitronectin, were 
found to be sufficient for recognition by integrins (Rouslahti, 1996). The cytoplasmic 
tails of integrins are generally short and always devoid of enzymatic features. Hence, 
integiins transduce signals by associating with adapter proteins that connect the integrin 
to the cytoskeleton, such as cytoplasmic kinase, and transmembrane growth factor 
receptors. Integiin signalling and assembly of the cytoskeleton aie then intimately 
linked. As integrins bind to the ECM, they become clustered in the plane of the cell 
membrane and associate with a cytoskeletal and signalling complex that promotes the 
assembly of actin filaments. The reorganization of actin filaments into larger sti’ess 
fibres in turn causes more integiin clustering, thus enhancing the matrix binding and 
organization by integiins in a positive feedback system. As a result, ECM proteins, 
integiins, and cytoskeletal proteins assemble into aggregates on each side of the
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membrane (reviewed in Giancotti and Ruoslahti, 1999). These well-developed 
aggregates can be detected by immunofluorescence microscopy and are known as focal 
adhesions. In this manner, integrins, like dystroglycan, serve as integrators of the ECM 
and cytoskeleton.
1.5.2 Integrin mediated focal adhesion signalling pathways
In integrin-dependent focal adhesion complex activation, integrins activate valions 
protein tyrosine kinases, including focal adhesion kinase (FAK), Src family kinases, 
Abl, and a serine-threonine kinase, integrin-linked kinase (ILK) (Wary et a l, 1996; 
Lawis et a l, 1996). Adhesion processes of cells also appeal* to activate the ERKl/2 
cascade (section 3.1.1), which regulates the activation of transcription factors and 
promote the expression of molecules for cell proliferation and cell growth (Assoian, 
1997; Renshaw et al, 1997; Schwartz, 1997). Integrin engagement to ECM along with 
focal adhesion assembly is able to activate the ERKl/2 cascade that is involved in the 
regulation of cell survival (reviewed in Howe et al, 1998). Two sets of signalling 
pathways induced by integiin engagement have been shown to be involved in the 
assembly of focal adhesion complexes in cells, the FAK pathway and the Fyn/Shc 
pathway (Juliano, 2002).
1,5.2.1 The FAK pathway
The integrin-dependent pathways involving FAK and Src-family kinases have been 
studied in some detail. The FAK pathway is activated by most integrins (Fig 1.5 A). 
The activation of FAK is not well understood, but it is coupled to the assembly or 
disassembly of focal adhesions. FAK may be recruited to nascent focal adhesions 
because it interacts, either directly or thiough the cytoskeletal proteins talin and paxillin, 
with the cytoplasmic tail of integrin P subunits (Miyanoto, et al, 1995). Upon 
activation, FAK autophosphorylates Tyi*397 and is recruited to focal adhesions, thereby 
creates a binding site for the Src homology 2 (SH2) domain of Src or Fyn (Schaller et 
al, 1994; Schlaepfer, et al., 1994). The Src kinase then phosphorylates a number of 
focal adhesion components. The major tar gets include paxillin, tensin, and Cas, a
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Figure 1.5 Direct cell growth signaling bv integrins-mediated focal adhesions
Two models are shown depicting how integrins may directly stimulate the ERK 
cascade. (A) Integrin engagement causes recruitment and activation of FAK and its 
autophosphorylation. This creates a binding site for the Src tyrosine kinase, which then 
further phosphorylates FAK. This allows the Grb2 SOS complex to bind, thus 
triggering Ras activation and subsequent activation of Raf, MEK, and ERK. A second 
pathway leads from p i30 Cas and Crk to c-Jun kinase activation. (B) Certain integrins 
(but not all) associate with Fyn and She via caveolin. The phosphorylation of She by the 
Fyn tyrosine kinase allows recruitment of Grb2-S0S and activation of the cascade.
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docking protein that recruits the adapter protein Crk, which can stimulate the JNK 
pathway (Vuori, et al., 1996; Schlaepfer, et al., 1997). Active Src phosphorylates FAK 
at Tyr925, creating a binding site for the complex of the adapter Grb2 and Ras 
guanosine-triphosphate exchange factor Sos (Son of sevenless) (Schlaepfer, et al., 
1994). Paxillin is a multi-domain adaptor protein that shown to associate with SH3 
domain of Src (Turner, 2000). Activation of FAK leads to the recruitment and activation 
of Src in focal adhesions (reviewed in Schaller, 2001) that subsequently interacts with 
paxillin and activates Grb2-Sos. Hence, by the activation of FAK in response to integiin 
engagement, paxillin, Src, Grb2-Sos aie activated and recruited to focal adhesions. 
Association of active Src with paxillin and FAK then activates Grb2-Sos followed by 
exchange of Ras-GDP to Ras-GTP, which subsequently activates the downstream ERK 
cascade (reviewed in Howe et al., 1998). Whereas FAK is phosphorylated on tyrosine 
residues upon assembly of focal adhesions, it becomes phosphorylated on serine 
residues and disassociates from Src and Gas during mitosis (via activation of JNK) 
(Yamakita et al., 1999). These events may loosen cell-substrate contacts and allow cells 
to divide and move apart.
1.5.2.2 The Fyn/Shc pathway
In addition to activating FAK, some P 1 and oty integrins also activate the tyrosine kinase 
Fyn and, through it, the adapter protein She (Figl.5 B) (Wary et a l, 1996). In this 
pathway, caveolin-1 appeal's to function as a membrane adapter, which couples the 
integrin a  subunit to Fyn. This function of caveolin-1 is consistent with its ability to 
bind cholesterol and glycosphingolipids and organize specialized plasma membrane 
“rafts,” which are enriched in the Src-family kinases such as Fyn, Yes, and Lck 
(reviewed in Harder and Simons, 1997). Upon integrin binding to ECM, Fyn becomes 
activated, and its SH3 domain interacts with a proline-rich site in She. She is then 
phosphorylated by Fyn at Tyr317 and combines with the Grb2-SOS complex (Wary et 
al, 1996), thereby stimulating the ERK cascade. Although most integiins interact with 
caveolin-1 and Fyn, only a subset of integrins can activate Fyn and thereby recruit She 
(Waiy et al, 1998). Yes and Lck are known to be enriched in rafts and may mediate the 
activation of She when Fyn is not expressed (Wei, et al, 1999).
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It is likely that both FAK and She contribute to the activation of the Ras-extracellulai' 
signal-regulated kinase (ERK) MAPK cascade when Shc-linked integrins bind to ECM 
(Giancotti and Ruoslahti, 1999). The relative contribution of each pathway may depend 
on the cell type and perhaps also on how far the adhesion process has progressed. In 
many cell types, She appears to be responsible for the initial high-level activation of 
ERK upon cell adhesion. FAK, which is activated more slowly, may sustain the ERK 
activation (Howe and Juliano, 1998; Pozzi, et al., 1998). The integrins that do not 
activate She are weak activators of ERK and cell proliferation (Howe and Juliano, 1998; 
Mainiero et a l, 1997). The ability of integrins to activate ERK may be especially 
important when the concentration of growth factors available to the cell is limited. In 
this setting, proliferation is likely to require co-stimulation of ERK through integrins 
and growth factor receptors.
1.5.3 Focal adhesions and cytoskeleton signalling
1.5.3,1 Activation o f Rho GTPases and Rho Kinase
In addition to regulating cell growth and survival signalling, focal adhesion signalling 
has also been shown to be involved in the formation of actin stress fibres. It has been 
indicated that integrin engagement can regulate the organisation of the cytoskeleton 
through regulating the activation of Rho GTPases (Hall, 1998). The Rho GTPases, 
which are a group of small GTPases belonging to the Ras superfamily, have been 
identified as important regulators for modulating actin organisation (reviewed in van 
Aelst and Dsouza-Schorey, 1997). Like other members of the Ras superfamily of 
proteins, the Rho GTPases acts as a molecular switches cycling between an active GTP- 
bound and inactive GDP-bound form (reviewed in Nobes and Hall, 1994). Guanosine 
nucleotide exchange factors (GEFs) facilitate the exchange of GDP for GTP, and 
GTPase-activating proteins (GAPs) increase the rate of GTP hydrolysis of Rho GTPases 
(Fig 1.6 A). In resting cells, inactive GDP-bound Rho GTPases are found in the 
cytoplasm as a complex with Rho guanine nucleotide dis association protein (RhoGDI) 
which inhibits GDP/GTP exchange. GDP-bound Rho GTPases released from GDI are 
translocated and activated during Rho GTPase dependent events (Takai, et al, 1995)
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Figure 1.6 Activity cycle of Rho GTPases and cytoskeleton morphology induced bv 
active Rac. Rho or Cdc42
(A) At the plasma membrane, Rho GTPases cycle between active GTP bound form and 
inactive GDP bond form. Guanosine exchange factors (GEFs) facilitate the exchange of 
GDP for GTP, and GTP-activating proteins (GAPs) increase the hydrolysis rate of 
RhoGTPases. In resting cells, inactive GDP bound Rho GTPases form a complex with 
Rho guanosine disassociation inhibitor (RhoGDI) in the cytoplasm, thereby inhibiting the 
GDP/GTP exchange rate of GDP bound Rho GTPases (grey panel). ERM (ezrin/radixin/ 
moesin) proteins interacting with RhoGDI leads to the disassociation of GDI from GDP 
bound Rho GTPases, thereby enabling the GDP bound Rho GTPases to translocate and 
couple to the GDP/GTP exchange cycle in the plasma membrane. (B) The actin 
cytoskeleton moiphology trigged by activation of Rho GTPases. (a) Activation of Rho 
induces an increase in the number of stress fibres, (b) Activation of Rac induces cells to 
form peripheral lamellipodia. (c) Activation of Cdc42 induces the formation of numerous 
actin-rich filopodia in the periphery extended from the cell body.
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(Fig 1.6 A, grey panel). The mechanism by which GDP-bound Rho GTPases are 
released from RhoGDI is still unclear. However, it has been shown that ERM (ezrin / 
radixin/ moesin) proteins might play a role in disassociating GDI from GDP-bound Rho 
GTPases, thereby releasing GTP bound Rho GTPases and increase the GDP/GTP 
exchange rate of Rho GTPases and the organisation of cytoskeleton (Takahashi et al, 
1997). Over 30 members of the Rho family are known in mammals (reviewed in 
Bishop and Hall, 2000). The members of Rho family GTPase, Rho, Rac and Cdc42, are 
shown to be responsible for the formation of specific actin cytoskeletal structures 
(reviewed in Hall, 1998) (Fig 1.6 B). The activation of Rho leads to the assembly of 
stress fibres (Fig 1.6 B, a) and formation of focal adhesion complexes (Ridley and Hall, 
1992). Rac activation induces the formation of an actin meshwork at the cell periphery, 
producing lamellipodia (Fig 1.6 B, b) (Ridley et al, 1992). Activation of Cdc42 in cells 
has been shown to lead to the formation of actin-rich membrane protrusions and 
microspikes, such as microvilli and filopodia (Kozma et a l, 1995) (Fig 1.6 B, c)
Rho activation results in the formation of focal adhesions and the contractile bundles of 
actin and myosin promoting the formation of sti'ess fibres (Fig 1.7) (Ridley and Hall, 
1992). Induction of these stinctures is known to be mediated by Serine/threonine 
kinases, which are downstream effectors of Rho-kinase (Matsui et a l 1999), 
ROKa (RhoA-binding kinase a) or its close relative pl60ROCK (ROKj3) (reviewed by 
Van Aelst & D’Souza-Schorey 1997). Rho GTPase binds to these kinases and increases 
their activity (Amano et a l 1997, Leung et a l  1995). Activated Rho-kinase inhibits the 
inactivation of myosin light chain (MLC) tinough the inactivation of MLC phosphatase 
(MLCP) by phosphorylating the myosin binding subunit (MBS) of MLCP (Kimura et 
a l 1996, reviewed by Ridley, 2001). This, in turn, enhances the binding of myosin to 
actin filaments and subsequently enhances the formation of stress fibres (Leung et a l 
1995, Chrzanowska-Wodnicka and Bumdge 1996, Amano et a l 1997).
1,5.3,2 Adhesion dependent Rho activation
The regulation of Rho A activity by integi'ins is complicated. Integrins can either 
stimulate or inhibit RhoA activity depending on the cell type, engagement of specific
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Figure 1.7 Mechanisms for Rho-induced stress-fibre formation through the 
activation of Rho kinase
Under the regulation of integiin dependent signalling in focal adhesion, activation of 
Rho leads to the activation of the downstream effector Rho kinase (Rho-K), Activation 
of Rho-K leads to phosphorylation of myosin light chain phosphatase resulting in the 
inactivation of MLCP. As MLCP is inactive, myosin light chain (MLC) will no longer 
be dephosphorylated as normal. Subsequently elevated levels of phosphorylated MLC 
would then be maintained in the cell through the action of myosin light chain kinase 
(MLCK). Phosphorylated myosin (containing the MLC) leads to bundling of actin 
filaments forming actin stress fibres. Activation of MLCK has been shown to regulated 
by ERK activation.
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integi'ins, and the time course of engagement (Ren, et al, 1999; O’Connor et al, 2000; 
Ai’thur, et a l, 2000), This duality may reflect the role of integrin-mediated signals in 
promoting membrane extensions, a condition in which low RhoA activity is desirable, 
versus the role of integrins in establishing strong attachments across which tension is 
tiansmitted, for which higher Rho activity is needed. In fibroblasts, integrin engagement 
initially inhibits Rho activity but later activates it, correlating with the completion of 
cell spreading (Ren et al, 1999), during which time integrin-mediated activation of Rac 
or Cdc42 is high (del Pozo, et a l, 2000; reviewed in Hall, 1998). Barry and colleagues 
found that addition of RGD peptides to quiescent fibroblasts stimulated focal adhesion 
and stress fibre assembly (Bany, et al, 1996). Arthur and colleagues identified a 
pathway by which integiin engagement results initially in a decrease in RhoA activity 
(Arthur, et al, 2000). It was found that incubation of fibroblasts with integrin ligands 
caused a rapid drop in Rho activity, but that this did not occur in cells deficient in the 
Src family tyrosine kinases (Src, Fyn, and Yes). c-Src has been identified to be required 
for this integi'in-mediated drop in Rho activity (Arthur et a l, 2000). v-Src expression in 
fibroblasts has long been known to disrupt focal adhesions and stress fibres (Fincham et 
al, 1999). Downstream from c-Src, pl90RhoGAP was identified as a target that is 
phosphorylated and activated, in response to integrin engagement. Thus, the short-term 
effect of integrin engagement leads to the inhibition of Rho activity via the activation of 
c-Src and pl90RhoGAP (Arthur et al, 2000). The pathway by which integrin-mediated 
adhesion results in long-term activation of RhoA has not been determined. It seems 
likely that the initial activation of pl90RhoGAP must be switched off, but whether there 
is an additional activation of a Rho-specific GEF remains to be elucidated. Numerous 
GEFs for the Rho family of GTPases have been discovered (Bishop and Hall, 2000) but 
little infoi-mation exists concerning how these GEFs become activated by integrin 
signalling. One exception is Vavl, a hematopoietic GEF for Rho family GTPases. Vavl 
is tyrosine phosphorylated and activated in response to integrin engagement or 
clustering (Gotoh, et a l, 1997. Miranti, et al, 1998). The integrin-mediated inactivation 
of Rho and focal adhesion assembly is shown in figure 1.8.
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Figure 1.8 Multiple signaling pathways control focal adhesion assembly bv 
coordiiiateiv regulating the activation of the small GTP-binding protein RhoA
Integi'ins transmit both positive and negative signals to RhoA. Initially, engagement of 
integi'ins with ECM inhibits RhoA. Integrins activate p i 90 RhoGAP through a c-Src- 
dependent mechanism. Integrins also activate Racl or Cdc42 as the cell spreads, which 
can antagonize RhoA activity. As stable adhesions form, integrins activate RhoA, most 
likely through an integrin-dependent RhoGEF. Downstream of RhoA, actin-myosin 
contractility stimulates actin stress fiber formation and clustering of integrins and 
associated proteins to form focal adhesions. This pathway is triggered by a RhoA 
effector, Rlio kinase.
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1.6 Aims of the study
In addition to integrin-mediated focal adhesion signalling, gi'owth factors receptors such 
as receptor tyrosine kinases (RTK) have long been known to promote the activation of 
the ERK cascade and mitogenesis (reviewed in Clark and Brugge, 1995). This 
convergence of integrin-mediated ERK signalling and RTK-mediated ERK signalling 
raises the possibility that integrin-mediated ERK signalling might be responsible for 
signalling beyond mitogenesis. Evidence supporting this aspect has been reported 
(Table 1.2). First, integrin activation was found to be suppressed by activation of 
Ras/Raf-initiated ERK pathway. The activation of ERK downstream substrate INK is 
not involved in the ERK-dependent integrin inhibition, suggesting that integrin activity 
is regulated by a transcriptional-independent ERK activation in cytoplasm (Hughes et 
al., 1997). Additionally, the direct association of ERKs with integrin in some tumour 
cells was found, implying that routes to modulate cytoskeleton organisation between 
integiin and cytoplasmic ERKs exist in normal cells (Ahmed et a l, 2002). Moreover, 
calpain, a pro tease which cleaves actin binding proteins in adhesion disassembly, has 
been reported to be inhibited by both integrin-mediated and EGF-dependent ERK 
activation (Glading et a l, 2000). The evidence implies that ERKs might play a role in 
regulating adhesion protein assembly.
An interesting finding is that active ERK2 has been shown to directly interact with and 
activate myosin light chain kinase (MLCK), which phosphorylates myosin light chain 
(MLC) subsequently enhances stress fibre and focal adhesion formation (Klemke et al, 
1997). Thus ERK, in addition to a role as a mitogenetic activator, could co-operate with 
Rho kinase, which inhibits MLCP to regulate myosin and modulate cell motility (Fig 
1.7). Fincham and colleagues (Fincham et al, 2000) have demonstrated that active 
ERKs targets to newly forming focal adhesion sites in rat embryo fibroblast (REF52) 
cells. The activation and tai'geting of ERKs is induced by the activation of v-Src protein, 
in response to integrin engagement. Thus, a signalling pathway has emerged which is 
triggered by integrin engagement followed by activation and targeting of ERK to 
adhesions, and subsequent activation of MLCK to regulate cytoskeletal reorganisation.
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Table 1.2 Evidence of ERK-mediated non-mitogenetic regulation
Description Cell type Reference
Activity of MAP kinase regulates 
Cell motility
Stoker and Gherardi, 1991 
Klemke et ai,  1994 
Leavesley e? a/., 1993 
Yenush e ta l ,  1994
Activation of integrin is inhibited 
by the activation of ERK cascade.
CHO Hughes etal., 1997
MLCK is activated by active ERKs COS-7 Klemke et at., 1997
ERKs inhibit protease Calpain NR-6 
(mouse fibroblast)
Glading et al,  2000 
Glading et al,  2001
Blocking of integrin-mediated ERK 
activation inhibits the migration of 
cells.
COS-7 Klemke e tal ,  1997
ERK directly associates with 
integrin
WiDr, HT29,
SW480
(human colon cancer cell line)
Ahmed et al, 2002
Active ERK localise at newly 
formed adhesion in leading 
edge of the cell.
REF52 Fincham et ai,  2000
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Previous work has shown that a-dystroglycan co-localised at focal adhesion sites with 
active ERK (Spence, et al., 2003a). As mentioned above, dystroglycan has been 
considered to be a signalling molecule playing a role in regulating cell adhesion and 
cytoskeleton reorganisation in non-muscle cells. Dystroglycan is an ECM laminin 
receptor and has been shown to associate with Grb2-Sos and FAK, and could be able to 
trigger Ras-mediated ERK activation. If engagement of dystroglycan activates Grb2- 
Sos and activates the ERK cascade, it is possible that dystioglycan plays a role in ERK- 
dependent adhesion and mediates actin stress fibres reorganisation tluough the 
activation of ERK and MLCK. To date, however, the study of relationship between 
cytoplasmic ERK and dystroglycan has not been reported. Therefore, this study aimed 
to investigate the role of dystroglycan in cell adhesion-mediated signalling with 
particulai' emphasis on the role of the ERK cascade.
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Chapter 2 
Methods and materials
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2.1 Materials
2.1.1 Chemicals, reagents and Kits
Appendix I
2.1.2 Media and general buffers
Appendix II
2.1.3 Plasmid and clones
Appendix III
2.1.4 Cell lines
Appendix IV
2.1.5 Antisera
Appendix V
2.1.6 Oligos
Appendix VI
2.2Molecular biology methods
2.2.1 Bacterial strain
E. coli strain DH5a was used for all cloning, amplification and propagation of plasmid 
DNA in this study. Genotype of DHSais: F", 08Od/ût:ZAM15, A {lacZYA"argF)'Ul69, 
deoR, recAl, endAl, hsdRllirk', mk'*'), phoA, supEAA, X , thi-l, gyrA96, relAl. 
DH5a culture in the stationary phase was suspended in 50% sterilised glycerol solution 
at the ratio of 3:2 and stored at -80°C until needed.
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2.2.2 Growth of bacteria
DH5a was gi'own at 37°C in sterilised 2x YT liquid medium or on sterilised 2x YT 
solid medium. To maintain selection for plasmid DNA, transformed DH5a was grown 
in 2x YT liquid medium or 2x YT solid medium containing ampicillin (25pg/ml) or 
kanamycin (30pg/ml).
2.2.3 Transformation of DH5a
2.2.3.1 preparation o f  calcium competent cells
DH5a was transferred from a frozen stock, streaked and incubated at 37"C on 2x YT 
solid medium for overnight. A single colony from this culture was ti’ansferred to 5ml 2x 
YT liquid medium and incubated at 37 °C for overnight. lOOjul of this culture was 
transferred to 100 ml 2x YT liquid medium and incubated at 37°C until the ODôoo value 
reached to 0.6. This culture was then centrifuged at 4°C for 20 minutes at 2500Xg and 
the supernatant discarded. The cell pellet was resuspended in 10 ml of lOOmM calcium 
chloride solution and on ice for at least 45 minutes. These competent cells were used 
fresh or aliquoted into Eppendorf tubes (lOOjil aliquots) and stored at -80°C.
2.2.5.2 Transformation o f calcium competent cells
90|uil of calcium competent cells were thawed on ice, and mixed with the 10 pi DNA to 
be transformed. The mixture was then incubated on ice for 30 minutes, heat shocked at 
42°C for 2 minutes and transferred into 0.9ml 2x YT liquid medium. The cells were 
allowed to recover for 30 minutes at 37 °C before being spread onto 2x YT solid 
medium supplemented with ampicillin or kanamycin. To isolate single colonies, these 
cells were incubated at 37°C for 16 hours overnight.
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2.2.4 Preparation of plasmid DNA
2.2.4.1 Small-scale preparation o f plasmid DNA by spin column
Plasmid DNA was prepared using QIAprep Miniprep kit, following the manufacturers’ 
guidelines. DNA was extracted from 3ml E. coli culture, resuspended in 50pl of 
distilled water and stored at -20°C.
2.2.4.2 Large-scale preparation o f  plasmid DNA for transfection
Large scale DNA for transfection was prepaied using QIAprep Midiprep kit, following 
the manufacturers’ guideline. DNA was extracted from 50ml E. coli culture, 
resuspended in 300pl of distilled water and stored at -20°C.
2.2.5 Spectrophotometric quantification of DNA
The concentration of DNA was determined by measuring the absorption of 100 times 
diluted DNA solution at 260nm for DNA or 280nm for RNA using HeA-iosy 
spectrophotometer (Unicam) and Ultra-micro cuvette (Sigma-Aldrich). For double­
stranded DNA, an OD260 value of 0.1 represents a DNA concentration of 
approximately 50pg/ml. For determination of the quality of plasmid DNA, both OD260 
and OD280 value were detected. A value of OD260/ OD280 >1.5 meant that the quality 
of the batch of DNA purification was sufficient for mammalian cell transfection 
(section 2.3.2).
2.2.6 Restriction digestion of DNA
Restriction enzymes were purchased from Boehringer Mannheim, or New England 
Labs. For Sail and Smal double digestion, the required quantity of DNA was mixed 
with 5 units of Sail in Y+/TANGO (Fermantas) buffer at 2x concentration, and was 
incubated at 37°C for 2 hours. The enzyme activity of Sail was then terminated by 
heating to 65°C for 20 minutes. After cooling down to room temperature, distilled water 
was added to the mixture until Y+/TANGO buffer reached to Ix concentration. 5 units 
of Smal was then added into the mixture and incubated at 25 °C for 3-5 hours until it 
was used for ligation. For other digestions, requisite quantity of DNA was digested in
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10-20jil volumes containing appropriate buffers at Ix concentration and restriction 
enzyme at 1-5 units. These mixtures were incubated at the recommended temperature 
following the guideline and the digestions were examined by using agarose gel 
electrophoresis (section 2.2.7).
2.2.7 Agarose gel electrophoresis
Agarose gel electrophoresis of DNA fragments was performed with 0.8% (WA7) 
agarose gel by using EM-100 Mini Gel Unit (Cambridge). Gels were prepaied by 
melting appropriate amount of agarose in 0.5x TBE buffer and adding ethidium bromide 
to a final concentration of 0.5 jil/ml. Samples to be analysed were mixed with agarose 
gel loading buffer and directly loaded into the gel. The gels were placed in 0.5x TBE 
buffer in the gel running chamber and typically run at lOOV for 20-30 minutes. 
HyperLadder I (Bioline), size range from 200-10000bp, was used as the size marker.
2.3 Cell culture
2.3.1 Growth of cell lines
REF52 and COS7 cells were maintained in DMEM media supplemented with 10% FBS 
in 5% CO2 atmosphere at 37°C in 75T flasks. Confluent cells were passaged using 
0.25% trypsin solution and reseeded at a dilution of 1:4 for REF52 cells or 1:10 for 
COS7 cells. Primary culture of utrophin null and the utrophin wild type of mouse 
embryo fibroblast were cultured in DMEM media supplemented with 10% FBS in 5% 
CO2 atmosphere at 37°C in 75T flask. For utrophin knockout primai’y cultures of rat 
embryonic fibroblasts, cells were kept in the same condition as above and used for 
transfection within 10 days.
2.3.2 Transfection and cotransfection
Expression of plasmid DNA in mammalian cells were carried out by using 
Lipofectamine™ reagent, following the manufacturers’ guidelines. Cells were seeded in 
tissue culture dishes or flasks and allowed to spread and gi’ow at 37 °C in DMEM 
supplement with 10% FBS and 5% CO2 overnight (less than 24 hour) until 80-95%
40
confluent. For transfection, the appropriate amount of DNA was mixed with 
lipofectamine reagent in OPTIMEM serum free medium and incubated at room 
temperature for 20 minutes. At this time, the cells were washed 2-3 times with 
OPTIMEM; and the DNA-lipofectamine mixtures were added immediately to the cells. 
The cells were then incubated at 37°C for 5 hours to overnight until required. The same 
protocol but with reduced concentration of DNA were used for cotransfection. The 
conditions for transfection or cotransfection of each construct to each cell line aie in 
appendix VIII.
2.3.3 Harvesting cells in RIPA buffer
Cells were washed gently 2-3 times in cold PBS before being harvested in ice-cold 
RIPA buffer including 1 mM sodium orthovanadate, lOOnM Calyculin A, ImM PMSF, 
lOjiM TPCK, lOjLiM Leupeptin, ImM Pepstain, 10|4g/ml Aprotinin, and lOjig/ml 
Benzamidine. These cells were lysed on ice (or at 4°C) for 30 minutes. The lysate was 
then collected by cell scraper, centrifuged for 15 minutes at ISOOOxg. The supernatant 
was used fresh or stored at -80°C until needed.
2.3.4 EGF treatment
For the assay of activation of ERK, the cells on the dishes were washed 3 times with 
DMEM and then incubated at 37°C in DMEM supplemented with 20ng/ml EGF at 5% 
CO2 for 1 hour.
2.3.5 U0126 treatment
For the assay of inhibition of ERK, lOpM U0126, the ERK inhibitor, were added to the 
EGF treated or untreated cells and incubated at 37°C in DMEM at 5% CO2 for further 
30 minutes.
2.4 Protein Biochemistry methods
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2.4.1 Quantification of protein concentration
The protein concentration in cell extracts was quantified using MicroBCA protein 
quantification kit (Pierce), following the manufacturers’ guidelines. A series of BSA 
solutions were prepared by diluting 2mg/ml BSA stock in distilled water to give a 
dilution series ranging from 20-200|ig/ml. 2ml working reagent was added to each 
lOOOjuil of standard solution and incubated at 65 “C for 1 hour. The OD562 of each sample 
was measured and the values were used to plot a graph of BSA concentration versus 
OD562- Protein samples were treated in the same manner and the concentration was 
interpolated from the standard plot.
2.4.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-polyacrylamide gels were run using the Mini-proteanll protein electrophoresis 
system (BioRad). The 10% separating gel solution was prepaied and poured between 
two set of glass plates and allowed to polymerise at room temperature for 20-30 minutes 
followed by addition of the 5% stacking gel solution (1.66 ml 30% polyacrylamide 
solution, 2.5 ml stacking gel buffer, 5.76ml distilled water, 40pl TEMED, 120pl 10% 
APS) and a comb was inserted into the top of the gel. After the polymerisation was 
complete, the comb was gently taken out and the wells were washed with distilled 
water. The gel assembled was placed in the electrophoresis apparatus and the chamber 
and the tank were filled with Ix SDS-PAGE running buffer. Protein samples were 
mixed with an equal volume of 2x SDS loading buffer, boiled for 2 minutes and loaded 
onto the gels. Pre-stained broad range protein marker (NEB; size range 6.5-175 KDa) 
was used as the size marker. The gel was run for 20-30 minutes at 50V until the sample 
dye reached the interface of stacking gel and separating gel; then, the running voltage 
was increased to lOOV for further 1.5-2 hour until the sample dye completely left the 
gel.
2.4.3 Immunoprécipitation
Cell extracts haiwested in RIPA buffer (section 2.3.3) were quantified using MicroBCA 
assay (section 2.4.1). At this time, protein A Sepharose beads (50% slurry in RIPA 
buffer) was added to the sample at a final dilution of 1:10 and incubated at 4"C for 1
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hour on a roller to reduce non-specific binding. The protein A Sepharose beads were 
removed by centrifugation at ISOOOxg for 30 seconds, and the supernatants were 
incubated with appropriate primary antibodies at 4°C for 2 hours on a roller. 50|il of 
Protein A Sepharose (50% slurry in RIPA buffer) was then added into each of cell 
extract and incubated at 4°C for a further 1 hour on a roller. Following the primary 
antibodies and protein A Sepharose interaction, the cell extracts were centrifuged at 4°C 
for 30 seconds at ISOOOXg, and the supernatant was removed. The protein A Sepharose 
beads were resuspended in ice-cold appropriate buffer and centrifuged as above; the 
wash was repeated for 3 times. After washing, the beads were used for SDS gel 
electrophoresis by adding SDS loading buffer, or used for other biochemical assay.
2.4.4 Western blotting
Proteins were electrophoretically transferred from the SDS-polyacrylamide gel to PVDF 
membrane using Trans-Blot cell transfer system (BioRad). The transfer was performed 
in CAPS/methanol transfer buffer and blotted at 4 °C for Ihour at 400mA.
2.4.5 Antibody binding and detection (Alkaline phosphatase development)
After protein transfer was complete, PVDF membrane was blocked in 5% skim milk 
powder in TBST buffer (V/W) for 30 minutes and then incubated overnight at 4°C with 
appropriately diluted primary antibodies in skimmed milk/TBST (see above) buffer on a 
roller. For the washing, the membrane was rinsed 3 times and washed 3 times (5 
minutes for each wash) in TBST buffer. The appropriately diluted AP-conjugated 
secondary antibody (see Appendix V) was then added to the membrane in TBST buffer 
and incubated for 1 hour at room temperature. After the interaction, the membrane was 
washed 3 times (5 minutes for each wash) in TBST buffer; the membrane was then 
developed in AP buffer containing 0.4mM NBT and 0.4mM BCÏP.
2.4.6 Development of the expression of AP-dystroglycan construct
AP-dystroglycan transfected cells were rinsed twice in PBS and fixed for 5 minutes at 
room temperature in PBS containing 3.7% formaldehyde. The cells were washed 3 
times in PBS and treated with PBS containing 0.1% Triton X I00 for 1 minute. The
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buffer was then removed, and the cells were washed 3-5 times in PBS. After washing, 
the overexpressed proteins in the cells were detected using AP buffer containing 0.4mM 
NBT and 0.4mM BCIP, gently shaking at room temperature until the pui-ple colour on 
the dishes was recognisable.
2.5 Protein immunofluorescence assay
2.5.1 Immuiiofluorescent staining of transfected cells
The transfected cells on coverslips were fixed at room temperature for 5 minutes in PBS 
containing 3.7% formaldehyde, washed 3 times in PBS and treated for 1 minute with 
PBS containing 0.1% of Triton-XlOO. After washing 3 times with PBS, the coverslips 
with cells were blocked at room temperature for 30 minutes in IFA blocking buffer and 
incubated at room temperature for 3 hours in IFA blocking buffer containing 
appropriately diluted primary antibodies (see Appendix V). The coverslips were washed 
3 times before interacting with IFA blocking buffer containing appropriately diluted 
fluorescence-conjugated secondary antibodies and incubated at room temperature for 1-
1.5 hours. After the interaction, the coverslips with cells were washed 3-5 times in PBS 
and sealed with mounting medium (Vector) on glass microscope slides.
2.5.2 Actin morphology
To detect the morphology of actin filaments, the transfected or untransfected cells on 
coverslips were incubated at room temperature for 45 minutes in blocking buffer 
containing 1:1000 diluted Rhodamine-phalloidin (TRITC, Sigma). The coverslips were 
washed 3 times in PBS before being sealed as above.
2.5.3 Fluorescent microscopy
The glass microslides with cell on the coverslips were viewed on Olympus BX60 
fluorescent microscope equipped for epifluorescence and with IPLab (Scanalytics) 
image capturing software. Immersion oil (Olympus) was used on the coverslips for oil 
lens.
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2.6 Construction of dystroglycan mutants
2.6.1 PCR mutagenesis
Sequences of dystroglycan or dystroglycan deletion mutants for cloning were generated 
by using a PCR mutagenesis technique. The PCR reaction mixture for 5 reactions were 
prepared as follow:
mDG-1 plasmid encoding full-length mouse dystroglycan was used as the template for 
generating full-length dystroglycan-GFP (apDG-GFP) construct. The construct apDG- 
GFP was then used as the template for constructing of dystroglycan deletion mutants. 
The reaction mixture was aliquoted into PCR reaction tubes and the reactions were 
carried out in a Biometra Personal Cycler (Whatman) with appropriate running 
conditions (appendix VII). The sequences of extracellular P-dystroglycan (apOGAep) 
or a  dystroglycan deletion (apOGAa) mutants were generated by using overlap 
extension site directed mutagenesis. Two double-stianded DNA fragments containing 
sequence overlapping to each other were generated respectively by two pairs of primers 
(PI and P2) in the first round of PCR reaction. The two products containing overlapping 
sequence generated from first round of PCR were then purified from agarose gel 
(section 2.2.7) and used as templates for second round PCR.
For 5 reaction |Xl
Distilled water 79.5 1
lOx PCR buffer 10
12.5mM dNTPs 2
Forward primer (100 pmol/gl) 2
Reverse primer (100 pmol/|xl) 2 :
Template plasmid (SOng/pl) 0.5
Taq polymerase 1 ;
SOmMMgCb 3
100
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2.6.2 Purification of PCR products
The PCR products were excised from agaiose gels as above (section 2.2.7). QIAquick 
gel extract spin kit was used to extract the DNA fragment from the agarose gels 
following the manufacturers’ guidelines. The eluted DNA fragments were resuspended 
in 30pl distilled water and digested with the appropriate restriction enzyme (section 
2.2.6). After the digestion, these DNA fragments were purified again in the same 
manner before being used for ligation.
2.6.3 Ligation of DNA
Vector and insert DNA fragments digested with appropriate restriction enzymes were 
mixed at a molar ratio 1:3 in 8pi of distilled water. The ligation of DNA fragments was 
carried out using Rapid Ligation Kit (Roche), following the manufacturers’ guidelines. 
20pl of ligation was used directly for transformation of calcium competent cells (section 
2.2.3).
2.6.4 Colony screening by PCR
Single colonies containing recombinant DNA were screened by colony PCR. The PCR 
reaction mixture was prepared as follows;
For 5 reaction____________ pi .
Distilled water 80
lOx PCR buffer 10
12.5mM dNTPs 2
Forward primer (too pmol/ul) 2
Reverse primer (100 pmol/fxl) 2
Taq polymerase 1
50mM MgCk______________3 .
100
20pl of the mixture was aliquoted into each PCR reaction tube, and several tubes of 
2xYT liquid medium (3ml/tube) containing appropriate antibiotics were also prepared.
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Single colonies were picked from the 2x YT solid medium plates by sterilised 
toothpicks; the cells were resuspended both in tubes with PCR reaction mixture and in 
tubes with 2xYT medium. The PCR reactions, 94°C Iminute, 65°C 1 minute, 72°C 1 
minute were run for 30 cycles; the PCR products were analysed by agarose gel 
electrophoresis to identified the containing plasmids. After the recombinant plasmids 
were selected, colonies carrying recombinant plasmid in the 2x YT liquid medium tubes 
were incubated at 37°C for overnight to amplify the plasmid.
2.7 Cell Adhesion assay
2.7.1 Coating of coverslips
Extracellular matrix proteins fibronectin, laminin or poly-L-lysine, were diluted in 
distilled water at the appropriate concentration and lOOpl added to each sterilised 13mm 
glass cover slip. These coverslips were oven dried at 50°C for 1 hour until all the liquid 
was evaporated, and then were transferred to 24 well culture dishes. After washing 5 
times in distilled water, these coverslips were airdried at room temperature for 1-2 hours 
until required. If not used fresh, the coated coverslips were stored at 4°C overnight.
2.7.2 Adhesion time course of transfected REF52
Lipofectamine™ transfected REF52 cells (section 2.3.2) were trypsinized from tissue 
culture flasks or dishes and resuspended in DMEM medium in absent of serum. The 
suspended cells were washed once and diluted to the appropriate concentration in 
DMEM. These cells were then seeded onto matrix-coated coverslips in 24 well culture 
dishes and were incubated in 37“C incubator at 5% CO2 . For the adhesion time course, 4 
coverslips with cells were collected and fixed for microscopy (section 2.5.1 and 2.5.3) 
at each time point.
2.7.3 Substrate dependent assay of dystroglycan transfected REF52
13 mm coverslips coated with l|Lig/ml of fibronectin, poly-L lysine or laminin were 
placed in 24 well culture dishes as above (section 2.7.1). Dystroglycan or dystroglycan
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mutant transfected cells were trypsinized and resuspended in DMEM in absent of serum. 
Resuspended cells were seeded onto coverslips in each well (approximately 1x10^) and 
incubated at 37°C for 3 hours. The coverslips were collected and fixed for microscopy 
(section 2.5.1 and 2.5.3).
2.8 ERK kinase activity assay
2.8.1 Preparation of ERK kinase assay sample
YFP-ERK construct was transfected into REF52 cells on lOOmm^ tissue culture dishes 
(approximately 5x10  ^ cells per dish) following the procedure in section 2.3.2. The 
transfected cells were incubated at 37 °C, 5% CO2 overnight in DMEM supplemented 
with 10% FBS, and were washed 3 times with DMEM to remove the serum. The cells 
were then incubated in at 37°C in DMEM in the presence of EGF or U0126 (see section
2,3.4 and 2.3.5). After the treatment, the cells were gently washed 3 times with PBS and 
lysed on ice for 30 minutes in 400|il/dish MAPK lysis buffer, supplemented with 
200mM (3-glycerophosphate, 0.5 mM DTT and ImM orthovanadate. The cell lysates 
were collected by cell scraper and stored at -80°C until required.
2.8.2 Myelin Basic Protein (MBP) ERK kinase activity assay
In order to identified the expressed YFP-ERK from the endogeneous ERK, the cell 
lysates were immunoprecipitated with anti-GFP antibodies as above (section 2.4.3); 
MAPK washing buffer was used for the first and second of the Protein A Sepharose 
bead washes. After the washing was complete, the beads were washed twice in MAPK 
kinase buffer containing lOmM (3-glycerophosphate, 2mM DTT and 0.5mM 
ortho vanadate. At this time, the kinase mix containing 170|Ltl kinase buffer, lOjil myelin 
basic protein and 10|il cold ATP was prepared. lOfiCi [32P]-ATP was added to the 
kinase mix in radiation hot room. 25pi of this kinase mix was added to each protein A 
beads sample and the mixtures were incubated at 30°C for 20 minutes. After the 
incubation, the samples were centrifuged for 1 minute at 18000xg and 10 ml of 
supernatant from each sample was spotted on each 3x3 cm^ of P81 paper. The P81
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paper squai'es with samples were immediately dropped into 0.5% phosphoric acid and 
washed three times for 5 minutes. After washing, the P81 paper squai'es were briefly 
rinsed with acetone and airdried for 20-30 minutes. The value of P32 was detected by 
using LS6500 Multi-purpose Scintillation Counter (Beckman).
Chapter 3
Expression of YFP -ERK construct in REF52 cells
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3.1 Introduction
3.1.1 ERK cascade
The transmission of extracellular signals into intracellular responses is a complex 
process that often involves the activities of mitogen-activated protein (MAP) kinases. 
Extracellular signal-regulated kinase (ERK) cascade, which is activated by the 
interaction of membrane receptors with the ECM, is one of the most important MAP 
kinase signalling cascades responsible for transmission of extracellular signals into 
intracellular responses (Nashida and Gotoh, 1993). ERKl and ERK2 are proteins of 44 
and 42 KDa that are 85% identical overall (reviewed in Boulton et a l, 1991) which are 
believed to have overlapping signalling capability and are also refened to as ERK 1/2 or 
p44^^^^ (Morino et al., 1995). ERKs are proline-directed serine-tlneonine
kinases, which contain a T-E-Y (Thr-Gly-Tyr) sequence. The activation of ERKs refers 
to the dual phosphorylation of threonine and tyrosine (Tp-E-Yp) residues of its T-E-Y 
motif in response to diverse extracellular stimuli (reviewed in Cobb and Goldsmith, 
2000). The activation of ERK 1/2 involves a three kinase cascade consisting of Raf 
(MEKK or MAPKKK) which activates a MEK (MAPKK), which than stimulates a 
phosphorylation-dependent increase in the activation of ERK. Upon activation, ERK 1/2, 
which is activated in the cytoplasm, translocates immediately to the nucleus and 
phosphorylates a variety of intracellular targets including transcription factors and 
transcriptional adaptor proteins, which regulate the expression of genes essential for cell 
proliferation, survival and growth (reviewed in Cyert, 2001). In mitogenesis, the 
tianslocation of ERKs to the nucleus is required for cell cycle progiession and cell 
differentiation (Brunet et a l, 1999; Robinson et al, 1998).
In addition to being activated through integrin-mediated focal adhesion signalling 
(section 1.5.2), the growth factor-induced ERK cascade is the major ERK signalling 
pathway that modulates cell proliferation and survival. The ERK cascade can be 
activated by soluble giowth factors that interact with receptor tyrosine kinases (RTKs) 
including neuronal giowth factor (NGF), epithelial growth factor (EGF) and platelet
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derived growth factor (PDGF) (reviewed in Clark and Brugge, 1995). The signalling 
pathway from RTK to ERK 1/2 is well studied (Fig 3.1) (reviewed in Paw son and Scott, 
1997; Pearson et al., 2001; Ftunter, 1995). Ligand binding to RTKs stimulates the 
dimérisation of RTK subunits and increases its tyrosine kinase activity. Activation of 
RTKs leads to the autophosphorylation of its cytoplasmic domain, creating a motif that 
can be recognised by SH2 domain of Grb2 adaptor protein. The guanine nucleotide 
exchange factor (GEF) Son of Sevenless (SOS) protein, which interact with the SH3 
domain of Grb2 then becomes engaged with the complex and induces Ras to exchange 
the GDP for GTP. GTP-liganded Ras is targeted to many effectors, including Raf. Ras 
binding to Raf results in a conformation change in Raf that localises it to the plasma 
membrane and increases its kinase activity to activate MEK-ERK cascade.
3.1.2 Aim of the experiment
To determine whether dystroglycan plays a role in focal adhesion signalling and MLCK- 
induced actin sti'ess fibre formation, mediated by activation of ERK, the first approach 
was to visualise the expression and localisation of ERK and dystroglycan during focal 
adhesion formation. Two fluorescent protein tagged constructs were made for this 
propose: YFP-ERK, a N-terminal yellow fluorescent protein-tagged p44^^^^ /P42^*^^  ^
and aj3DG-GFP, a C-teiininal GFP-tagged full-length dystroglycan. The constructs 
were expressed in REF52 cells. REF52 cells are an anchorage-dependent rat embryonic 
fibroblast cell, which spread rapidly and give rise to flat cells with prominent focal 
adhesions. They are widely used as a model for studying focal adhesion formation 
(Belkin and Smalheiser, 1996). We used the YFP-ERK construct to observe the 
localisation of ERK in focal adhesions and for further studies on the relationship 
between dystroglycan and ERK-dependent cytoskeleton reorganisation in the cytoplasm.
The expression and localisation of YFP-ERK in REF52 cells was determined by 
fluorescence microscopy. U0126 (CigHieNeSz), which is a chemically synthesised 
organic compound that inhibits MEK 1/2, was used to examine the biological activity of 
overexpressed YFP-ERK in the cells. Since MEK 1/2 is the only direct activator
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Figure 3.1 RTK induced ERK cascade in mammalian cells
Receptor tyrosine kinase (RTK) induced ERK cascade, in mammalian cells. Binding of 
the growth factors leads to the dimérisation of RTK and autophosphorylation of the 
cytoplasmic domain of RTK. Phosphorylation of RTK creates a motif that can be 
recognised by SH2 domain of Grb2 followed by activation of SOS, which associates 
with Grb2 via the SH3 domain. Activated SOS acts as a Ras GEF that induces the 
exchange of Ras-GDP to Ras-GTP, the active form of Ras. The membrane associated 
Ras-GTP is than able to bind to the N-teiminal of Raf, leading to the membrane 
localisation and a conformation change in Raf. The conformation change of Raf-1 also 
leads to the increase of its kinase activity to MEKl/2 that phosphorylates the 
serine/threonine residue of MEKl/2. Active MEK 1/2 subsequently phosphorylates the 
T-E-Y motif of ERK 1/2. The active ERK 1/2 can translocate to the nucleus followed 
by activation of its substrates including transcription factors and other transcription- 
related kinases to promote relevant gene transcription and regulate the survival events 
of the cell. Activation of ERK in cytoplasm has also been shown to induce the 
activation of MLCK and play a role in enhancing the formation of actin stress fibres.
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identified for ERKl/2, U0126 is sufficient to inhibit the activation of ERK 1/2 in the 
cascade (Davies et ah, 2000). The effect of treating the cells with U0126 on the 
translocation of YFP-ERK was observed in REF52 cells; the activity of YFP-ERK was 
then determined by using western blotting and MBP-ERK activity assay. Finally, the 
activation of YFP-ERK at focal adhesion sites in REF52 cells was determined by 
immunofluorescence staining of the YFP-ERK expressing cells using an anti-talin 
antibody. The expression and localisation of apDG-GFP in REF52 cells are examined 
and discussed in chapter 4.
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3.2 Results
3.2.1 Expression of YFP-ERK in REF52
A YFP-ERK construct was made by subcloning the cDNA into pRESYFP
mammalian cell expression vector. To examine the expression of the construct and the 
localisation of the YFP-ERK fusion protein in focal adhesions, the YFP-ERK construct 
was transfected into REF52 cells. By counting the YFP positive cells by microscopy, the 
transfection efficiency of YFP-ERK construct or pRESYFP empty vector in REF52 cells 
was determined to be 25-30% or 40% on average, respectively. In the transfection of 
YFP-ERK, but not pRESYFP, large numbers of cell were found rounded, lysed and 
floating in the culture medium after the standard transfection procedure, revealing that 
the ti'ansfection and expression of YFP-ERK might be lethal to the REF52 cells.
The expression of YFP-ERK in REF52 is shown in figure 3.2. A relatively high amount 
of YFP-ERK protein is concentrated at the nucleai' region rather than distributed in the 
cytoplasm (Fig 3.2 A). In contrast, the expression of YFP was distributed all around the 
cell body while higher concentration at nuclear region was still recognisable (Fig 3.2 B). 
The activation of ERK has been shown to occur in the cytoplasm followed by ERK 
translocating to nucleus for mitogenetic signalling (reviewed in Pouyssegur et al., 2002). 
The highly concentrated nuclear localisation of YFP-ERK which is consistent with what 
has been shown in the immunostaining of endogeneous active ERK indicates that the 
biological activity of the overexpressed YFP-tagged ERK might not be altered.
3.2.2 Western blotting assay of YFP-ERK activity
The expression and activity of YFP-ERK in REF52 cells was further determined by 
using western blotting. As shown in figure 3.3, the expression of YFP-ERK was detected 
by either anti-total ERK antibodies or anti-GFP antibody, and U0126 treatment has no 
effect on the expression of YFP-ERK in REF52 cells (Fig 3.3 A and B, upper panels). 
The expression of endogeneous ERKl and ERK2 were unaffected by expression of 
either YFP-ERK or pRESYFP whether U0126 is present or not (Fig 3.3 A, lower 
panel). The activity of YFP-ERK was determined by an anti-phospho ERK antibody.
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Figure 3.2 Overexpresion of YFP-ERK construct in REF52 cells
YFP-ERK (2fxg/|0,l) or pRESYFP empty vector (2|ig/p,l) were transfected into REF52 
cells plated on glass coverslips using the standard transfection procedure. The 
transfected cells were incubated overnight and fixed with 3.7% formaldehyde. YFP- 
ERK expressed in REF52 cells was clearly concentrated in nucleus (A). The YFP 
expressed in REF52 cells was distributed all mound the cell body, including the nucleus 
(B). Scale bai'= 25pm.
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Figure 3.3 Expression and inhibition YFP-ERK in REF52 cells
YFP-ERK (2pg/pl) or pRESYFP (2pg/pl) transfected REF52 cells with or without 
U0126 treatment were washed 3 times with PBS buffer lysed in SDS loading buffer. 
The expression and activity of YFP-ERK were detected by western blot with anti-ERK 
(A), anti-GFP (B) or anti-phospho ERK (C) antibodies, the dilution of primary 
antibodies in all eases are 1:1000. The expression of YFP-ERK was detected by anti- 
ERK or anti-GFP and showed no difference on U0126 treatment (upper panel, A and 
B). Expression of endogenous ERKl and ERK2 were constant in the absence or 
presence of U0126 (lower panel, A). The activation of YFP-ERK and endogenous 
ERKl and ERK2 were detected by anti-phospho-ERK, all active froms of ERKs were 
completely inhibited by U0126 treatment (upper panel C). For empty vector expression 
control, YFP expression was detected by anti-GFP antibodies (lower panel, B). 
Expression of ERKl and ERK2 were constant (lower panel A) and the activity of ERK 
was inhibited by U0126 (lower panel C).
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which only recognises the active form of ERK (Fig 3.3 C). Compared with the total 
expression of YFP-ERK detected by anti total ERK (Fig 3.3 A, upper panel), in the same 
amount of protein loading, only a small amount of YFP-ERK fusion protein was 
detected as activated. This activity of YFP-ERK (Fig 3.3 C upper panel), as well as 
endogenous ERKl and ERK2 (Fig 3.3 C lower panel), is completely inhibited in the 
presence of U0126. These results suggested that firstly, the expression and activation of 
endogenous ERKl and ERK2 is not affected by the expression of YFP-ERK. Secondly, 
part of the expressed YFP-ERK was activated and this activity was inhibited by U0126. 
Finally, U0126 treatment does not inhibit the expression but does inhibit the activation 
of YFP-ERK.
3.2.3 Effects of U0126 on YFP-ERK in REF52 cells
To further examine the biological activity of the overexpressed YFP-ERK, localisation 
of inactivated YFP-ERK was observed in the presence of U0126. As shown in figure 
3.4, U0126 treatment had no effect on the cells expressing YFP. YFP was distributed 
around the cell body and in the nucleus in the presence or absence of U0126 (Fig 3.4 A 
and C). In contrast, U0126 treatment led to a loss of nucleai' localisation of YFP-ERK. 
By comparison with the U0126 untieated YFP-ERK transfected cells, where most 
overexpressed protein was concentrated in the nuclear region (Fig 3.4 E), no or very 
little YFP-ERK was found localised in the nucleai' region in the transfected cells tieated 
with U0126 (Fig 3.4 G, solid arrow). More YFP-ERK was distributed in the cytoplasm 
rather than concentrated in the nuclear region in the present of U0126. These results 
suggested that the inhibition of the ERK activity of YFP-ERK prevents YFP-ERK from 
its nuclear translocation. Thus, YFP-ERK was expressed with biological activity in the 
REF52 cells. U0126 treatment has no significant effect on YFP, suggesting that the 
translocation of YFP-ERK was caused by the inhibition of ERK activation rather than an 
effect on the YFP.
3.2.4 MBP kinase activity assay of YFP-ERK
To further determine whether the biological activity of YFP-ERK was altered, the 
upstream pathway that activates YFP-ERK was examined. The serum-stai ved YFP-ERK
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Figure 3.4 U0126 treatment of YFP-MAPK overexpressed REF52 cells
REF52 cells plated on glass coverslips were transfected with pRESYFP empty vector 
(2jXg/|al) or YFP-ERK (2jJ,g/pl) following the standard transfection procedure. The 
transfected cells were incubated in DMEM containing 50|iM U0126 at 37°C for 30 min 
and fixed with 3.7% formaldehyde. The coverslips were sealed with mounting media 
(Vector), and the nucleus was stained as blue. Nuclear morphology of pRESYFP and 
YFP-ERK transfected cells in the presence of U0126 are shown in B and F. Compared 
with the untreated cells (A), treatment of U0126 in pRESYFP transfected cells showed 
no effect on the localisation of YFP (C). In YFP-ERK transfected cells, nuclear 
localisation of YFP-ERK was seen in U0126 untreated cells (E); treatment of U0126 
led to loss of the nuclear localisation of YFP-ERK, YFP-ERK was distributed in 
cytoplasm (G). The merged image showed that in YFP-ERK transfected cells, the 
nucleai' region is completely dai'k in the presence of U0126 (H), and the localisation of 
YFP was not affected by the treatment of U0126 (D). Dashed arrows point to the 
untransfected, and solid arrows points to the transfected cells. Scale bar =25p,m
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transfected REF52 cells were plated on fibronectin or ti'eated with EGF to examine 
whether ERK activity of YFP-ERK can be triggered by integrin engagement or RTK 
activation. As shown in figure 3.5, cells replated on fibronectin or treated with EGF 
showed significantly higher ERK activity (Fig 3.5, FN and EGF) than control cells 
plated on uncoated (Fig3.5, CON) or poly-L-lysine coated (Fig3.5, PEL) culture dishes. 
The activity of YFP-ERK was reduced nearly to the backgi’ound level by treatment of 
U0126 (Fig 3.5, FN+UO and EGF+UO), indicating that the YFP-ERK has its ERK 
activity, which is sensitive to U0126. This result suggested that the ERK activity of 
YFP-ERK could be stimulated by either integrin-mediated and growth factor-initiated 
signalling events. The activation of YFP-ERK triggered by EGF receptor is stronger 
than that induced by integrin, revealing the characteristics of overexpressed YFP-ERK is 
consistent with wild type or endogenous ERK (Morino et aL, 1995).
3.2.5 Adhesion time course
The ERK activity of YFP-ERK fusion protein was sufficient to be detected by 
immunoblotting and MBP activity assay. However, to study the role of ERK in the 
cytoplasm, the visualisation of YFP-ERK in adhesion sites is required. In the YFP-ERK 
ti'ansfected cells, the overexpressed YFP-ERK was diffuse all over the cell body and no 
adhesion-like structure could be recognised (Fig 3.2 A). The formation of focal 
adhesions and the activation of ERK has been determined in REF52 cells (Fincham et 
al., 2000). The YFP-ERK here has been determined to be a functional ERK. Thus, lack 
of visualisation of adhesion structures in the YFP-ERK ti'ansfected REF52 cells might be 
because the adhesion sites were difficult to recognise when YFP-ERK protein was 
expressed at very high levels and diffuse all over the cell body in the REF52 cells.
To address to this question, the YFP-ERK ti'ansfected REF52 cells were replated onto 
laminin coated glass coverslips and the change in localisation of YFP-ERK was 
monitored during cell adherence over 1-16 hours. As shown in figure 3.6 D, YFP-ERK 
transfected cells 16 hours after the transfection procedures; the nuclear localisation of 
YFP-ERK suggested that it was activated. In this state, no or very little adhesion was
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Figure 3.5 MBP-ERK activity assay in YFP-ERK transfected REF52 cells
REF52 cells were transfected with YFP-ERK (2jlg/|al) following the standard procedure. 
The transfected cells were incubated overnight and resuspended in DMEM in absent of 
serum. These transfected cells were replated on uncoated (CON), 10|ag/ml poly-L-lysine 
coated (PLL) or 10|Xg/ml fibronectin coated (FN) culture dishes and incubated at 37°C 
for 2.5 Itr. For EGF tieatment, 20ng/ml EGF was added to the cells at the first hour 
replated on uncoated culture dish and the cells were then incubated at 37 “C for a further
1.5 hours (EGF). For U0126 tieatment, 50p.M U0126 was added to the cells replated 
on uncoated (CON+UO), FN coated (FN+UO) or to EGF treated (EGF+UO) cells and 
incubated at 37 °C for a further 30 minutes. The ERK kinase activity of YFP-ERK in 
cells plated on FN (FN) and treated with EGF (EGF) is significantly higher than in the 
control cells. The ERK activity of YFP-ERK is reduced nearly to the background as a 
result of U0126 tieatment (CON+UO, FN+UO and EGF+UO) Kinase assays were 
carried out in triplicate for each sample. The assay was repeated twice in different 
transfections. Data shown are the mean +SD.
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Figure 3.6 Adhesion timecourse of YFP-ERK transfected REF52 cells
YFP-ERK (2^ig/ml) were transfected into REF52 cells following the standard procedure. 
The transfected cells incubated overnight were replated onto laminin-coated coverslips 
and incubated at 37°C for 4 hour in DMEM (A-C) or incubated at 37 for 16 hours in 
DMEM with 10% FBS (D). The coverslips incubated in serum free DMEM were fixed 
after 1, 2 and 4 hours during spreading and the coverslips incubated in serum containing 
DMEM were collected at 16 hours. The coverslips were fixed with 3.7% formaldehyde. 
After 1 hour, transfected cells had attached to the laminin. Some lamellipodia-like 
structures had staited to form at the cell periphery (A arrow). YFP-ERK based 
adhesion-like structures appeared after 2 hours (B arrows). The numbers of these 
structures are increased to maximal levels after 4 hours (C arrows). YFP-ERK was 
disti’ibuted all over the cell and no adhesion structure could be recognised after 16hr 
incubation (D). The scale bai' = 25p,m
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found in the well-spread ti'ansfected cells. However, adhesion-like structures are found 
during cell spreading (Fig A-C). One hour after spreading, some membrane ruffling and 
lamellipodia-like structures are formed in the cell periphery (Fig 3.6 A, arrows). 
Adhesion-like structures were found after 2 hours (Fig 3.6 B arrows), and the number of 
these structures maximised after 4 hours (Fig 3.6 C, aiTows). The time-lapse images of 
the translocation of YFP-ERK revealed that YFP-ERK does localise at the adhesion-like 
site during cell spreading. However, after 4 hours when the cell giadually came to a 
well-spread state, active and inactive YFP-ERK were present all over the cell, and the 
specific YFP-ERK-based adhesion-like structures were no longer recognisable.
3.2.6 Localisation of ERK at focal adhesion sites in REF 52cells
To further examine the adhesion structures foi-med in the REF52 cells expressing YFP- 
ERK during spreading, the YFP-ERK expressing cells were costained with anti-talin, 
which is a focal adhesion structure protein widely used as a maker of focal adhesion 
(Belkin and Smalheiser, 1996). As shown in figure 3.7, the YFP-ERK-based adhesion­
like structures in REF 52 cells (Fig 3.7 A, airows) were recognised by anti-talin antibody 
as well (Fig 3.7 B an'ows). The merged image of the adhesion site revealed that the 
YFP-ERK was not completely colocalised with talin at focal adhesion site (Fig 3.7 C, 
box). The closer examination of the this structure in the merged image showed that YFP- 
ERK is closer to the plasma membrane to talin staining, an overlap of approximately 
Ijuim was seen between YFP-ERK and talin (Fig 3.7 D), revealing that YFP-ERK 
localises at the tip of adhesion-like structures. It has been shown by immunostaining that 
active ERK is localised at the tip of talin-based focal adhesion sites in the newly fomiing 
leading edge in REF52 (Fincham, et aL, 2000). This staining pattern of talin and YFP- 
ERK is similar to that has been shown by Fincham and colleagues. However, these 
adhesion-like structures produced by YFP-ERK in REF52 cells do not appear to be 
typical adhesion structures. Therefore, it is necessai'y to determine whether YFP-ERK 
localised at the adhesion-like structure is expressed in an active form.
3.2.7 Activity of ERK at focal adhesion sites in ERF52
In an attempt to use the YFP-ERK consti’uct to study dystroglycan signalling, a method
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Figure 3.7 Colocalistion of YFP-ERK and talin in the adhesion sites in REF52 cells
YFP-ERK (2fxg/ml) was ti'ansfected into REF52 cells following the standard procedure. 
The transfected cells were replated onto laminin-coated coverslips and incubated at 37°C 
for 4 hour in DMEM (A-C). The coverslips were fixed with 3.7% formaldehyde and 
stained with anti-talin [(Sigma) at 1:1000]. At the fourth hour of cell spreading, YFP- 
ERK based adhesion structures were found most in one side of the cell (A arrows). 
These structures were stained by anti-talin antibody as well (B arrows). The merged 
image shows the localisation of YFP-ERK and talin are very close (C arrows). The 
magnified image showed that the YFP-ERK was not completely colocalised with talin 
(D). The scale bars =25 |am in C and =5 jam in D.
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to determine the activation of YFP-ERK in the adhesion sites is necessai'y. The anti- 
phospho ERK (NEB9105), which has shown to be very efficient for immunofluorescent 
staining of the active ERK, was used to detect the activation of YFP-ERK in adhesion 
sites. As shown in figure 3.7, however, the staining of anti-phospho ERK at the adhesion 
sites in YFP-ERK transfected REF52 cells was very weak (Fig 3.8 B, arrows) while 
YFP-ERK is forming relatively clear adhesion-like structure in the cell periphery (Fig 
3.8 A, arrows). This result suggested that either the antibody we were using might not 
sufficient to detect the phosphorylation of the activity of YFP-ERK in vivo by 
immunofluorescent staining, or the YFP-ERK might not be activated at these adhesion­
like sites.
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Figure 3.8 Phospho-spedfic ERK antiserum staining of focal adhesions in YFP- 
ERK transfected REF52 cells
YFP-ERK (2jig/ml) was transfected into REF52 cells following the standard procedure. 
The transfected cells were replated onto laminin-coated coverslips and incubated at 37°C 
for 4 hour in DMEM (A-C). The coverslips were fixed with 3.7% formaldehyde and 
stained with anti-pY ERK [(NEB) at 1:100]. At the fourth hour of spreading, YFP-ERK 
was localised at the adhesion sites in the cells (arrows, A). Extremely weak phospho- 
ERK was stained at the same adhesion sites (arrows, B). The scale bars =25|im
6 6

3.3 Discussion
To investigate whether dysti'oglycan is involved in the integrin-mediated ERK- 
dependent activation of MLCK, YFP-tagged ERK was constructed and expressed in 
REF52 cells. The ERK kinase activity assay of YFP-ERK which were carried out by 
using U0126 inhibition, western blotting assay and MBP-ERK kinase activity assay has 
shown that YFP-ERK is expressed as a functional ERK in RBF52 cells. The localisation 
of YFP-ERK was clearly visible in the REF52 cells. Compaied with the localisation of 
YEP, YFP-ERK was more concentrated at the nucleus, indicating the YFP-ERK is an 
active kinase. Additionally, the MBP ERK activity assay showed that both EOF and 
fibronectin could induce the activation of YFP-ERK, indicating that the activity of YFP- 
ERK is upregulated by either integrin-mediated or RTK-induced pathway. Together this 
suggested that the recombinant YFP-ERK in REF52 cells behaves like the wild type 
ERKs. Thus, the YFP-ERK construct could successfully produce an YFP-tagged 
functional ERK in REF52 cells.
3.3.1 Regulation of expression and activation of YFP-ERK
On western blotting, most endogenous ERK 1/2 in REF 52 cells was detected as the 
active form (Fig 3.3 A lower panel and C lower panel). However, compared with the 
total expression of YFP-ERK, only a small amount of YFP-ERK is activated (Fig 3.3 A 
upper panel and C upper panel). This result revealed that despite overexpression of 
YFP-ERK in the REF52 cells, only a constant amount of ERK was activated, implying 
a feed-back regulation might exist between ERK and its upstream regulators to control 
the activation of ERK. ERK is an important signalling molecule that enhances the cell 
adhesion, proliferation and survival signalling events, overexpression of ERK appealed 
to be lethal to the cells (section 3.2.1). Thus, a mechanism that regulates active ERK at 
a constant level in cells might be necessary. It has been shown that activation of integrin 
was suppressed by the activation of Ras-induced ERK cascade (Hughes et a l, 1997), 
supporting the idea that a negative regulation of ERK by its upstream regulator might be 
able to maintain the active ERK in a constant level. Additionally, a series of scaffold 
proteins of ERK cascade mediators was identified in yeast (reviewed in Pryciak, 2001).
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In mammalian cells, scaffold protein MP-l (MEK Paitner-1) binds specifically to 
MEK-1 and ERK-1 to form a protein complex that enhances the activation of ERK 1/2 
and its downstream signalling (Schaeffer et a l, 1998). KSR-1 (Kinase Suppressor of 
Ras) was shown to bind MEK and ERK (Therrien, et al, 1996). Activation of Ras has 
been shown to lead to the conformational activation of Raf, thereby recruiting KSR-1 
along with MEK and ERK to the membrane region (Yu et a l, 1998). Overexpression 
of KSR inhibited ERK-dependent biological effects (Cacace et a l, 1999). Such a dose- 
dependent reversal of effect is typical for a scaffold protein that can only assemble its 
target protein when present in an appropriate stoichiometiic ratio, but disperses the 
signalling complexes when overexpressed (Walter, 2000). Thus, although the regulation 
mechanism of MP-1 and KSR remains unclear, it is likely that the constant amount of 
activation of ERK is regulated by the interaction of ERK cascade mediators with 
scaffold proteins.
3.3.2 Traiislocatioii of YFP-ERK
Initially, YFP-ERK was consü'ucted to visualise the activation of YFP-ERK at focal 
adhesion sites. However, in REF52 cells, no YFP-ERK based-adhesion was found until 
the transfected cells were replated onto laminin. The time-lapse experiment showed that 
YFP-ERK-based adhesion-like structures were forming during 1-4 hours after replating. 
Interestingly, the result also showed that very little YFP-ERK was localised in the 
nucleai’ region during this period, indicating that activation of YFP-ERK for 
cytoplasmic function might be taking place earlier than that for mitogenesis during the 
cell spreading. It has been shown that the adhesion dependent activation of ERK was 
continually maintained at a constant level within few hours after cell spreading whereas 
the mitogen-dependent ERK activation increased rapidly and decreased to a level nearly 
equal to background levels within minutes (Pouyssegur et a l, 2002). Thus, the YFP- 
ERK expressed in REF52 cells in 1-4 hour during spreading might not be involved in 
the mitogenesis but involved in cytoplasmic focal adhesion signalling regulation in the 
first 4 hours after the replating.
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YFP-ERK accumulates in the nucleus as a result of long-term expression (Fig 3.2 A). 
Figure 3.2 A clearly showed that YFP-ERK is localised in the nucleus as a long-term 
effect of expression of YFP-ERK. In serum-starved NIH 3T3 cells, the nuclear 
accumulation of active ERK was increased maximally within 10 minutes after serum 
stimulation, and the nucleai' accumulation of ERK was reduced gradually within 2 hours 
until the ERK accumulation level in the nucleus was reduced neaiiy equal to the 
backgi'ound, indicating the ERK activation for mitogenesis takes place within 10 
minutes after stimulation. However, under the same conditions, total ERK started to 
translocate to the nucleus within 10 minutes and continued to accumulate, reducing the 
maximal level after 3 hours (reviewed in Pouyssegur et a t, 2002). This nuclear 
accumulation of ERK remained at a high level for 6 hours. These ERK tianslocation 
studies suggested that both active and inactive ERK are able to translocate to the 
nucleus; the translocation of ERK to the nucleus might be in an ERK activation- 
independent manner. In this study, we therefore do not know if the YFP-ERK localised 
at the nucleus is either the active or inactive form of ERK. The activation of YFP-ERK 
could not be determined by its translocation to nucleus.
3.3.3 Localisation of YFP-ERK at focal adhesion sites
The YFP-ERK-based adhesion-like structures formed during spreading were not 
completely colocalised with talin. The staining pattern of talin with YFP-ERK in the 
adhesion-like structures was similar to that shown by Fincham and colleagues (Fincham 
et al, 2000). However, no active YFP-ERK was found using anti-phospho ERK 
antibody at the adhesion sites by immunofluorescent staining. The western blot activity 
assay of YFP-ERK and endogenous ERK showed that most of the endogenous ERK in 
REF52 cells was active while only a very small amount of YFP-ERK, which was 
expressed in a fairly high level, was active (Fig 3.3). This suggested that the 
overexpression of YFP-ERK in the REF52 cells, MEK, the direct activator of ERK, 
might tend to interact with endogenous ERK rather than the highly expressed 
recombinant YFP-ERK. Therefore, despite the high expression, only a little of YFP- 
ERK could be activated in the ERK cascade. This might explain the failure of the 
phospho-ERK staining at YFP-ERK based adhesion sites.
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Additionally, the distribution and moiphology of YFP-ERK-based adhesion structures 
do not seem like the typical focal adhesion structures although some of them aie 
colocalised with talin. Moreover, perhaps due to the strong expression and lack of the 
control by other signalling molecules, the YFP-ERK tends to diffuse tiii'oughout the 
whole cell body and make the adhesion-like structures become difficult to distinguish. 
Initially, YFP-ERK was constructed in an attempt to visualise the localisation of active 
ERK in the cytoplasmic compartment and for the further study of dystroglycan and 
MLCK dependent actin regulation. Unfortunately, these disadvantages suggested that 
YFP-ERK might not be a perfect tool for these studies. However, due to the visible 
nuclear* translocation and the biological activity, the YFP-ERK construct still could be a 
useful tool for studying of the activation and translocation of ERK in mitogenesis.
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Chapter4
Expression of GFP-tagged dystroglycan and dystroglycan functional
domain deletion mutants
/
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4.1 Introduction
In order to investigate the relationship between dystroglycan and ERK at focal adhesion 
sites, YFP-ERK and dystroglycan-GFP expression vectors were constructed. As shown 
in chapter 3, YFP-ERK was poorly localised at focal adhesion sites, revealing that the 
YFP-ERK construct might not be useful for the study of localisation of ERK at focal 
adhesions and the further study of dystroglycan signalling. Here, the dystroglycan-GFP 
(a|3DG-GFP) was constructed and expressed in REF52 cells. The expression of a(3DG- 
GFP, however, surprisingly greatly altered the organisation of the cytoskeleton resulting 
in the formation many microspikes in REF52 cells, indicating that dystroglycan may act 
as a mediator of filopodia formation. Thus, the work has shifted to this interesting topic: 
the function of dystroglycan in the formation of micro spikes. First of all, it was 
determined that the filopodia formation and the filopodia phenotype is in response to the 
expression of dystroglycan. Then, a series of GFP-tagged dystroglycan functional 
domain deletion mutants were constructed and expressed in REF52 cells to determine 
which functional domains of dystroglycan are responsible for the filopodia formation. 
The filopodia phenotype induced by each dystroglycan mutant construct was observed. 
Finally, the dystroglycan dependent cytoskeleton reorganisation signalling will be 
examined and discussed in chapter 5.
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4,2 Result
4.2.1 Construction of GFP-tagged dystroglycan and functional domain deletion 
mutants
aP-dystroglycan is expressed as 859 a.a. propeptide in cells. This propeptide undergoes 
post-translational modification to generate mature a -  and (3-dystroglycan, and the 
mature a  and (3-dystroglycan aie presented on the plasma membrane. Functional 
domains on dystroglycan have been determined (fig 1.2) (Ibraghimov-Beslaovnaya et ai, 
1992). In this study, a/(3dystroglycan is delineated as 5 functional domains: N-terminal 
signal sequence (SS; l-28a.a), a-dystroglycan (a; 29-653a.a), extracellular domain of |3- 
dystroglycan (e(3; 654-750a.a), transmembrane domain of p-dystroglycan (TM; 751-774) 
and cytoplasmic domain of P-dystroglycan (cP; 775-893) (Fig 4.1 A). Full-length mouse 
dysti'oglycan cDNA (2679 bp.) was subcloned between the Sail and Smal sites in the 
pEGFP mammalian expression vector. GFP was conjugated at the C-terminus of the 
dystroglycan. For construction of GFP-tagged dystroglycan functional domain deletion 
mutants see figure 4.1 B.
4.2.2 Ëxamination of GFP-tagged dystroglycan construct (apDG-GFP) in REF52 
cells
4.2.2.1 Expression o f apDG-GFP in REF52 cells
The concentration of apDG-GFP (1.8 fxg/ml) used for transfection was modified for 
REF52 cells to achieve the highest transfection efficiency and the lowest cell death. The 
transfection efficiency of apDG-GFP obtained in REF52 cells was 15-20 % on average. 
Compared with the cells expressing GFP empty vector that showed a very smooth cell 
periphery (Fig 4.2 A), the cells expressing apDG-GFP presented many long and thin 
microspikes tlrroughout the plasma membrane (Fig4.2 C-E), These microspikes also 
presented on cell surface (Fig 4.2 C, arrows). Some of these microspikes were clustered 
together forming a crown-like structure (Fig 4.2.D arrows). Transfection of apDG-GFP 
construct has altered certain signalling events leading to this moiphology change.
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Figure 4.1 Construction of dvstroglvcan-GFF and dystroglycan functional domain 
deletion mutants
(A), Dystroglycan has five distinct functional domains. From N-terminus; SP: N-terminal 
signal peptide, 1-28 a.a.; a: a  dystroglycan, 29-653 a.a.; e^: extracellular domain of P- 
dystroglycan, 654-750 a.a.; TM: ti'ansmembrane domain of p dystroglycan, 751-774 a.a.; 
cp: cytoplasmic domain of P-dystroglycan, 775-893 a.a. (B), The GFP-tagged 
dystroglycan and dystroglycan functional domain deletion mutants. GFP (220a.a) is 
conjugated at the C-terminal of dystroglycan or dystroglycan mutants. aPDG-GFP: Full- 
length a- and P-dystroglycan (893a.a). apAcPDG-GFP: p-dystroglycan cytoplasmic 
domain (cp; 121a.a) deletion mutant. cPDG-GFP: GFP-tagged 121a.a p-dystroglycan 
cytoplasmic domain. pDG-GFP: GFP-tagged full-length P-dystroglycan (242a.a). 
aPAoDG-GFP: a-dystroglycan (625a.a) deletion mutant; full-length p-dystroglycan is 
directly fused at the C-terminal of signal peptide (SP, 29a.a). aPAePDG-GFP: P- 
dystroglycan extracellulai* domain (97a.a) deletion mutant. oDG-GFP: GFP-tagged full- 
length p-dystroglycan deletion mutant; a-dysti'oglycan with its N-terminal SP sequence 
were fused at the N-terminal of GFP. All deletion mutants were cloned between Sail and 
Smal sites in pEGFP (N-3) vector. An extra alanine was added at the C-terminal end to 
accommodate the Smal restriction site.
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Figure 4.2 Expression of DG-GFP construct in REF52 cells
REF52 cells were transfected with apDG-GFP (1.8|ag/ml) construct (C-E), or pEGFP 
empty GFP vector (A); or the negative control, which was treated with equal amounts of 
lipofectamine as transfected cells but with no DNA (B). The transfected cells on glass 
coverslips were incubated at 37°C overnight after the standard transfection procedure. 
The coverslips with cells were fixed with 3.7% formaldehyde. Many long and thin 
microspikes were found in the cells transfected with apDG-GFP (C-E). These 
microspikes also distributed on the surface (C, arrows) of the cells. Some of these 
microspikes were clustered as a crown-like structure (D, arrows). The pEGFP empty 
vector (2jig/ml) transfected cells showed typical GFP expression and nuclear 
accumulation, cell body diffusion (A) and smooth cell periphery (A, arrow). No 
fluorescence localisation was identified in the negative control except for the 
background autofluorescence from the lipofectamine transfection reagent (B). Scale 
bar=25p,m
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This unexpected change of morphology in apDG-GFP transfected cells has raised 
several questions. First, what are these micro spikes present in a^DG-GFP transfected 
cells, and do these structures correspond to actin reanangement? Second, which factor in 
apDG-GFP transfected cells induces the change of morphology? Does dystroglycan 
mediate the formation of these microspikes? Third, if it does, which functional domain 
of dystroglycan is responsible for the formation of microspikes? Fourth, if cytoskeleton 
reorganisation is involved in the formation of the microspikes, what is the signalling 
pathway? Do small Rho GTPases or other integrin-dependent signalling, such as ERK 
signalling play a role in this morphology change?
4.2,2,2 Filopodia formation o f a ^ G -G F P  transfected REF52 cells on Laminin
To address the question of whether the change of moiphology was induced by 
expression of dystroglycan and to further investigate these microspikes in a^DG-GFP 
transfected cells, ot^DG-GFP transfected cells were replated onto laminin, which is a 
substrate for dystroglycan, and the actin-containing structures stained with rhodamine- 
conjugated phalloidin. As shown in figure 4.3, after incubating in DMEM containing 1% 
FBS overnight on laminin, all the tiansfected cells were well spread. Numerous 
branching microspikes were expressed throughout the periphery of aPDG-GFP 
transfected cells (Fig 4.3 A). In contrast, the pEGFP empty vector transfected cells 
incubated in the same conditions on laminin showed a smooth cell periphery (Fig 4.3 B). 
Upon actin staining, remarkable actin-rich rings were found in the cell cortex forming a 
doughnut-like actin structure (Fig 4.3 B). Based in the actin-rich cortex region, the actin 
bundles protruded outward from the cell body and extended into each microspike (Fig 
4.3C). The magnification of the merged images at the microspikes (Fig 4.3 D) indicated 
that the microspikes present in apDG-GFP transfected cells are branching fibre-like 
actin-rich structure, a so called filopodia. Normal stress fibre actin phenotype was seen 
in pEGFP transfected REF52 cells (Fig 4.3 F), as well as that in untransfected REF52 
cells (data not shown), revealing the ring-like and the filopodia actin phenotype might be 
induced by expression of dystroglycan.
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Figure 4.3 Expression of aB DG-GFP in REF52 on laminin
aP DG-GFP (L8p.g/ml) or pEGFP (2p,g/ml) empty vector transfected REF52 cells were 
replated on to laminin (2jj,g/ml) coated coverslips and incubated in DMEM containing 
1% FBS at 37°C for overnight. Cells were fixed with 3.7% formaldehyde and stained 
with rhodamine-phalloidin [(Sigma) at 1:1000]. Plenty of branching micro spikes were 
expressed in the periphery of ocp DG-GFP transfected cells (A). Remarkable ring-like 
actin rich structures were present in the cell cortex region in apDG-GFP transfected 
cells (B), while stress fibre actin phenotype was found in pEGFP empty vector 
transfected cells (E and F). The merged image show that the microspikes expressed in 
apDG-GFP transfected cells are actin-rich structures (C). In the magnified images (D), 
these actin filament, based in the ring-like structure in cortex, extended into each branch 
of the microspike and are expressed throughout the cell body. These structures are very 
like filopodia. The filopodia structure was not seen in pEGFP transfected cells (E-G). 
The scale bars in D = 5pm. Others =25pm.
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Compared with the apDG-GFP transfected cells shown in figure 4.2 C-E, no significant 
increase in filopodia number was observed in the pEGFP transfected cells replated on 
laminin. However, the morphology of filopodia present in a^DG-GFP transfected cells 
was more organised both in size and in length, implying that in the apDG-GFP 
transfected cells, laminin engagement might play a role in the arrangement of the 
filopodia. To further examine whether the formation of filopodia resulted from the 
expression of dystroglycan, the filopodia formation was monitored in ocPDG-GFP or 
pEGFP empty vector transfected cells replated on laminin. The number of cells with 
filopodia was counted at 1, 3, 5, and 7 hours; the cells presenting more then 30 
microspikes were counted as filopodia positive. As shown in figure 4.4, after one hour of 
spreading, nearly 82% of apDG-GFP transfected cells were filopodia positive (Fig 4.4, 
blue circles), while only half the number of pEGFP transfected cells were filopodia 
positive (Fig 4.4, red square). However, in the pEGFP transfected cells, the number of 
filopodia positive cells increased to 70%, which was very close to a(3DG-GFP 
transfected cells, at the third hour, this number dropped dramatically until less than 10% 
at 7 hours (Fig 4.4, red curve). In contrast, the number of filopodia positive cells in 
apDG-GFP transfected cells was almost constant between 79-80% during the 7 hours 
(Fig 4.4, blue curve), suggesting that expression of «POG-GFP leads to the formation of 
filopodia, which are normally present within the first 3 hours of cell spreading. Thus, the 
filopodia formation did indeed result from the expression of dystroglycan, not from GFP.
4.2,23 Examination o f utrophin in a^DG-GEP transfected REF52 cells 
In non-muscle cells, utrophin is the molecule that directly interacts with dystroglycan 
and connects it to actin filaments (Ervasti and Campbell, 1993; Winder et al, 1995). 
Phosphorylation of the P-dystioglycan cytoplasmic tail leads to the reduction of binding 
affinity between utrophin and P-dystroglycan (James et a l, 2000). Therefore, utrophin is 
possibly a mediator of dystroglycan-dependent filopodia formation. In an attempt to 
determine whether utrophin is a mediator of dystroglycan-dependent filopodia 
formation, we first examined the utrophin expression in ocpDG-GFP transfected cells. As 
shown on the western blot in figure 4.5, an approximately 70KDa GFP-tagged PDG was
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Figure 4.4 Quantification of the filopodia formation in aBDG-GFP transfected cells 
on laminin
Monitoring the formation of filopodia in aPDG-GFP or pEGFP transfected REF52 cells, 
the transfected cells were replated onto laminin (2p,g/ml) coated coverslips and incubated 
at 37 °C in DMEM. Coverslips with cells were fixed after one, three, five and seven 
hours; and the number of cell with filopodia (more than 30 filopodia) was counted. In aP 
DG-GFP transfected cells, the number of filopodia positive cells is steady between 79- 
82% within the 7 hours (blue curve), while the pEGFP transfected cells (red curve) 
reached 72% by the 3rd hour and then quickly dropped down until less then 10%. The 
counting was repeated twice at each time point in two transfections. Data are means ± 
SD.
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Figure 4.5 Expression of utrophin in dystroglycan overexpressed REF52 cells
Western blotting of apDG-GFP, pEGFP empty vector transfected and untransfected 
REF52 cells. Cell lysates were blotted with anti pDG antibody ((3DG-1710) at the 
concentration of 1:1000, anti-GFP antibody at the concentration of 1:1000, or anti C- 
terminus utrophin (Rab6) at the concentration of 1:10000. Overexpression of a^DG-GFP 
or GFP protein did not alter the expression of 43KDa endogenous PDG, which was 
detected by anti pDG-1710 antibody (A lower panel). 70KDa PDG-GFP fusion protein 
was detected by anti-PDG (A, upper panel) or anti-GFP antibody in «PDG-GFP 
transfected cells (B upper panel). Utrophin expression (C), is not affected by 
overexpression of «P DG-GFP or pEGFP.
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detected by anti GFP antibody (Fig 4.5 A upper panel) or anti [3DG 1710 antibody (Fig
4.5 B upper panel) in a^GD-GF? transfected cells. However, expression level of 
utrophin was not affected by overexpression of aPGD-GFP or GFP (Fig 4.5 C), 
revealing that utrophin expression is not regulated by overexpression of dystroglycan.
To further determine the role of uti’ophin in dystroglycan-dependent filopodia formation, 
we transfected a^DG-GFP construct into utiophin-knockout mouse embryonic 
fibroblast primary culture. As shown in figure 4.6, the filopodia phenotype was present 
in aPDG-GFP transfected utrophin knockout mouse embryonic primary culture (Fig 4.6 
D), as well as the wild type mouse embryonic primary culture (Fig 4.6 C), indicating that 
utrophin might not be involved in the dystroglycan-dependent filopodia formation. 
Transfection of GFP empty vector did not cause the formation of filopodia whether in 
utrophin knockout or wild type cells (Fig 4.6, A and B), suggesting that dystroglycan is 
responsible for the formation of filopodia. At the same time, the effect of dystroglycan in 
utrophin wild type and knockout cells was measured by counting the number of cells 
presenting filopodia phenotype (Fig 4.6 E). No significant difference in dystroglycan- 
dependent filopodia formation was seen between utrophin wild type and knockout cells 
(Fig 4.6 E, green columns), indicating that the defect in utrophin expression has no 
influence on the dystroglycan-dependent filopodia formation. Therefore, despite linking 
dystroglycan physically to the cytoskeleton, utrophin is not a mediator of dystroglycan 
dependent filopodia formation, nor required for it.
4.2.3 Expression of cp deletion mutant construct (apAcP-GFP) in REF52 cells
In the experiments above, expression of dystroglycan has been shown to induce the 
formation of filopodia. Experiments were canied out to further determine which 
functional domain of dystroglycan was responsible for the filopodia formation 
signalling. Since the cytoplasmic domain of P-dystroglycan has been shown to associate 
with cytoskeleton related signalling molecules (section 1.4), it is the best candidate 
domain that may mediate the signalling events of dystroglycan-dependent filopodia 
formation. In an attempt to determine the role of P-dystroglycan cytoplasmic domain in
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Figure 4.6 Expression of dystroglycan GFP in utrophin null cells
Utrophin wild type or utrophin knockout mouse embryo fibroblast primary culture were 
transfected with apDG-GFP (1.8|Ag/ml) (C and D) or pEGFP (2|ag/ml) (A and B). The 
cells were tiansfected on glass coverslips and then incubated at 37°C overnight after the 
transfection procedure. Coverslips with cells were fixed with 3.7% formaldehyde. The 
cells with more than 30 microspikes were identified as filopodia positive. In cells 
transfected with apDG-GFP, the filopodia phenotype was present in utrophin wild type 
(C) as well as in utrophin knockout cells (D); both utrophin wild type and knockout cells 
showed fairly high number of filopodia positive cells (80% and 82%) (E, green 
columns). The transfection of pEGFP did not induce the formation of filopodia in 
utrophin wild type or knockout cells (A) with less then 10 % of utrophin wild type or 
knockout cells with the filopodia phenotype (E, red columns). The counting was 
repeated twice in two different ti'ansfections. Data aie mean + SD. The scale bars= 25|Lim.
8 2
pEGFP apDG-GFP
UTR+/+
U T R /
Filopodia formation in utrophin knock-out 
cells transfected with a^DG-GFP
I
5
s
Ioc
£8
O
25
100
90
80
70
60
50
40
30
20
10
0
kÜwCL
UTR +/+
euk OnÜ kÜ ÜÛ woa CL0
UTR -/-
dystroglycan- dependent filopodia formation, the construct of GFP-tagged 
P dystroglycan cytoplasmic domain deletion mutant (apAcp-GFP) was expressed in 
REF52 cells. As shown in figure 4.7 A and B, most of the aPAcp-GFP ti’ansfected cells 
plated on glass coverslips had a smooth cell periphery. Replating the ti’ansfected cells on 
laminin, revealed no significant induction of filopodia (Fig 4.7 C). Instead of the ring­
like actin structure, fairly high number of actin stress fibres, as has been shown in 
pEGFP transfected cells (Fig 4.3 F), was present in aPAcp-GFP transfected cells (Fig
4.7 D). Therefore, the dystroglycan dependent filopodia formation appeared to be 
inhibited by the absence the cytoplasmic domain of P-dystroglycan.
4.2.4 Substrate effects on dystroglycan dependent filopodia formation
Since adhesion dependent tyrosine phosphorylation of dystroglycan has been reported to 
regulate the affinity between p-dystroglycan and the utrophin WW domain (James, et al., 
2000), adhesion dependent signalling might be involved in the dystroglycan dependent 
cytoskeleton reorganisation. Additionally, in vivo formation of filopodia is induced by 
integrin mediated Cdc42 activation (Kozma et al, 1995). Therefore, despite utrophin not 
mediating the dystroglycan-dependent filopodia formation, it is possible that integrin 
dependent or adhesion dependent signalling is involved in the dystroglycan dependent 
filopodia formation. To determine whether integiin is required for dystroglycan 
dependent filopodia formation, we replated the transfected cells onto fibronectin, which 
is a ligand for integrin, or poly-L-lysine, which prevents integrin from activation, and 
monitored the morphology change in apDG-GFP or aPAcp-GFP transfected cells. As 
shown in figure 4.8 A, after incubation in serum free DMEM for 4 hours, filopodia 
phenotype was present in aPDG-GFP transfected cells plated on laminin (Fig 4.8 A), as 
well as on fibronectin (Fig 4.8 B), while the cells were not spread on poly-l-lysine (Fig
4.8 C) or uncoated glass control (Fig 4.8 D). In contrast, whether plating on laminin or 
fibronectin, the filopodial phenotype was not induced by expression of GFP in the cells 
(Fig 4.8 E and F).
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Figure 4.7 Expression of B dystroglycan cytoplasmic domain deletion mutant
aBAcB-GFP I
aPAcP-GFP (1.8|ag/ml) was transfected into REF52 cells plated on glass coverslips
following the standai’d transfection procedure (A and B). The a|3AcP-GFP transfected 1
cells were replated onto laminin coated coverslips and incubated in DMEM containing i
1%FBS at 37 °C overnight (C). The cells were fixed with 3.7% formaldehyde, and the |
cells replated on laminin were further stained with rhodamine-phalloidin [(Sigma) at 
1:1000]. Expression of aj3Ac(3-GFP did not induce the formation of a filopodial |
phenotype in REF52 cells (A and B). The apAcp-GFP transfected cells replated on I
laminin showed no induction of filopodia either (C). Stress fibre actin phenotype was j
present in the «PAcP-GFP transfected cells (D). (E), merged image of apAcp-GFP and 
actin. Scale bar= 25|im
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Figure 4.8 Formation of fiiopodia in aBDG-GFP transfected cells on extracellular 
substrates
REF52 cells transfected with a(3DG-GFP (1.8|ig/ml) or pEGFP (2.0jig/ml) were replated 
onto glass coverslips or glass coverslips coated with laminin (2p-g/ml), fibronectin 
(2|ig/ml) or poly-L-lysine (2p,g/ml) and incubated at 37°C in serum free DMEM for 5 
hours. The coverslips with cells were fixed with 3.7% formaldehyde. a|3DG-GFP 
transfected cells can spread well on laminin or fibronectin and present a fiiopodia 
phenotype (A and B). Whether on laminin or fibronectin, apAcp-GFP transfected cells 
can also spread well, but no induction of fiiopodia phenotype was found (E and F). 
Wliether transfected with aPDG-GFP or aPAcP-GFP, cells were unable to spread on 
poly-L-Lysine (C and G) or on uncoated glass coverslips (D and H) in the absence of 
serum. The scale bai-25p,m.
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Counting the number of fiiopodia phenotype positive cells on the substrates reveals a 
similarly high percentage of fiiopodia positive cells (70% and 68%) in apDG-GFP 
transfected cells plated on laminin and on fibronectin (Fig 4.9, green columns). The 
formation of fiiopodia was reduced in aPAcP~GFP ti'ansfected cells, and the percentage 
of fiiopodia positive cells in aPAcP-GFP transfected cells on laminin and on fibronectin 
was very similar (22% and 21%); (Fig 4.9, red columns). Therefore, the dystroglycan 
dependent fiiopodia formation appeared not to be specific for laminin engagement to 
dystroglycan; fibronectin can induce the dystroglycan dependent fiiopodia formation as 
well. The disruption of integrin engagement inhibited the foraiation of fiiopodia (Fig 4.8 
PLL and GLA). Since both laminin and fibronectin aie extracellular ligands of integiins, 
the dystroglycan dependent fiiopodia formation, which was considered to be mediating 
cy to skeleton reorganisation signalling via its cytoplasmic domain, seems more likely to 
be dependent on integrin-mediated cell adhesion instead of dystroglycan-laminin 
engagement. Thus, more evidence supporting P-dystroglycan cytoplasmic domain 
mediates the formation of fiiopodia is required.
Additionally, compared with approximately 70% of a(3DG-GFP transfected cell 
presenting a fiiopodia phenotype, a|3Acp-GFP transfected cells showed a significant 
reduction of fiiopodia formation (Fig 4.8, LN). Obviously, the (3-dystroglycan 
cytoplasmic domain plays an important role in the dystroglycan dependent fiiopodia 
formation. However, it could not be ruled out that approximate 20% of apAc(3“GFP 
transfected cells still are expressing more the 30 microspikes. It is likely that in addition 
to |3-dystroglycan cytoplasmic domain, other factors may participate in dystroglycan- 
dependent fiiopodia formation as well.
4.2.5 Expression of cP dystroglycan construct (cPDG-GFP) in REF52 cells
To further examine how P-dystroglycan mediates the formation of fiiopodia, GFP- 
tagged P-dystroglycan cytoplasmic domain alone was transfected into REF52 to see if it 
can induce the formation of fiiopodia. Interestingly, while the expression of apAcp-GFP 
has shown that p-dystroglycan cytoplasmic domain is required for the formation of the
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Figure 4.9 Substrate effects on dvstroglvcaii mutants transfected cells
REF52 cells transfected with apDG-GFP (1.8|ag/ml), pEGFP (2.0|ag/ml) or ocPAcP-GFP 
(2.0jj,g/ml) were replated onto glass coverslips or glass coverslips coated with laminin 
(2pg/ml), fibronectin (2p.g/ml) or poly-L-lysine (2jig/ml) and incubated at 37°C in serum 
free DMEM for 5 hours. The coverslips with cells were fixed with 3.7% formaldehyde. 
Cells with more than 30 microspikes are identified as fiiopodia positive. Nearly 70% of 
cells transfected with apDG-GFP had a fiiopodia phenotype on laminin (LN green 
column), and similar number (68%) was present on fibronectin (FN green column). On 
poly-L-lysine (PLL green column) or on uncoated glass coverslips (GLA green 
column), aPDG-GFP transfected cells were unable to spread and less than 10% of cells 
were fiiopodia positive. In apAcp-GFP transfected cells, number of fiiopodia positive 
cells was reduced to approximately 20% on laminin (LN red columns) and on 
fibronectin (FN red columns). apAcp-GFP transfected cells were unable to spread on 
poly-L-lysine or on uncoated glass coverslips, and less then 10% of cells were 
determined as fiiopodia positive (PLL and GLA, red columns). Less then 5% of pEGFP 
empty vector transfected cells presented fiiopodia (yellow columns). The counting(100- 
200 cells) was repeated for 4 times in each transfection. Data are mean +SD (n=4).
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Substrate effects on fiiopodia formation in aPGD-GFP and on 
aPAcp-GFP transfected REF52
90
Transfection
constructs
Substrates
2: & 2: &
8 t  I  8
CO. COL lUÜ Ü O.
ÊLt
L N
t |ea ca UJ g g Q.
F N
i  8:
8 I
*g
u. oo  a8o.
P L L
^
G L A
□□
aBDG-GFP 
oBAcB—GPP 
pEGFP
L N  Laminin 
F N  Fibronectin 
P L L  Poly-L-Lysine 
G L A  Uncoated glass coverslips
fiiopodia phenotype, cP-GFP, which contains only the cytoplasmic domain of p- 
dystroglycan, was insufficient to induce the fiiopodia phenotype (Fig 4.10 A and B). The 
cP-GFP in the cells localised not only in the cytoplasm but also at the nuclear region; in 
fact, the major pool of overexpressed cp-GFP appeared to be in the nuclear region. 
Interestingly, no particulai" nucleai" signal sequence on P-dystioglycan, has been 
reported, the nuclear import of cP might be caused by the transporting of its GFP tag. 
Replating the cp-GFP transfected cells on laminin did not induce any formation of 
fiiopodia phenotype (Fig 4.10 C). A normal actin stress fibre phenotype was found in the 
transfected cells (Fig 4.10 D and E).
The unexpected result that cp-GFP is insufficient to induced the formation of fiiopodia 
raised two possibilities: first, despite the cytoplasmic domain of p-dystroglycan 
mediating the formation of fiiopodia, contribution from other dystroglycan functional 
domains must be required for the p-dystroglycan cytoplasmic domain to interact with 
cytoskeleton reorganisation signalling molecules. Second, since cP-GFP localised to the 
nuclear region, it may have failed to induce any foimation of fiiopodia. It is likely that 
coiTect localisation of dystroglycan is important for dystroglycan to act as a mediator for 
fiiopodia formation.
4.2.6 Expression of P dystroglycan (pDG-GFP) construct in REF52 cells
If contributions from other functional domains are necessary for the PDG-dystroglycan 
cytoplasmic domain to mediate the formation of fiiopodia, which functional domain on 
dystroglycan would it be? In an attempt to determine which domain of dystroglycan is 
required, several dystroglycan functional domain deletion mutants were constructed. 
First, GFP tagged full-length P-dystroglycan (PDG -GFP), which lacks a-dystroglycan 
and the N-terminal signal peptide, was expressed in REF52 cells.
As shown in figure 4.11, relatively high amounts of PDG -GFP still localised to the 
nuclear region and did not induce the formation of fiiopodia (Fig 4.11 A and B). 
Compai'ed with the expression of cPDG -GFP shown in figure 4.10, PDG -GFP was
Figure 4.10 Expression of dvstroglvcaii cytoplasmic domain cB-GFP
cP-GFP (1.8pg/ml) was transfected into REF52 cells plated on glass coverslips following 
the transfection procedure and incubated at 37 °C overnight (A-B). The cp-GFP 
transfected cells were subsequently replated onto laminin (Ipg/ml) coated coverslips and 
incubated in DMEM containing 1% FBS at 37 °C overnight (C-E). The cells were fixed 
with 3.7% formaldehyde and cells replated on laminin were further stained with 
rhodamine-phalloidin [(Sigma) at 1:1000]. Expression of cp-GFP in REF52 cells did not 
induce fiiopodia formation, the overexpressed cP-GFP was concentrated mainly in the 
nucleus and slightly less in the perinuclear region (A and B). Fiiopodia phenotype was 
not found in cP-GFP transfected cells plated on laminin either (C). Stress fibre actin 
phenotype was present in cp-GFP transfected cells (D). (E), the merged image of cP-GFP 
(green) and actin (red). Scale bar=25p.m
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Figure 4.11 Expression of B dystroglycan. BDG-GFP. in REF52 cells
REF52 cells plated on glass coverslips were transfected with pDG-GFP (l.Spg/rnl) 
Following the transfection procedure, they were incubated at 37°C overnight (A-B). The 
PDG-GFP transfected cells were subsequently replated on laminin (2|u,g/ml) coated 
coverslips and incubated in DMEM containing 1% FBS at 37 °C overnight (C-E). The 
coverslips were fixed with 3.7% formaldehyde. PDG-GFP transfected cells replated on 
laminin were stained with rhodamine-phalloidin [(Sigma) at 1:1000]. Expression of 
pDG-GFP did not induce the formation of fiiopodia, the PDG-GFP concentrated mainly 
in the nuclear region and diffused around the perinuclear region (A and B arrows); very 
little of PDG-GFP was found in other regions of the cytoplasm. Replating the PDG-GFP 
transfected cells onto laminin did not induce the formation of fiiopodia (C). Actin stress 
fibre phenotype was present in PDG-GFP transfected cells (D), (E), The merged image 
of PDG-GFP (green) and actin (red). Scale bar=25|im.
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localised both in perinucleai' and cytoplasmic region of the cells. Again, replating the 
PDG "GFP transfected cells onto laminin did not induce fiiopodia foimation (Fig 4.11 C) 
or alter the stress fibre actin phenotype (Fig 4.11 D and E). Thus, even with extracellular 
and transmembrane domains of p-dystioglycan, the cytoplasmic domain still failed to 
mediate the formation of fiiopodia, suggesting the extracellular and transmembrane 
domains of p-dystroglycan might be insufficient to contribute cytoplasmic domain to 
mediate the formation of fiiopodia.
4.2.7 Expression of a-dystroglycan deletion mutant construct (aPAaDG-GFP) in 
REF52 cells
With its extracellular domain, PDG-GFP still localised to the nucleai' region and was 
unable to induce the formation of fiiopodia, indicating that the additional domain 
required to mediate the formation of fiiopodia might not lie in p-dystioglycan. cPDG- 
GFP and pDG-GFP showed an unusual nuclear localisation, implying that the 
translocation of cPDG-GFP or PDG-GFP might be altered in the absence of a- 
dystroglycan or the N-terminal signal peptide. Thus, the additional domain required to 
mediate the formation of fiiopodia is more likely lie in a-dystroglycan or in the N- 
terminal signal peptide, and these two domains might be involved in the trafficking of 
dystroglycan to plasma membrane.
To determine whether the N-terminal signal peptide is required for dystroglycan 
dependent fiiopodia formation, we constructed the a-dystroglycan functional domain 
deletion mutant (aPAa DG-GFP), in which the N-terminal signal peptide (l-28a.a) was 
fused to the N-terminal of p-dystroglycan-GFP. As shown in figure 4.12, expression of 
aPAa DG-GFP did not induce the formation of fiiopodia (Fig 4.12 A and B). Fiiopodia 
formation and actin reorganisation was not found in the apA a DG-GFP transfected cells 
replated on laminin either (Fig 4.12 C and D). The stress fibre phenotype was present 
in aPAaDG-GFP transfected cells (Fig 4.12 D and E).
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Figure 4.12 Expression of dystroglycan a  subunit deletion mutant Aa-GFP
REF52 cells plated on glass coverslips were transfected with apAaDG-GFP (1.8jig/ml) 
following the transfection procedure cells and incubated at 37°C overnight (A and B) 
The apAotDG-GFP transfected cells were subsequently replated onto laminin coated 
glass coverslips and incubated in DMEM containing 1% FBS at 37°C overnight (C). The 
coverslips with cells were fixed with 3.7% foimaldehyde. apAaDG-GFP transfected 
cells were further stained with rhodamine-phalloidin [(Sigma) at 1:1000], Fiiopodia 
phenotype was not present in aPAaDG-GFP transfected cells (A and B). The aPAaDG- 
GFP localised mainly in the perinuclear region (A arrow), and a lot of vesicle-like grains 
distributed around the cytoplasm (B arrow). Replating the aPAaDG-GFP transfected 
cells on laminin did not induce the formation of fiiopodia (C) or the reorganisation of 
actin filament; actin stress fibre phenotype was found in the cells (E). (D), the merged 
image of aPAaDG-GFP (green) and actin (red). Scale bar = 25jam
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The localisation of apA a DG-GFP is very different from that found in the expression of 
cpDG-GFP or pDG-GFP. The apA a DG-GFP was mainly localised in the perinuclear 
region instead of in the nucleus (Fig 4.1 lA, arrow). Additionally, high levels of 
aPAa DG-GFP staining were toward in the cytoplasm forming a vesicle-like structures 
(Fig 4.11 B, arrow). Since the N-terminal signal peptide is predicted to direct 
dystroglycan to the ER lumen and to be cleaved off as soon as the aP-dystroglycan 
precursor is elongated through the ER membrane (Fig 4.16), the possible impact of the 
N-terminal SP for dystroglycan- dependent fiiopodia formation could be to regulate 
dystroglycan trafficking instead of to regulation of dystroglycan signal transduction. The 
vesicle-like structures of aPAa DG-GFP distributed in the perinuclear region 
demonstrates that apA a DG-GFP is still maintained in the submembrane system such as 
ER, Golgi, and transporting vesicles. Despite the ER-Golgi or post-Golgi processing and 
transporting of dystroglycan, these results suggest that although the N-terminal SP 
peptide is required to direct dystroglycan to its exocytotic route away from the nucleus, 
it is still insufficient for p-dystroglycan to mediate the formation of fiiopodia. Thus, both 
a-dystroglycan and the N-terminal SP domain might be necessai'y for dystroglycan- 
dependent fiiopodia formation.
Together the results shown in section 4.2.5 to 4.2.7, suggested that cP alone is 
insufficient to mediate the dystroglycan dependent fiiopodia formation; ep, TM, or 
dystroglycan N-terminal SP is not the domain required for cP to mediate the foimation 
of fiiopodia either. Thus, a-dystroglycan is the suspected functional domain that 
conti'ibutes to P-dystroglycan cytoplasmic domain to mediate the formation of fiiopodia. 
Inconsistently, however, the results in section 4.2.4 showed that a-dystroglycan-laminin 
engagement is not necessary for dystroglycan-dependent fiiopodia formation. The 
explanation for the phenomenon is that while a-dystioglycan might be unnecessary for 
dystroglycan signal transduction, it plays a crucial role in the biosynthesis of the 
dystroglycan propeptide, especially in the protein tiansporting and localisation pathways.
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4.2.8 Expression of eP dystroglycan deletion mutant (aPAeP-GFP) in REF52 cells
To examine the hypothesis above and determine the role of a-dystroglycan in 
dystroglycan dependent fiiopodia formation, a P-dystroglycan extracellular domain 
deletion mutant (aPAeP-GFP) was constructed and expressed in REF52 cells. Very 
interestingly, the expression of aPAeP-GFP showed that the fiiopodia phenotype was 
restored (Fig 4.13 A and B). The morphology of the aPAeP-GFP ti'ansfected cells was 
very similar to that of apDG-GFP transfected cells; hundreds of fiiopodia were 
expressed throughout the cell surface. Replating the aPAep-GFP transfected cells on 
laminin, produced a clear fiiopodia phenotype (Fig 4.13 C) with reduced numbers of 
stress fibres observed (Fig 4.13 D).
As a control, aDG-GFP, which composes of a-dystroglycan and its N-terminal signal 
sequence, was constructed and expressed in REF52 cells. The expression of aDG-GFP 
in REF52 cells is weaker than the other dystroglycan mutant constructs in the 
experiment. As shown in figure 4.14 A-C, the expression of aDG-GFP did not induce 
any fiiopodia formation in the REF52 cells, revealing that a-dystroglycan is insufficient 
to induce the formation of fiiopodia. Thus, in the aPAeP-GFP, the cytoplasmic domain 
of p-dystroglycan instead of a-dystroglycan is responsible for induction of the formation 
of fiiopodia.
However, as shown in section 4.2.5 to 4.2.7, the dystroglycan mutants without the a  
subunit localised to the nucleus or the submembrane system in the cytoplasm and failed 
to mediate the formation of fiiopodia. Therefore, supporting our hypothesis, a- 
dystroglycan is indeed necessary for dystroglycan dependent fiiopodia formation; but 
instead of participating in the cytoskeleton reorganisation signalling events, 
a  dystroglycan probably plays a crucial role in the post-translational modification and 
targeting of dystroglycan to its membrane location.
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Figure 4.13 Expression of B-dvstroglvcan extracellular domain deletion mutant 
AeBDG-GFP. in REF52 cells
REF52 cells plated on glass coverslips were transfected with apAePDG-GFP (1.8pg/ml), 
following the transfection procedure and cells were subsequently incubated at 37 °C 
overnight (A and B), The aPAaDG-GFP transfected cells were replated onto laminin (2 
jag/ml) coated glass coverslips and incubated in DMEM containing 1% FBS at 37°C 
overnight (C). The coverslips with cells were fixed with 3.7% formaldehyde. apAe^DG- 
GFP transfected cells plated on laminin were further stained with rhodamine-phalloidin 
[(Sigma) at 1:1000]. Fiiopodia phenotype was present at the cell periphery (A, arrow) 
and on the suiface (B, arrow) in the cells expressing AePDG-GFP. Fiiopodia phenotype 
(C) and reduced number of stress fibre (D) were found in the AePDG-GFP transfected 
cells replated on laminin. (E), The merged image of AePDG-GFP (green) and actin (red). 
Scale bar = 25|Lim
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Figure 4.14 Expression of (XDG-GFP in REF 52 cells
REF52 cells plated on glass coverslips were transfected with oDG-GFP (1.8|ig/ml) 
following the transfection procedure and they were subsequently incubated at 37 °C 
overnight (A-B). The PDG-GFP transfected cells were replated on laminin (2p,g/ml) 
coated coverslips and incubated in DMEM containing 1% FBS at 37 °C overnight (C-E). 
The coverslips were fixed with 3.7% formaldehyde. Expression of aDG-GFP did not 
induce the formation of fiiopodia. The fluorescent level of the aDG-GFP was low, and 
the aDG-GFP protein diffused all around the cells. No significant localisation of aDG- 
GFP was seen in the cells. Scale bar=25|am.
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4.2.9 Expression of alkaline phosphatase conjugated P-dystroglycan (AP-pDG) 
construct in REF52 cells
As shown in the results, defects in a-dystroglycan disrupt the formation of fiiopodia due 
to the loss of localisation of the p-dystioglycan cytoplasmic domain. Therefore, the 
localisation of dystroglycan seems to play a critical role in the formation of fiiopodia. 
Dystroglycan is a transmembrane protein; to determine whether the membrane 
localisation is crucial for P-dystroglycan cytoplasmic domain to mediate the formation 
of fiiopodia, an alkaline phosphatase conjugated p-dystroglycan (AP-PDG) construct 
was expressed in REF52 cells. The AP-PDG construct expresses a fusion protein of 
alkaline phosphatase (AP) conjugated to the N-terminal of p-dystroglycan 
transmembrane and cytoplasmic domain (Rentschler et al, 1999). Since AP is a secreted 
protein that undergoes the exocytotic sorting from the Golgi and is released from the 
plasma membrane, the conjugation of the P-dystroglycan transmembrane and 
cytoplasmic domain could maintain the AP on the plasma membrane surface 
with P-dystroglycan cytoplasmic domain at the intracellular region proximal to the 
membrane (Fig 4.15 A). Thus the AP-PDG fusion protein is predicted to mimic the 
localisation of the cytoplasmic domain of p-dystroglycan in the plasma membrane 
region but without a-dystroglycan. The expression of AP-pDG can be detected by 
standard AP development (section 2.2.1.11).
As shown in figure 4.15 B, REF52 cells expressing AP-PDG showed similar 
morphology to the expressing aPDG-GFP; many thin and long fiiopodia were found 
extended around the cell surface (Fig 4.15 B, arrows), suggesting that fiiopodia 
formation signalling in the AP-PDG transfected cells was activated due to the membrane 
localisation of P—dystroglycan cytoplasmic domain. Despite of the loss of function of a- 
and eP-dystroglycan, P-dystroglycan cytoplasmic domain can still mediate the formation 
of fiiopodia. This finding suggests that it is the membrane localisation of P-dystroglycan 
that is crucial for the P-dystroglycan cytoplasmic domain to mediate fiiopodia formation, 
a-dystroglycan, which appealed to be necessary for dystroglycan dependent fiiopodia 
formation, is involved in targeting P-dystroglycan to its membrane localisation. In fact.
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Figure 4.15 Expression of alkaline phosphatase tagged B-dvstroglvcan construct 
(AP-BDG) in REF52 cells
(A) A model of AP-PDG and its localisation to the plasma membrane Alkaline 
phosphatase (AP) was conjugated to the N-terminal of p dystroglycan transmembrane 
domain (TM) and cytoplasmic domain. The p-dystroglycan transmembrane domain 
maintains the AP on the plasma membrane surface, allowing P-dystroglycan cytoplasmic 
domain to localise to the proximal membrane region. AP-pDG (2|ig/ml) was transfected 
into REF52 cells on glass coverslips. The coverslips with cells were fixed with 3.7% 
formaldehyde and treated with 0.1% Triton X-100 in PBS, and then developed in AP 
buffer containing 0.4mM NET and 0.4mM BCÏP. Fiiopodia phenotype was present in 
the cells transfected with AP-PDG (B). The distribution of fiiopodia is all around the cell 
(B, arrows). Scale bar=25fam
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cP - DYSTROGLYCAN
(Adapted from Rentschler et al., 1999)
with its membrane localisation, P-dystroglycan cytoplasmic domain can mediate the 
formation of fiiopodia independently of a-dystroglycan or the extracellular domain of 
p-dystroglycan.
A summary of expression, localisation and fiiopodia phenotype induction of the 
dystroglycan mutant constructs is shown in table 4.1
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Table 4.1 Localisation and fiiopodia formation of GFP-tagged dvstroglvcaii and 
dystroglycan mutants transfected REF 52
Constructs Approximate size 
of the protein 
expressed in Cos? 
cells
Descriptions of 
expression
Protein
localisation
Fiiopodia
phenotype
pEGFP 27KDa EGFP tagged 
mammalian cell 
expression vector
Nucleus and 
Cytoplasm
aPDG-
GFP
80KDa Full-length aP 
dystroglycan
Plasma membrane
apAcpDG-
GFP
55KDa Dystroglycan cP 
deletion mutant
Plasma membrane —
cpDG-
GFP
30KDa Dystroglycan 
cP domain alone
Mainly in nucleus 
and diffused in 
cytoplasm
PDG-
GFP
ND* Dystroglycan full- 
length p alone
Mainly in nucleus 
and concentrated in 
perinucleai' region
aPAocDG-
GFP
ND* Dystroglycan 
a  domain deletion 
mutant
Mainly in perinucleai' 
region and vesicle­
like grains in 
cytoplasm
apAepDG-
GFP
ND* Dystroglycan 
eP domain deletion 
mutant
Plasma membrane +
aDG-
GFP
ND* Dystroglycan full- 
length P deletion 
mutant
Cytoplasm
AP-PDG ND* Alkaline phosphatase 
conjugated 
P dystroglycan 
(TM+cP)
Plasma membrane H-
* ND=Unidentified
1 0 0
4,3 Discussion
The a(3DG-GFP construct was made initially to investigate the relation between ERK 
and dystroglycan. However, the dramatic actin phenotype in the a(3DG-GFP transfected 
cells implied that dystroglycan might play a role in cy to skeletal reorganisation, which 
ERK might be not directly involved in. The microspikes present in apDG-GFP 
transfected cells were identified as filopodia. To date dystroglycan-dependent filopodia 
formation signalling has not been reported. Therefore, the interest shifted to the study of 
dystroglycan-dependent filopodia formation and associated signalling. First, the 
cytoplasmic domain of p-dystroglycan was determined to be responsible for the 
formation of filopodia. Additionally, integrin signalling was shown to be involved in the 
dystroglycan dependent filopodia formation. The interaction of dystroglycan PPPY 
motif and utiophin WW domain appeared to have no effect on the dystroglycan 
dependent filopodia formation. Moreover, different dystroglycan functional domain 
deletion mutants led to differing localisations of dystroglycan, but only dystroglycan 
localised to the plasma membrane is able to mediate the formation of filopodia (Table 
4.1), Therefore, the spatial localisation might be very important for P-dystroglycan to 
carry out its biological function. The other functional domains of dystroglycan, during 
post-translational modification or post-Golgi sorting, could contribute to p-dystroglycan 
function as targeting it to its membrane localisation.
4.3.1 Spatial importance for P-dystroglycan cytoplasmic domain in induction of 
filopodia formation
The formation of filopodia induced by expression of apOG-GFP was significantly 
greater than induced by the expression of P-dystroglycan cytoplasmic domain deletion 
mutant (ocpAcpDG-GFP), suggesting that the p-dystroglycan cytoplasmic domain is an 
important mediator of dystroglycan-dependent filopodia formation. This result was 
perhaps not too surprising since the cytoplasmic domain of P-dysti'oglycan has long been 
considered to be associated with signalling molecules and regarded as a potential 
mediator of cytoskeleton reorganisation (Yang et al, 1995; Henry and Campbell, 1996;
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Winder, 2001). However, the result of cPDG-GFP expression showed that despite being 
an important mediator for dystroglycan-dependent filopodia formation, p-dystroglycan 
cytoplasmic domain on its own is insufficient to induce filopodia formation. Expression 
of cpDG-GFP, PDG-GFP or aPAotDG-GFP which all lack a-dystroglycan were unable 
to induce the formation of filopodia, whereas the filopodia phenotype was restored in the 
cell expressing apAePDG-GFP construct, indicating that a-dystroglycan, is as important 
as P-dystroglycan cytoplasmic domain inducing dystroglycan dependent filopodia 
formation. However, as dystroglycan-dependent filopodia formation appeared to be 
induced by fibronectin, a-dystroglycan seemed to be unnecessary for the dystroglycan- 
dependent filopodia formation.
The explanation of why a-dystroglycan plays an inconsistent role in the dystroglycan 
dependent filopodia formation could be that a-dystroglycan is required for the 
dystroglycan propeptide to complete the post-translational modification and 
consequently localise dystroglycan to the plasma membrane. Membrane localisation 
would be crucial for dystroglycan to mediate the formation of filopodia. This hypothesis 
is strongly supported by the expression of AP-pDG that mimics the localisation of the 
endogenous aP-dystroglycan heterodimer on the plasma membrane. Although the a 
subunit is deleted, the p-dystroglycan cytoplasmic domain of AP-pDG was localised to 
the intracellular proximal membrane region, and could mediate the formation of 
filopodia. This suggested that a-dystroglycan, or a-dystroglycan-laminin engagement, is 
not necessary for P-dystroglycan cytoplasmic domain to mediate the formation of 
filopodia; it is the membrane localisation that allows p-dystroglycan cytoplasmic domain 
to mediate the formation of filopodia. The role of a-dystroglycan in the dystr’oglycan 
dependent filopodia formation is to target dystroglycan to the membrane localisation.
In previous studies of dystroglycan function, a great deal of effort was placed on the 
study of a-dystroglycan. Dystroglycan is thought to be a laminin receptor which might 
stimulate cell adhesion and cytoskeletal organisation signalling (Ervasti and Campbell, 
1991; reviewed in Durbeej et al., 1998a). The results here show strong evidence that p-
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dystroglycan is able to mediate the cytoskeletal organisation signalling, independent of 
a-dystroglycan. In this case, a-dystroglycan is required for p-dystroglycan targeting to 
the plasma membrane instead of transmitting extracellular signalling to stimulate P- 
dystroglycan dependent filopodia formation.
These results show that the plasma membrane localisation is required for P-dystroglycan 
to act as a mediator for filopodia formation. It may reflect a possible biological role of p- 
dystroglycan cytoplasmic domain in the formation of filopodia. During the formation of 
actin-based membrane protrusions or filopodia, a variety of essential molecules 
including Rho GTPases, Ar*p2/3 complex, N-WASP, actin, etc., are recruited or 
accumulated in the membrane cortex (reviewed in Mullins et al., 1998) (Chapter 5) The 
results here show that integrin-mediated adhesion signalling was also required for the 
dystroglycan-dependent filopodia formation signalling, suggesting that crosstalk 
between integrins and cytoplasmic domain of p-dystroglycan might be very important 
for dystroglycan to mediate filopodia formation. Therefore, the membrane localisation of 
p-dystroglycan cytoplasmic domain could allow dystroglycan to interact with membrane 
signalling molecules, including crosstalk with integrins, and to act as a mediator of actin 
filopodia formation. The molecular* basis of filopodia formation and the mechanisms of 
dystroglycan in the formation of filopodia will be discussed in Chapter 5.
4.3.2 Role of p-dystroglycan C-terminal tail PPPY motif in dystroglycan dependent 
filopodia formation
The results have shown that the 120 a.a. (776-893) p-dystroglycan cytoplasmic domain 
ia a mediator of filopodia formation, however, which motif in the p-dystroglycan 
cytoplasmic domain is responsible for the dystroglycan-dependent filopodia formation? 
Several proline-rich regions, which are potential candidates for the signalling adaptor 
motifs, have been identified in the p-dystroglycan cytoplasmic domain. Of these, the 
PPPY motif at the very C-terminal tail of p-dystroglycan is the best characterised (Jung 
et al, 1995; Rentschler et al, 1999). Since the PPPY motif is the signalling motif that 
directly regulates the association between dystroglycan and actin cytoskeleton thr*ough
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the interaction with utrophin/dystrophin WW domain (Winder, 1997), it is the PPPY 
motif of P-dystroglycan that was initially suspected to be the mediator for dystroglycan 
dependent filopodia formation. However, as seen in the experiments shown in section 
4.2.2.3, aPDG-GFP ti’ansfected uti'ophin-knockout cells clearly expressed a filopodia 
phenotype, suggesting that utiophin might not be a mediator of p-dystroglycan 
cytoplasmic domain dependent filopodia formation. Therefore, the PPPY-WW 
interaction might not be involved in the dystroglycan dependent filopodia formation. 
However, since integiin dependent adhesion, which leads to the tyrosine 
phosphorylation at Y892 of PPPY motif, might be involved in the dysti’oglycan 
dependent filopodia formation signalling, the PPPY motif might still be involved in 
dystroglycan-dependent filopodia formation.
In addition to the WW domain, the N-terminal SH3 domain of Grb2 SH2 (Yang et al, 
1995; Jung et a l, 1995) and caveolin were also shown to associate with the PPPY motif 
of P-dystroglycan. Interestingly, WW, Grb2 and caveolin are all molecules which 
compete for the PPPY motif (Rosso et al, 2000; Sotgia et al, 1999) (section 1.4). The 
tyrosine phosphorylation of Y892 of PPPY appeal's to play an important role in 
regulating the binding of these competitors. Tyrosine phosphorylation at Y892 has been 
shown to lead to the reduction in its binding affinity to the WW domain (Ilsley et al,
2001) and recruitment of SH2 containing molecules (Sotgia et a l, 2001). Caveolin 
appeared to bind PPPY motif in an Y892 phosphorylation independent manner (Sotgia 
et al., 2001) however, the interaction with caveolin inhibits phosphorylation at Y892 
(Sotgia et al., 2003). Therefore, the precise role of this regulation is still elusive. While 
evolutionarily unrelated, the Grb2 SH3 domain shows a striking structural similarity to 
the WW domain (Yu, et a l, 1994; Feng et al, 1994; Lim et a l, 1994) and it also 
interacts with the PPPY motif of p-dystroglycan (Jung et a l, 1995). Grb2, which 
associates with the PPPY motif, has been shown to associate with FAK via its SH2 
domain (Cavaldesi et a l, 1999), to date, however, Grb2-FAK mediated dystroglycan 
signalling events have not been reported, and it has also not yet been determined 
whether the binding of Grb2 is regulated by the Y892 phosphorylation of the PPPY 
motif. The role of Grb2 in P-dystroglycan signalling is still elusive. It has been shown
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that tyrosine phosphorylation at Y892 of p-dystroglycan led to the recruitment of SH2 
containing proteins (Sotgia et al., 2001). Therefore, Grb2 might still be a potential 
adaptor for dystroglycan to couple to other signalling pathways.
4.3.3 Dystroglycan functional domains in its post-translational processing
As mentioned above, the results have shown that in order to induce filopodia formation, 
P-dystroglycan localised to the plasma membrane is able to mediate the signalling 
independent of a-dystroglycan-laminin interaction. However, a-dystroglycan is required 
for P-dystroglycan to target to its membrane localisation. This interesting finding implies 
that the interaction of dystioglycan a- and p- subunit during biosynthesis, perhaps 
during the post-translational processing, plays an important role in leading dystroglycan 
to its membrane localisation. Dystroglycan is encoded by a single mRNA and translated 
to a 97 KDa ap-dystroglycan propeptide (Ibraghimov-Beskrovnaya et a l, 1992). This 
propeptide undergoes post-translational modification, including glycosylation at several 
sites and proteolytic cleavage at Ser 653, to generate mature a- and P- dystroglycan 
subunits (Ervasti and Campbell, 1993) (section 1.2). It has been shown that level of both 
a -  and P-dystroglycan were greatly reduced on the muscle membrane of dystrophin 
gene deficient mdx mice or DMD patients while the mRNA for dystroglycan propeptide 
was still expressed at normal levels (Ibraghimov-Beski'ovnaya et ah, 1992), suggesting 
the reduction of dystroglycan in DMD patients or mdx mice is in response to a defect in 
posttranslational modification instead of the transcription of dystroglycan. Thus the 
proper presence of dystroglycan at the plasma membrane might be modulated by its 
posttranslational modification.
4.3.3.1 Glycosylation o f  dystroglycan in biosynthesis
Dystroglycan is a highly glycosylated protein with both O-linked and N-linked 
glycoconjugation (Ibraghimov-Beskrovnaya et al, 1992). To date, the structure of the 
glycoconjugation and the role of glycosylation in dystroglycan function ai'e still poorly 
understood. The O-linked glycosylation with large amounts of sialic acid present on 
amino acid residues 318-484, forms a region of mucin-like structure on a-dystioglycan
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(Ibraghimov-Beskrovnaya et al, 1992). Chemical deglycosylation that removes all 
glycosylation on dystroglycan causes the loss of binding of dystroglycan to laminin, 
while removal of N-linked glycosylation of dystroglycan did not affect on laminin 
binging activity of dystroglycan (Ervasti and Campbell., 1993), suggesting that O-linked 
sugars on a-dystroglycan are responsible for its laminin binding activity. The O-linked 
glyeans of a-dystroglycan has been identified in bovine peripheral nerve as an O- 
mannosyl linkage, which is raiely expressed in other mammalian proteins (Chiba et al, 
1997). An O-mannosyl stincture, Neu5Ac(a2-3)Gla(Pl-4)GlcNAc(pl-2)Man-Sei7Thr, 
isolated from dystroglycan has been proposed to be required for laminin binding, 
however, this a poor inhibitor of the binding of dystroglycan to laminin, suggesting that 
on a-dystroglycan, it is not the main structure for laminin binding (Chiba et al, 1997). 
Sialic acid has been reported to inhibit laminin binding to a-dysti’oglycan in bovine 
peripheral nerve at a very low concentration and might be critical for laminin binding 
(Yamada et a l, 1996a). However, enzymatic removal from skeletal muscle dysti'oglycan 
has no effect on laminin binding (Ervasti et al, 1997). Furthermore, dystroglycan from 
brain and cardiac muscle has decreased terminal sialoglycosylation compared to skeletal 
muscle dystroglycan but dystroglycan from all three tissues binds tightly to laminin 
(Ervasti et al, 1997). Therefore, although it is well accepted that glycoconjugates aie 
important for ligand binding, the hypothesis that specific glycoconjugates on 
dystroglycan are involved directly in ligand binding is still controversial.
While O-linked glycoconjugates of a-dystroglycan have been accepted to be involved in 
the binding of laminin, the function of the N-linked glycoconjugates on dystroglycan are 
uncertain. Treatment with N-glycanases that completely removed all N-linked 
oligosaccharides did not alter the binding activity of dystroglycan to laminin suggesting 
N-linked sugars are not required for ligand binding (Ervasti and Campbell, 1993). 
Unlike O-linked glycosylation, structures of N-linked glycosylation in cells are more 
diverse. Removal of N-linked glycoconjugates by treatment of FNGaseF or blocking the 
synthesis of N-linked glycosylation by using tunicamycin has no effect on the 
proteolytic cleavage at Ser653 of dystroglycan propeptide to from a  and P subunits, 
suggesting that the N-linked oligosaccharides not required for the proteolytic cleavage of
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dystroglycan precursor peptide (Holt et al, 2000). Interestingly, while the N-linked 
sugar chains might not be involved in the proteolytic cleavage event, blocking N-linked 
glycosylation inhibits the trafficking of P dystroglycan. In the presence of tunicamycin, 
p-dystroglycan was accumulated in perinuclear region instead of localising in peripheral 
cell membrane (Holt et ah, 2000). Thus, N-linked oligosaccharides on dystroglycan 
might play an important role in directing dystroglycan to its membrane localisation.
Four potential N-glycosylation sites have been identified on dystroglycan, three of them 
are on a  (Asn-141, Asn-641 and Asn-649) subunits and the other one (Asn-661) is on a 
P-subunit; none of their structures have been identified, the function of these N-linked 
glycoconjugates is also unclear. The results presented here showed that the formation of 
filopodia in cells is not altered in cells expressing P-dystroglycan extracellular domain 
deletion mutant (aPAeP-GFP) or AP-tagged P-dystroglycan (AP-pDG) lacking the P- 
dystroglycan extracellulai- domain, suggesting that P-dysti'oglycan extracellular domain 
containing its N-linked sugar chain, is not required for dystroglycan targeting to plasma 
membrane. The other two N-linked glycoconjugates which are very close to each other 
are located at the C-terminal end of a-dystroglycan (Asn-641 and Asn-649). It is likely 
that these two N-linked sugar chains might be involved in regulation of binding affinity 
between dystroglycan a  and p subunits. However, a recent study has determined that the 
amino acid sequence 550-585 on a-dystroglycan is sufficient for binding to the 
extracellular domain of P-dystroglycan (Bozzi et ah, 2001). Therefore, the N-linked 
oligosachanide at Asn-641 and Asn-649 might not directly affect the binding of a- and 
p- dystroglycan subunits.
N-linked sugar chains on a  and P dystroglycan have been shown to be unnecessary for 
proteolytic cleavage but are required for the proper localisation of P-dystroglycan (Holt 
et ah, 2000), raising a possibility that the N-linked glycoconjugates of dystroglycan play 
a role in dystroglycan submembrane trafficking. Since all the dystroglycan deletion 
mutants lacking the a-subunit cannot induce the formation of filopodia due to the 
unsuccessful tai'geting to plasma membrane, this suggests that a-dystroglycan is
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required for dystroglycan targeting to plasma membrane, and it is very likely the N- 
linked glycoconjugates on a-dystroglycan play an important role in dystioglycan 
trafficking and membrane localisation.
4.3.3.2 Hypothesis fo r  dystroglycan trafficking
The processing and maturation of dystroglycan is still elusive. However, recent studies 
of Fukuyama congenital muscular- dystrophy (FCMD), congenital muscular dystrophy 
type 1C (MDCIC) and Muscle-Eye-Brain (MEB) disease have provided some clues. 
FCMD is one of the congenital muscular- dystrophies (CMD), which is caused by the 
mutation in the gene encoding fukutin (Kondo-Iida, et al, 1999). FCMD patients suffer 
congenital muscular dystrophy with mental retardation and neuronal migration defects 
(Fukuyama et al., 1981). The muscle biopsies have shown that the glycosylation of a- 
dystroglycan on the muscle membrane of FCMD patients was greatly reduced (Hayashi 
et al., 2001). Laminin binding activity of dystroglycan on FCMD muscle membrane was 
greatly reduced as well (Cote et al, 2002; Cohn et a l, 2002), indicating that O-linked 
glycoconjugates on a-dystroglycan which are responsible for laminin LG domain 
binding, ar-e affected by the abnormality in fukutin. Similar levels of a-dystroglycan 
reduction and loss of laminin binding ability were also found in the muscle membrane of 
an MEB patient (Chiba et a l, 1997). MEB is an autosomal recessive disorder 
characterised by congenital muscular dystrophy, ocular abnormalities, and brain 
malformation (Santavuori et a l, 1989). Recently, MEB has been shown to be caused by 
mutation in the protein peptide-O-mannosyl-GlcNac transferase (POMGnTl) (Yoshida 
et al, 2001). Therefore, the reduction of a-dystroglycan in muscle membrane, which 
causing MEB or FCMD, might result from the defect in O-linked glycosyltiansferases 
and failure of the processing the O-linked glycoconjugates on a-dystroglycan. 
Interestingly, while there was a greatly reduced level of glycosylated a-dystroglycan, the 
normal level of p-dystroglycan localised on plasma membrane was still found in FCMD 
or MEB muscles (Michele et al, 2002), suggesting that the expression or localisation of 
P-dystroglycan is not affected by the abnoi-malities of O-linked glycosylation of a- 
dystroglycan. The membrane targeting of P-dysti'oglycan might be unaffected by the O- 
linked glycoconjugates on a-dystroglycan.
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The function of fukutin in FCMD is unknown. However, a homologue for fukutin, 
fukutin related protein (FKRP), which was identified in MDCIC, has been studied very 
recently (Aravind, et at, 1999; Brockington et at, 2001; Esapa et at, 2002). MDCIC is 
caused by mutation in FKRP; patients with MDCIC have severe musculai* dystrophy as 
well. A reduction in glycosylated a-dystroglycan has been found in MDCIC patients, 
revealing that the FKRP might be involved in the glycosylation and maturation of 
dystroglycan (Brockington et at, 2001). The primary sequence showed that both FKRP 
and fukutin aie possibly glycosyl transfer as es (Aiavind, et a t, 1999). More recently, 
FKRP has been shown to target to the Golgi appaiatus by its N-terminal transmembrane 
domain, and directly affects the glycosylation of dystroglycan in CHO cells (Esapa et at, 
2002). 60KDa and a 90KDa a-dystroglycan isoforms were detected in cells 
coexpressing FKRP and chick dystroglycan (ChDG) while the 160KDa mature a- 
dystroglycan was detected in cells expressing ChDG alone, indicating glycosylation of 
a-dystroglycan is affected by FKRP (Esapa et at, 2002). Interestingly, the western 
blotting of p-dystroglycan in the ChDG and FKRP coexpressing cells showed that P- 
dysti'oglycan was also reduced from mature 43KDa to an approximately 41 KDa isoform, 
indicating the N-linked glycosylation on p-dystroglycan is also affected by FKRP. 
Additionally, FKRP mutants which aie unable to target to the Golgi apparatus did not 
appear to affect the glycosylation of a- and p-dystroglycan, demonstrating that FKRP is 
a Golgi associated protein that directly alters the glycosylation of a- and p-dystroglycan 
in the subcellular state (Esapa et at, 2002).
These findings raise several ideas for the post-translational processing of dystroglycan. 
First, during trafficking, full-length a-dystroglycan and the extracellular domain of P- 
dystroglycan are presumably localised at the ER lumen or Golgi lumen while the 
cytoplasmic domain is at the surface of ER or Golgi membrane. Therefore the 
glycosylation modifications of a-dystroglycan and extracellular domain of P- 
dystroglycan can take place in the ER or Golgi lumen. Second, since glycosylated 
reduction of a-dystroglycan in MDCIC results from mutations in the FKRP gene, the 
expression of FKRP is expected to restore the glycosylation of a-dystroglycan. However,
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the coexpression of FKRP and dystroglycan subsequently reduced the glycosylation of 
a-dystroglycan, implying that FKRP might not be the only Golgi associated protein that 
modulates the glycosylation of dystroglycan. Several glycosyltransferases on the Golgi 
membrane which might have opposing function to FKRP, might be involved in the 
glycosylation of dystroglycan. Since increasing numbers of gene encoding 
glycosyltransferases or homology to glycosyltransferases are found to be mutated 
resulting in the reduction of a dysti'oglycan glycosylation (Michele and Campbell, 2003), 
the glycosylation of dystroglycan might be catalysed by a group of glycosyltransferases, 
perhaps forming a protein complex on the Golgi membrane. Finally, it has been shown 
that O-linked glycosylation on a-dystroglycan has no effect on trafficking of 
dystroglycan but N-linked glycosylation has (Holt et al, 2000), and our results showed 
that a-dystroglycan is necessary for p-dystroglycan targeting to the plasma membrane. 
Thus, the N-linked glycosylation on a-dystroglycan seem to play a role in dystroglycan 
trafficking. The hypothesis of posttranslational route of dystroglycan is shown in figure 
4.14
Altogether, in this chapter, it has been found that expression of dystroglycan 
dramatically induces the formation of actin-rich filopodia phenotype in REF52 cells, 
suggesting a novel role for dystroglycan triggering actin filopodia formation. The 
functional domain of dystroglycan responsible for the formation of filopodia is located 
in the cytoplasmic domain of p-dystroglycan. However, the PPPY motif of P- 
dystroglycan, which is responsible for the regulation of WW domain, Grb2, and caveolin 
binding, might not be a direct mediator for dystroglycan-dependent filopodia formation. 
P-dystroglycan with proper plasma membrane localisation can mediate the formation of 
filopodia independent of a-dystroglycan, suggesting that P-dystroglycan can undergo 
intiacellular regulation which is not directly affected by a-dystroglycan-laminin 
interaction. Integrin dependent adhesion signalling is involved in the dystroglycan 
dependent filopodia formation, implying crosstalk between integrin and dystroglycan.
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Figure 4.16 Model of posttranslational modification route of dystroglycan
Dystroglycan propeptide is translated from single mRNA by ribosomes on rough 
endoplasmic reticulum (ER). The N-terminal signal peptide (SP) which directs 
dystroglycan prepeptide to the ER lumen is cleaved and then digested in the ER 
membrane. Dystroglycan propeptide is translated as a transmembrane peptide with 
a-dystroglycan and extracellular P dystroglycan in the lumen and cytoplasmic 
p-dystroglycan on the ER surface. The DG propeptide undergoes the primary 
glycosylation (1° glycosylation) adding the N-linked oligosaccharides core, and then 
transports to Golgi membrane. Treatment with tunicamycin inhibits the activity of UDP- 
N-acetylglucosamine glycosyltransferases and blocks formation of N-linked 
oligosacchaiide cores consequently dismpts the N-linked glycosylation and trafficking of 
dystioglycan. In the Golgi lumen, by interacting with a series of membrane associated 
glycosyltransferases which might act as a protein complex, a-dystroglycan and 
extracellular P-dystroglycan undergo secondary glycosylation (2° glycosylation) that 
adds O-linked oligosaccharides and modifies the N-linked oligosaccharides to 
dystroglycan. Biosynthesis of a-dystroglycan in FCMD, MDCIC or MEB patients has 
a defect in secondary glycosylation; however these defects might not directly affect the 
exocytosis of dystroglycan. A structure in dystroglycan resulting from secondary 
glycosylation could be recognised by certain molecules in the Golgi and “label” the 
dystroglycan. The labeled dystroglycan could be sorted to vesicles and targeted to the 
membrane by exocytosis.
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The spatial importance of the membrane localisation for P -dysti'oglycan acting as a 
mediator for filopodia formation implies that during the formation of filopodia, p- 
dystroglycan might be required for other membrane associated molecules to promote the 
reorganisation of actin cytoskeleton. Finally, despite a-dystroglycan not being directly 
required to regulate the dystroglycan-dependent filopodia formation signalling, it is 
required for p-dystroglycan targeting to the plasma membrane, suggesting a- 
dystroglycan might play an important role in the subcellular trafficking and 
posttranslational sorting of dystroglycan.
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Chapter 5
Dystroglycan dependent activation of RIio GTPases and the 
organisation of the actin cytoskeleton
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5.1 Introduction
5.1.1 Cdc42 dependent actin dynamics of the cell cortex
As shown in chapter 4, the actin cytoskeleton was significantly altered by introducing a 
aPDG-GFP construct into REF52 cells, suggesting dystroglycan is involved in 
cytoskeleton reorganisation in cells. In mammalian cells, cell locomotion, cell adhesion 
and spreading, cell polarity, cell movement and wound healing, have all been shown to 
depend greatly on the organisation of the actin cytoskeleton. The RhoGTPases Rho, Rac 
and Cdc42 are known to be responsible for the formation of specific actin cytoskeletal 
structures (reviewed in Hall, 1998) (Fig 1.6 B). Since dystroglycan was initially 
suspected to regulate the actin cytoskeleton through adhesion signalling, it was initially 
presumed to be involved in Rho and Rho-dependent stress fibre foimation (section 
1.5.3). However, the expression of apDG-GFP induced a clear actin-based filopodia 
moiphology change in REF52 cells which is very similar to that induced in 
constitutively activated Cdc42 construct transfected cells (Fig 1.6 B, b and Fig 4.3 C). 
This striking similarity of actin morphology caused by apDG-GFP sti’ongly implied 
that activation of Cdc42 might be involved in the dystroglycan dependent filopodia 
formation.
Cdc42, a member of small Rho GTPase family, was originally detected in the yeast 
Saccharomyces cerevisiae as a mutation that caused defects in budding and cell polarity 
(Johnson and Pringle, 1990). The studies in yeast suggested that Cdc42 might play a 
role in cell polarity through an effect on the actin cytoskeleton (Reviews in Herskowitz, 
1995). A human homologue of Cdc42 was also identified (Hail et al, 1991). 
Microinjection of mammalian Cdc42 into fibroblasts revealed a distinct signalling 
pathway linking plasma membrane receptors to actin cytoskeleton organisation. While 
both Rac and Cdc42 happened to be involved in the formation of actin rich membrane 
protrusions (Luo, et al, 1994), expression of Cdc42Hs has been shown to trigger the 
formation of actin-rich filopodia protrusions at the cell periphery followed by the 
formation of lamellipodia and membrane ruffling (Kozma et al, 1995). It is suggested
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that Cdc42 could be directly responsible for the formation of filopodia which then leads 
to the activation of Rac,
5.1.2 Model of Cdc42 dependent ülopodia formation
Both filopodia and lamellipodia actin structures have been shown to drive formation of 
actin-rich membrane proti’usion at the cell periphery (reviewed in Pollard et ah, 2000). 
Polymerisation and organisation of actin filaments in protrusions are regulated by Rac 
or Cdc42 are highly dynamic. Studies of actin organisation at the leading edge of 
mammalian cells have suggested a Cdc42 dependent pathway in the cell cortex which is 
mediated by actin binding protein profilin/cofilin, Arp2/3 and WASPs, leading to the 
formation of dendritic network in actin-based protrusions (Pollard et al., 2000). Since 
filopodial protrusion was found to be a process based on the lamellipodia mesh work, it 
was thought to occur by the mechanism which was originally proposed for both 
lamellipodia and filopodia (Pollaid et al., 2000). However, recent studies into filopodia 
formation suggested that the formation of filopodia, might be initiated by organisation 
and paiallel bundling of the dendritic meshwork of lamellipodia instead of direct 
elongation of actin filaments from the dendritic meshwork (Svitkina et al, 2003).
In lamellipodia, which aie broad, flat protrusions, actin filaments form a branched 
network (Svitkina et al., 1997; Svitkina and Borisy, 1999), The current model for 
lamellipodial dynamics (Borisy and Svitkina, 2000; Pollard et al, 2000) suggests a 
branched actin filament array consists of repeated cycles of dendritic nucléation, 
elongation, capping, and depolymerization of filaments (Fig 5.1 A). Dendritic 
nucléation is mediated by the Arp2/3 complex, which is activated by members of 
WASP family proteins (WASP, N-WASP and SCAR)(reviewed in Higgs and Pollard,
2001). Both WASP and N-WASP has been identified as downstream effectors of active 
Cdc42 (Symons et a l, 1996; Miki et a l, 1996) while SCAR was identified as an 
effector of active Rac (Machesky, et a l, 1998). During nucléation, membrane 
associated Cdc42-GTP recruits and activates WASP. Activation of WASP leads to the 
recruitment and activation of the Ai"p2/3 complex, which binds to the side of actin 
filaments, and tiiggers the elongation of actin filaments from the Aip2/3 complex side.
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Figure 5.1 Model of Cdc42-dependent lamellipodia formation and filopodia 
organisation
(A), The cun’ent model for lamellipodial dynamics is a repeated cycle of dendritic 
nucléation, elongation, capping, and depolymerisation of filaments During nucléation, 
membrane associated Cdc42-GTP recruits and activates WASP and Arp2/3 complex, 
targeting actin filaments to the plasma membrane (1). Activation of Arp2/3 complex 
stimulates the elongation of branched actin filaments from the Arp2/3 binding site at an 
angle of 70° (2). The growing filament pushes the membrane forward (3). When a 
filament elongates beyond the efficient length for pushing, the growth of the actin 
filament is terminated by capping protein (4). Cofilin binding to F-actin leads to the 
depolymerisation of the actin filament (5). (B), Formation of filopodia is initiated by 
organisation of the lamellipodia meshwork. In the organisation to form filopodia, 
elongation of some baibed ends in the meshwork is terminated by capping protein, but 
other barbed ends are continuously elongated by binding with a complex of molecules 
(tip complex) (1). Then, with the elongation initiated from the Arp2/3 complex, these 
barbed ends drift during elongation and collide with each other (2-4). Finally, 
converged filaments with linked barbed ends continue to elongate together and the 
multi meric filopodial tip complex initiates filament cross-linking by recruiting and/or 
activating fascin (5), which bundles the actin filaments as they continuously elongate 
and push the filopodia forwai'd.
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forming an actin filament branch (Machesky and In sail, 1998; Rohatgi et ah, 1999; 
Taken aw a and Miki, 2001). During a period of elongation after nucléation, the filament 
pushes the membrane. When a filament elongates beyond the efficient length for 
pushing, the giowth of the actin filament is thought to be terminated by capping protein 
(reviewed in Cooper and Schafer, 2000). Depolymerization is assisted by proteins of the 
ADF/cofilin family (reviewed in Bamburg, 1999). The actin disassociated by cofilin 
binding is recycled to form new actin filaments. By the polymerisation and 
depolymerisation of the actin filament, the membrane can be pushed forward.
Filopodia, are thin cellular processes with long and paiallel actin filaments which are 
organized into tight bundles. Other cellular stiuctures, such as retraction fibres, and 
microvilli aie related to them (Small, 1988; Lewis and Bridgman, 1992; Small et al, 
2002). Filopodia structure is found to be processed based on the lamellipodia meshwork 
and was initially considered to be regulated by the same mechanism as that of the 
formation of lamellipodia. However, the Aip2/3 complex, which initiates the branching 
of actin filaments in the lamellipodia meshwork, is absent from established filopodia 
(Svitkina and Borisy, 1999). Additionally, some proteins, including Ena/VASP proteins 
(Lanier et al, 1999), N-WASP, CRI6 (Ho et al., 2001), myosin X (Berg and Cheney,
2002), talin (DePasquale and Izzai'd, 1991), syndapin I (Qualmann and Kelly, 2000), 
Abl interactor proteins (Stradal et al., 2001), and Vav (Kranewitter et al, 2001) were 
found enriched in filopodia tips, and a cross-linking protein, fascin was found to 
mediate actin filament bundling in filopodia (reviewed in Bartles, 2000; Kureishy et al,
2002), suggesting these proteins might be involved in filopodia formation. The role of 
most of these proteins remains largely unknown with the exception of Ena/VASP 
proteins. In lamellipodia, Ena/VASP has been shown to bind barbed ends of actin 
filaments and protect them from being capped at the leading edge of lamellipodia, 
which results in foimation of longer filaments within the lamellipodial dendritic 
network (Bear et a l, 2002). These data suggest that Ena/VASP proteins that are 
enriched at filopodial tips may mediate continuous elongation of filopodial actin 
filaments. In accordance with these studies, Svitkina and colleagues have recently 
examined the dynamics of Ai'p2/3 complex, Ena/VASP and fascin in filopodia in B16F1
117
mouse melanoma cells and established a model for filopodia initiation from 
lamellipodia meshwork (Svitkina et al., 2003).
According to this model (Fig 5.IB), a lamellipodial network is formed by Arp2/3- 
mediated dendritic nucléation. Firstly, elongation of some barbed ends in the network is 
terminated by capping protein, but other baibed ends acquire a privileged status by 
binding a complex of molecules (tip complex) that allows them to elongate 
continuously. Ena/VASP proteins are likely members of the tip complex. Then, with the 
elongation initiated from Arp2/3 complex, privileged baited ends drift laterally during 
elongation and collide with each other. Finally, converged filaments with linked barbed 
ends continue to elongate together and the multimeric filopodial tip complex initiates 
filament cross-linking by recruiting and/or activating fascin, which bundles the actin 
filaments as they continuously elongate and push the filopodia forward. In the nascent 
filopodium, the filopodial tip complex retains its functions of promoting coordinated 
filament elongation and bundling, as well as fusion with other filopodia.
5.1.3 Cdc42 activity assay in (xPDG-GFP transfected cells
To investigate the potential role of Cdc42 in dystroglycan dependent filopodia 
formation, initially, Rho GTPase activity pull-down assay (Benai'd, et al, 1999) was 
planned to be used to deteimine the activity of Cdc42 in dystroglycan transfected cells. 
To carry out this assay, a very high number of apDG-GFP transfected cells is 
necessary. However, neither by using G418 selection, nor by using different types of 
transfection procedure was it possible to achieve a transfection efficiency of a^DG- 
GFP in REF52 cells gieater than 25%. By using FACS sorting system to select the 
apDG-GFP in transfected REF52 cells, less then 5% of GFP positive cells were 
collected. These numbers of cells were insufficient to come out a Rho GTPase activity 
assay. Therefore, apDG-GFP and REF52 cells was not a useful system for determining 
the relationship between dystroglycan and Rho GTPases by using Rho GTPase activity 
assay. Despite the insufficiency for Rho GTPases activity assay, the post transfectional 
moiphology changes of cytoskeleton were very clear in aPDG-GFP transfected REF52.
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Thus, the coti'ansfection of dominant negative or constitutively activated mutants of 
Rho GTPases could be used in a(3DG expressing REF52 cells for the study of activation 
of Rho GTPase. By cotransfecting Rho GTPase mutant constructs that block or activate 
the Rho, Rac or Cdc42 pathway in a(3DG“GFP transfected REF52 cells, it was possible 
to observe the changes in filopodia formation.
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5.2 Results
5.2.1 Morphological similarity of V12Cdc42 transfected cells with a|3DG-GFP 
transfected cells
The constitutively activated constructs of Rho GTPases, V14Rho, V12Rac or 
V12Cdc42, were expressed in REF52 cells. Transfectants with the constitutively 
activated constructs showed the expected Rho, Rac or Cdc42 activated actin phenotype. 
Compared with the untransfected cells (Fig 5.2 A) the cells expressing V14Rho had a 
significantly increased number of stress fibres (Fig 5.2 B, an'ow). The cells expressing 
V14Rac presented lamellipodia at the cell periphery (Fig 5.2 C, arrows). Intioducing 
V12Cdc42 into REF52 cells led to the formation of a ring-like actin structure in the cell 
cortex (Fig 5.2 D dashed aiTOw) and, based on this ring-like actin structure, numerous 
actin filopodia bundles were present throughout the cells (Fig 5.2 D solid aiTow). This 
actin filopodia morphology was strikingly similar with that seen in a(3DG-GFP 
transfected REF52 (Fig 5.2 E). Therefore, activation of Cdc42, more likely than 
activation of Rho or Rac, might be a consequence of overexpression of apDG-GFP in 
REF52 cells.
5.2.2 Effects of coexpression of dominant negative Rho GTPases constructs on 
«PDG-GFP transfected REF52 cells
To further examine the role of Cdc42 in dystroglycan dependent filopodia formation, 
the dominant negative Rho GTPase constructs N14Rho, N12Rac or N17Cdc42 were 
coexpressed with apDG-GFP in REF52 cells. As shown in figure 5.4, the filopodial 
phenotype induced by expression of apDG-GFP in REF52 cells was not significantly 
affected by coexpressing N14Rho (Fig 5.3 A and B) or N12Rac (Fig 5.3 C and D). 
However, the cells cotiansfected with N17Cdc42 and apDG-GFP showed a smooth 
periphery and presented no filopodia (Fig 5.3 E and F), suggesting disruption of Cdc42 
activation might be able to inhibit the dystroglycan dependent filopodia formation. 
Quantification of the effect on the N17Cdc42 on dystroglycan dependent filopodia 
formation is shown in figure 5.4. Compared with the contiol cells coexpressing apDG-
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Figure 5.2 Actin phenotypes of constitutively Rho GTPases constructs transfected
celts and aBDG-GFP transfected cells
REF52 cells incubated on glass coverslips were transfected with constitutively activated, 
V12Rac (2|ag/ml), V14Rho (2jag/ml) or V12Cdc42 (2|ag/ml) by using lipofectamine 
following the standard procedure. The untransfected control cells were treated following 
the same procedure but without adding DNA to the lipofectamine reagent. The 
coverslips with tiansfected or untransfected cells were incubated at 37°C overnight and 
fixed with 3.7% formaldehyde, and then stained with rhodamine- phalloidin [(Sigma) at 
1:1000]. The untransfected REF52 cells showed a normal actin stress fibres actin 
phenotype (A). A significant increase in the number of stress fibre was found in the 
V14Rho expressing cells (B, arrow), and formation of lamellipodia was induced by 
expression of V12Rac (C, arrows). REF52 cells transfected with V12Cdc42 presented a 
ring like actin structure in the cortical region (D, dotted arrow) and filopodia were 
visible (D, solid arrow). These actin structures were very similar to those found in 
aPDG-GFP transfected REF52 cells (E). Scale bar= 25|am.
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Figure 5.3 Coexpressing aBDG-GFP with dominant negative Rho GTPase 
constructs in REF52 cells
REF52 cells incubated on glass coverslips were cotransfected with a^DG-GF? (Ipg/ml) 
and either, c-Myc-tagged N12Rac (l|ig/ml), N14Rho (lp,g/ml) or N17Cdc42 (l|ag/ml), 
by using lipofectamine following the standard procedure. The coverslips with transfected 
cells were fixed with 3.7% formaldehyde and treated with PBS containing 0.1% Triton 
X I00, and then stained with anti c-Myc antibody [(Santa Cruz) 1:100]. The images of 
cells expressing apDG-GFP (A, C and E) and stained with anti c-Myc (B, D and F) 
were captured. The coexpression of N14Rho (A and B) or N12Rac (C and D) in a^ DG- 
GFP transfected cells did not appear to affect the dystroglycan dependent filopodia 
formation (A and B, arrows; C and D arrows); the cotransfected cells presented 
filopodia on the cell periphery and cell surface. The cells coexpressing oc^DG-GFP and 
V12Cdc42 were very smooth in the cell periphery (E and F); no filopodia were 
produced in these cotransfected cells.
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Figure 5.4 Quantification of the effect of dominant negative Rho GTPase constructs 
coexpressing with aBDG-GFP with in REF52 cells
REF52 cells incubated on glass coverslips were cotransfected with a|3DG-GFP (Ifig/ml) 
and either CMV-mycl plasmid (Ipg/ml), c-Myc-tagged N12Rac (l|ig/ml), N14Rho 
(ljj,g/ml) or N17Cdc42 (l}Xg/mI), by using lipofectamine following the standard 
procedure. The coverslips with transfected cells were fixed with 3.7% formaldehyde and 
treated with PBS containing 0.1% Triton XlOO, and then stained with anti c-Myc 
antibody [(Santa Cruz) 1:100]. The costained cells presenting more than 30 microspikes 
were identified as filopodia positive cells. Compared with the control cells coexpressing 
otPDG-GFP with CMV-mycl of which 84.9% ai*e filopodia positive, (green column), 
the number of filopodia positive cells in N12Rac (blue column) or N14Rho (red 
column) coexpressing cells were not changed significantly. However, the number of 
filopodia positive cells coexpressing N14Cdc42 dropped to 12% (yellow column), by 
comparison. The counting (100-200 cotransfected cells) was repeated twice in two 
different transfections. Data are mean ± SD.
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GFP with empty vector CMV-mycl (Fig 5.4, green column), the coexpression of 
aPDG-GFP with N14Rho (Fig 5.4, blue column) or N12Rac (Fig 5.4, red column) had 
no significant effect on the formation of filopodia. However, the filopodia formation 
was reduced by coexpressing aPDG-GFP with N17Cdc42 (Fig 5.4, yellow column). 
While blocking the activation of Rac or Rho did not alter the dystroglycan dependent 
filopodia formation, the disruption of Cdc42 activation largely reduced the dystroglycan 
dependent filopodia formation. Therefore, Cdc42 activation might be, at least partly, 
required for dystroglycan dependent filopodia formation.
5.2.3 Coexpression of constitutively activated Cdc42 construct and «PDGAcp-GFP in 
REF52 cells
The results in section 4.2.3 and 4.2.9 have shown that cytoplasmic domain of 
dystroglycan is responsible for the aPDG-dependent filopodia formation. To examine 
whether cytoplasmic domain of dystroglycan could mediate the dystroglycan dependent 
Cdc42 activation inducing filopodia formation, constitutively activated V12Cdc42 
construct was coexpressed with dystroglycan mutant aPAcPDG-GFP in REF52 cells. 
Expression of apAcpDG-GFP mutant has been determined to disrupt the formation of 
filopodia due to the lack of the p-dystroglycan cytoplasmic domain (see section 4.2.3). 
As shown in figure 5.5, filopodia phenotype was present in V12Cdc42 transfected 
REF52 cells (Fig 5.5 A and B). However, cells coexpressing a(3Ac|3DG-GFP and 
V12Cdc42 had a very smooth cell periphery (Fig 5.5 C and D), indicating that 
V12Cdc42 induced filopodia formation might be interrupted by the expression of 
ocPAcPDG-GFP. Quantification of the effect of a(3Ac(3DG-GFP on V12Cdc42 induced 
filopodia formation is shown in figure 5.6. Compared with the V12Cdc42 transfected 
REF52 cells (Fig 5.6, red column) 77% of which are filopodia positive, the number of 
filopodia positive cells in aj3AcpDG-GFP and V12Cdc42 cotransfection dropped down 
to approximately 14% (Fig 5.6, yellow column). These results showed that the 
activation of Cdc42 leading to the formation of filopodia was inhibited by coexpressing 
dystroglycan lacking the cytoplasmic domain. Therefore, in dystroglycan dependent 
filopodia formation, the p-dystroglycan cytoplasmic domain appeared to be required for
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Figure 5.5 Coexpression of constitutively activated Cdc42 construct with 
dvstroglvcan mutants
REF52 cells incubated on glass coverslips were cotransfected with c-Myc-tagged 
V12Cdc42 (Ifig/ml) with aPAcPDG-GFP (Ifig/ml) or cpDG-GFP (Ijlg/ml). For the 
control, REF cells incubated on glass coverslips were transfected with V12Cdc42 (Ifig 
/ml). The transfection or cotransfection was carried out by using lipofectamine following 
the standard procedure. Transfected or cotransfected cells were fixed with 3.7% 
formaldehyde and treated with PBS containing 0.1% Triton XlOO, and then stained with 
anti c-Myc antibody [(Santa Cruz) 1:100] or rhodamine-phalloidin [(Sigma) at 1:1000]. 
Filopodia phenotype was presented in V12Cdc42 transfected cells in both actin and c- 
Myc staining (A and B). Coexpression of aPAcPDG-GFP with V12Cdc42 in REF52 
cells did not induce the formation of filopodia; the cotransfected cells were smooth at the 
periphery (C and D). Coexpressing of cPDG-GFP withV12Cdc42 did not induce the 
formation of filopodia either; the cotransfected cells were also smooth at the periphery 
(E and F). Scale bar=25p.m.
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Figure 5.6 Quantification of the coexpression of constitutively activated Cdc42 
construct with dvstroglvcan mutants
REF52 cells incubated on glass coverslips were cotransfected with c-Myc-tagged 
V12Cdc42 (lp,g/ml) with otPAcPDG-GFP (lp,g/ml) or c^DG-GFP (Ijag/ml). For the 
control, REF cells incubated on glass coverslips were transfected with a^DG-GFP (Ipg 
/ml), V12Cdc42 (Ijig /ml), apAcpDG-GFP (l|ig/ml) or cPDG-GFP (Ipig/ml). The 
ti'ansfection or cotransfection was carried out by using lipofectamine following the 
standard procedure. Transfected or cotransfected cells were fixed with 3.7% 
formaldehyde and treated with PBS containing 0.1% Triton XlOO, and then stained with 
anti c-Myc antibody [(Santa Cruz) 1:100] or rhodamine-phalloidin [(Sigma) at 1:1000]. 
The cotransfected cells presenting more than 30 microspikes were identified as filopodia 
phenotype positive cells. REF52 cells expressing V12Cdc42 or apDG-GFP present 
filopodia at a high percentage approximately 80% (green and red columns). The 
number of filopodia positive cells was reduced to approximately 14% by coexpressing 
aPAcPDG-GFP (yellow column), or approximately 21% by coexpressing cPDG-GFP 
(orange column) with V12Cdc42. The control cells expressing apAcpDG-GFP (blue 
column) or cpDG-GFP (pink column) alone were 21% and 3% filopodia positive, 
respectively. The counting (100-200 cotransfected cells) was repeated at least twice in 
different transfections. Data are mean ± SD.
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the Cdc42 dependent filopodia formation, and might play a role in upregulating the 
activation of Cdc42 or downregulating Cdc42 downstream effectors.
5.2.4 Coexpressioii of constitutively activated Cdc42 construct and apDG-GFP in 
REF52 cells
To further examine the relationship between the P-dystroglycan cytoplasmic domain 
and Cdc42, the cpDG-GFP constiuct was coexpressed with V12Cdc42 in REF52 
cells. cPOG-GFP mutant was determined to be defective in mediating the formation of 
filopodia due to the improper localisation of p-dystroglycan cytoplasmic domain (see 
section 4.2.5). As shown in figure 5.5 E and F, the cell coexpressing cp-GFP and 
V12Cdc42 did not present a filopodia phenotype. Quantification of the effect cpDG- 
GFP on V12Cdc42 induced filopodia formation is shown in figure 5.6. Compared with 
that of V12Cdc42 transfected REF52 cells (Fig 5.6, red column), the filopodia 
formation was significantly inhibited by coexpressing cP-GFP with V12Cdc42 (Fig 5.6, 
orange column), suggesting that plasma membrane localisation is crucial for P- 
dystroglycan to stimulate Cdc42-dependent filopodia formation.
Together these results have shown that the active Cdc42 appeared to be a mediator of 
dystroglycan-dependent filopodia formation and might itself be regulated by 
dystroglycan. The cytoplasmic domain of p-dystroglycan is responsible for mediating 
Cdc42 dependent filopodia formation, and the membrane localisation of P-dystroglycan 
cytoplasmic domain is critical for the stimulation of Cdc42-dependent filopodia 
formation. Since Cdc42-dependent filopodia formation was significantly inhibited by 
coexpression of aPAcpDG-GFP, the aPAcPDG-GFP construct could be used as an 
dominant negative dystroglycan construct for other studies of dystroglycan in the future.
5.2.5 Focal adhesions in apDG-GFP transfected cells
Rho is one of the well-studied members of Rho GTPases. Activation of Rho leads to 
increasing number of stress fibres and assembly of focal adhesion complex (section
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1.5.3). In this work, Rho was initially suspected to be a mediator for dystroglycan 
signalling that regulates focal adhesion assembly and actin stress fibre formation. 
However, here activation of Cdc42 and formation of actin filopodia rather than Rho 
activation and stress fibre formation appeared be regulated by dysti’oglycan. The 
activation of Rho has been shown to be inhibited by activation of Cdc42 (Arthur and 
Bunidge, 2001; Ren et al, 1999; Hall, 1998). To examine whether focal adhesion 
formation is affected by dystroglycan signalling, the aPDG-GFP transfected cells were 
stained with anti-talin antibody. As shown in figure 5.7, in the apDG-GFP transfected 
REF52 cells (Fig 5.7 D), the focal adhesion plaques were found distributed around the 
cells (Fig 5.7 E), and no particular colocalisation of focal adhesions with a^DG-GFP 
was observed (Fig 5.7 F). There was no significant difference in distribution of talin 
staining between apDG-GFP (Fig 5.7 E) and pEGFP empty vector transfected cells 
(Fig 5.7 B). However, in some cells expressing very high levels of a^DG-GEP (Fig 
5.7G dashed arrow), talin-containing focal adhesions appeared to be absent (Fig 5.7H, 
dashed arrow), implying that Rho dependent focal adhesion formation might be 
inhibited in this state. This interesting finding revealed that focal adhesion formation in 
REF52 cells might be reduced by high-level overexpression of a^DG-GFP, indirectly 
supporting the suggestion that Cdc42 is activated in the REF52 cells due to the 
expression of dystroglycan. However, since only cells expressing a very high-level of 
apDG-GFP had reduced talin staining, Rho dependent focal adhesion formation 
signalling might not normally be inhibited by dystroglycan.
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Figure 5.7 Immunostaiiiing of talin in aBDG-GFP transfected REF52 cells
REF52 cells transfected with aPDG-GFP or pEGFP were replated on laminin coated 
coverslips and incubated in DMEM containing 1% FBS at 37 °C overnight. The 
coverslips with cells were fixed with 3.7% foimaldehyde and stained with anti-talin 
[(Sigma) at 1:1000]. The filopodia phenotype was seen in a^DG-GFP transfected cells 
(D) but not in pEGFP transfected cells (A). Talin adhesion plaques were distributed 
around the apDG-GFP transfected cells (E), however, in the merged image, no 
particular colocalisation of apDG-GFP with talin was seen (F). Similar distribution of 
adhesion plaques was present in pEGFP transfected cells (B), and no remarkable 
colocalisation of GFP with adhesions were seen either (C). In the same transfection of 
aPDG-GFP, some transfected cells with high expression level of aPDG-GFP (G) 
showed little staining with anti-talin antibodies (H). The merged image showed that no 
adhesion sites were present in the cell expressing very high level of aPDG-GFP (I). The 
dashed anows point to aPDG-GFP transfected cells, solid arrows to apDG-GFP 
untransfected cells. The scale bars=25jim.
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5.3 Discussion
5.3.1 Cdc42 mediates dystroglycan in dependent filopodia formation
Expression of a^DG-GEP in REF52 cells has been shown to lead to the reorganisation 
of the actin cytoskeleton resulting in the formation of actin-rich ring-like structures at 
the cell cortex and filopodia on the cell surface. In this chapter, it has been determined 
that both the actin-rich ring-like structure and the filopodia are typical actin phenotypes 
induced by Cdc42 activation in REF52 cells. The coexpression of dominant negative 
Cdc42, but not Rho or Rac, with ocpDG-GFP led to a significant reduction in 
dystroglycan-dependent filopodia formation, suggesting that activation of Cdc42, 
instead of Rho or Rac, might be required for the dystroglycan-dependent filopodia 
formation in REF52 cells. Coexpression of aPAc^DG-GFP with constitutively activated 
V12Cdc42 disrupted the formation of filopodia mediated by Cdc42 activation, 
indicating that the cytoplasmic domain of P-dystroglycan is required for the Cdc42 
dependent filopodia formation. In the studies in chapter 4, membrane localisation of P- 
dysti’oglycan was determined to be crucial for downstream filopodia formation. A 
similar and consistent result was revealed here also. Coexpression of cPDG-GFP with 
V12Cdc42 significantly inhibited the Cdc42-induced filopodia formation, suggesting 
that the cytoplasmic domain of dystroglycan, with its proper membrane localisation, 
might be necessary for Cdc42-dependent filopodia formation.
Since a Cdc42 activity assay in this work was not feasible, it was not possible to 
determine whether activation of Cdc42 is upregulated or downregulated by the 
cytoplasmic domain of dystroglycan. However, significant inhibition of the filopodia 
formation was a consequence of either disruption of Cdc42 activation or disruption of 
dystroglycan functional domain, implying that dystroglycan and Cdc42 could regulate 
each other in the formation of filopodia. Since no direct association between Cdc42 and 
dystroglycan has ever been determined, this finding implied that other mediators are 
responsible for the regulation between dystroglycan and Cdc42. In vivo activation of 
Cdc42 resulting from GDP-GTP exchange has been determined to be triggered only by 
GEFs (reviewed in Bishop and Hall, 2000). Thus, dystroglycan could upregulate Cdc42
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thi’ough activation of Cdc42 specific GEFs. All GEFs are identified as plasma 
membrane associated proteins (Cerione and Zheng, 1996). Interestingly, plasma 
membrane localisation was determined to be necessary for dystroglycan to mediate 
Cdc42-induced filopodia formation. This finding implies a situation where dystroglycan 
regulates Cdc42 GEFs at the plasma membrane followed by activation of Cdc42 and the 
formation of filopodia.
5.3.2 Mediators between dystroglycan and Cdc42
The PPPY motif in the C-terminal tail of dystroglycan has been identified as a 
signalling mediator that associates with WW, Grb2 or caveolin (section 1.4). However, 
it has been shown previously that expression of dystroglycan could induce the 
formation of filopodia independent of utrophin. This raised the possibility that p- 
dystroglycan itself might regulate Cdc42-mediated filopodia formation through other 
protein binding motifs. Sequence analysis of dystroglycan has shown that dystroglycan 
has no significant homology with any other protein in data base (Ibraghimov- 
Beskrovnaya et ah, 1992) except for a recent study, which has shown that a- 
dystroglycan contains two cadherin-like domains (Dickens, et a l, 2002).
However, examining the amino acid sequence of cytoplasmic P-dystroglycan by eye, a 
small positively charged juxtamembrane region, referring to amino acid sequence 
RKKRK, was revealed (Fig 5.8). Similar positively charged juxtamembrane regions 
have been found in CD44, CD43, ICAM and L-selectin (Fig 5.8), and identified as the 
binding regions for ERM (ezrin-radixin-moesin) family proteins. ERM family proteins 
have been shown to be concentrated in actin rich membrane protrusions e.g. microvilli 
and filopodia, in many cell types (Berryman et a l, 1993; Amieva and Furthmayr, 1995; 
Yonemura et al, 1999), and have been identified as crosslinkers between plasma 
membrane proteins and actin filaments (reviewed in Tsukita and Yonemura, 1995). This 
interesting finding revealed that ERM family proteins might be involved in 
dystroglycan dependent filopodia formation signalling. Indeed, in a more recent study 
that further examines the relationship between dystroglycan and ezrin, a member of 
ERM protein family, P-dystroglycan was found to colocalise with ezrin in microvilli
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Figure 5.8 The sequence of dvstroglvcan iuxtamembrane region and ezrin 
association sequence in the membrane protein
The domain organisation of dystroglycan, SP, a , ep, TM, and cp see figure 4.1. The 
amino acid sequence of dystroglycan 776-782, is a positively charged 
juxtamembrane region, which is predicted to bind ezrin. A similar positively 
chai'ged juxtamembrane region is present in the ERM associated transmembrane 
proteins, including CD44, CD43, ICAM-1, and L-selectin (Heiska et a l, 1998; Legg 
and Isacke 1998; Yonemura et a l, 1998; Ivetic et al, 2002), and has been identified 
as the binding region recognised by ERM proteins.
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structures in JEG-3 cells as well as in REF52 cells (Spence et al., 2003 b). Both 
coimmunoprecipitation and P-dystroglycan-GST pull-down assay have indicated that 
ezrin might directly associate with p-dystroglycan. Furthermore, expression of the 
dystroglycan construct mutated at RKKRK, which is the predicted ezrin binding region, 
led to a significant reduction of actin rich protrusion in the cells, indicating that 
RKKRK motif of dystroglycan is necessary for regulation of actin rich membrane 
protrusions. Thus, dystroglycan might be involved in the organisation of the actin 
cytoskeleton and formation of membrane protrusions by interacting with ezrin through 
its RKKRK motif. Ezrin is therefore a novel molecule identified to bind to the RKKRK 
motif in the cytoplasmic domain of dystroglycan.
Ezrin contains a N-terminal globular- domain followed by a a-helical region, a short 
proline-rich linker and a charged C-terminal domain. The membrane protein binding 
activity is localised in the N-terminal PERM domain while the F-actin binding activity 
is localised in a C-terminal 15 aa. F-actin binding sequence (Pearson et al, 2000). In 
vivo, ERM proteins undergo a conformational activation process and cycle between 
cytosol and plasma membrane compartments. In cytosol, ezrin has been found to form 
head-to tail autoinhibitory inactive structure (Berryman et a l, 1995). Once activated, 
the binding affinity between N-terminal and C-terminal of ezrin is reduced by its 
phosphorylation at Ser567, thereby releasing both PERM domain and F-actin binding 
domain and allowing ezrin to associate with F-actin and target to the membrane protein 
(Gary and Brestcher, 1995). In a fractionation assay in Swiss 3T3 cells expressing 
ocPDG-GFP, ezrin was found concentrated in the actin containing triton-insoluble 
fraction associating with F-actin instead of in the soluble cytoplasm fraction (Spence et 
al, 2003b), suggesting that expression of dystroglycan induces the activation of ezrin. 
Additionally, disruption of dystroglycan binding to ezrin led to a significant reduction 
of dystroglycan-dependent membrane protrusions, indicating that ezrin could mediate 
the dystroglycan-dependent cytoskeleton organisation.
Interestingly, it was shown that the ^-dystroglycan-dependent activation of ezrin was 
greatly inhibited by coexpression with N17Cdc42, suggesting that ezrin activation and
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targeting to dystroglycan may be under the control of Cdc42 activity (Spence et at, 
2003b). Expression a dominant negative construct of P21 associated kinase (PAK), a 
downstream effector for Cdc42, in a|3DG-GFP expressing Swiss 3T3 cells inhibited the 
activation of ezrin, revealing that PAK might play a role in the activation of ezrin. In the 
same Swiss 3T3 cell line expressing a^DG-GFP, coexpression of dominant negative 
PAK mutant, which has a defective in Cdc42 binding site, also led to a reduction in 
ezrin activation, suggesting that both Cdc42 and PAK are mediators for dysti'oglycan to 
induce the activation of ezrin (Spence et ah, 2003b). Thus, the activation of ezrin 
triggered by Cdc42 could be mediated by PAK.
Together, active ezrin could be recognised by the RKKRK motif and target F-actin to 
dystroglycan. The interaction of dystroglycan and ezrin appeai*ed to be necessai-y for 
completing the dystroglycan-dependent filopodia formation. Active ezrin has been 
shown to act as a crosslinker between actin filaments and membrane proteins, however, 
the precise signalling function of ezrin is still unclear. The studies here implied that in 
dystroglycan-dependent filopodia formation, active ezrin might play a role in both 
mediating the formation of membrane protrusion and providing a physical linkage 
between dystroglycan and actin filaments. This also indicates the importance of the 
proper membrane localisation of dystroglycan cytoplasmic domain in the formation of 
filopodia not only for triggering the activation of Cdc42 but also for being recognised 
by active ezrin and forming the physical link to F-actin.
In accordance with these findings, a possible signalling pathway for actin cytoskeleton 
organisation triggered by dystroglycan is shown in figure 5.9. Expression of 
dystroglycan leads to the activation of Cdc42. Activation of Cdc42 triggered by 
dystroglycan leads to filopodia formation through two routes. First, activation of Cdc42 
leads to the activation of WASP/Arp2/3 complex and promotes actin polymerisation, 
thereby forming an actin filaments meshwork in the cortex and initiates filopodia 
formation. Second, in regulating the formation of actin-based filopodia or microvilli, 
activation of Cdc42 triggered by dystroglycan could also lead to the activation of ezrin 
by PAK. Integrin engagement is also required for dystroglycan dependent filopodia
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formation and crosstalk between integrin and dystroglycan might also play a role in 
dystroglycan-dependent filopodia formation. It has been identified in many studies that 
integrin engagement leads to the activation of Cdc42 and the downstream induction of 
filopodia (Price et ai, 1998; reviewed in Schoenwaelder and Burridge, 1999). Therefore, 
integrin engagement could also be able to trigger the Cdc42-PAK-ezrin pathway and 
target ezrin to dystroglycan.
Finally, previous work using yeast two hybrid assay revealed that actin interacts with P- 
dystroglycan (Ilsley, 2001). Further work resolving the interaction between actin and 
p-dystroglycan showed that purified p dystroglycan was co-sedimentated with F-actin 
at low-speed in the pellet fraction, indicating that P-dystroglycan might associate with 
actin filaments directly. Additionally, both the falling-ball assay and electron 
microscopy images have shown that single actin filaments were bundled in the presence 
of p-dystroglycan. These results suggested that in vitro, P-dystroglycan might associate j
with F-actin and promote the bundling of F-actin (Chen et ah, 2003). This interesting
finding implied that P-dystroglycan might act as an actin binding protein that recruits F- !
Iactin to the cortical region where the actin polymerisation to form filopodia or t
microvilli is taking place (Fig 5.9 dashed aiTOw). The hypothesis for the mechanism of j
dystroglycan-dependent filopodia or microvilli formation is shown in figure 5.10. II
5.3.3 Regulation of dystroglycan dependent filopodia formation through the
mediators
5.33.1 Role o f  PAK
As mentioned above, the activation of ezrin regulated by Cdc42 is mediated by PAK.
Whether PAK is involved in the activation of moesin or radixin has not been reported.
However, Rac/Cdc42 dependent activation of PAK has been shown to induce the 
phosphorylation of merlin, which is identified as a member of ERM protein family, at 
its residue S518 and is involved in the regulation of cell proliferation (Xiao, et al,
2002). Since PAK is a multi-functional-domain protein, a variety of molecules, 
including some which might be important for regulating cytoskeleton dynamics, have 
been shown to interact with different binding regions of PAK (reviewed in Bokoch,
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Figure 5.9 Signalling of dvstroglvcan induced formation of membrane 
protrusions
Dystroglycan localised at the plasma membrane is able to trigger the activation of 
Cdc42. The activation of Cdc42 leads to the activation of WASP/Arp2/3 thereby 
promoting the polymerisation of actin filaments and inducing the formation of 
filopodia at the leading edge of cells. However, activation of Cdc42 triggered by 
dystroglycan also leads to the activation of ezrin mediated by PAK. Active ezrin 
interacting with F-actin could be targeted to dystroglycan, leading to the aggregation 
and polymerisation of filopodia or microvilli. This pathway was interrupted by 
expression of dominant negative Cdc42 (N17Cdc42) or dominant negative PAK 
constructs (DN-PAK). Integrin signalling is required for dystroglycan dependent 
filopodia formation. Crosstalk between integrin and dystroglycan might be involved 
in the dystroglycan-dependent filopodia formation. Integrin is also an upregulator of 
Cdc42 and might be able to tiigger the activation of ezrin through Cdc42 and PAK, 
thereby converging on the dystroglycan signalling pathway. Additionally, F-actin 
was found to directly associate with P-dystroglycan; a direct modulation of actin 
filament by dystroglycan might exist (dashed arrow).
136
DG Integrin
Cdc42 Cdc42Cdc42N17
Cdc42N17
PAKPAKWASPs/
Arp2/3F-actin
DN-PAK
Ezrin Ezrin
Actin
polyineration DG
opAcpOGFilopodia
DN-PAK
2003). Myosin light chain kinase (MLCK) was found to be phosphorylated by PAK 
(Sanders et ah, 1999). The phosphorylation of MLCK leads to the activation of its 
kinase activity and induces the phosphorylation of myosin light chain (MLC), thereby 
promoting the actin-myosin interaction resulting in formation of actin stress fibres (Fig 
1.7). Thus, by regulating the activation of PAK, activation of Cdc42 appeared to induce 
the foraiation of stress fibres. Recently, PAK interacting exchange factor (PIX), which 
is a family of new by identified PAK binding proteins, was found contain a DH/ PH 
domain, which was identified as an GEF functional domain for GDP/GTP exchange, 
suggesting that PIX might have GEF activity (reviewed in Hoffman and Cerione, 2002). 
It has been shown that the activity of PAK and the level of Cdc42-GDP were enhanced 
by PIX directly binding to PAK, suggesting that by binding to PAK, PIX might be able 
to act as a GEF for activation of Cdc42 and is involved in the formation of membrane 
protrusion (reviewed in Daniels and Bokoch, 1999). Therefore, PAK could be an 
upregulator for activation of Cdc42 as well.
Additionally, PAK activation was found to lead to the activation of LIM kinase 
(Edwards et aL, 1999). LIM kinase contains two LIM domains, which are protein 
interaction motifs found in proteins commonly associated with the cytoskeleton (Carlier, 
1998). It has been shown that active LIM kinase was sufficient to trigger the 
phosphorylation of cofilin (Ai’ber, et aL, 1998; Yang et al., 1998). Phosphorylation of 
cofilin reduces its severing activity and results in an inhibition of F-actin 
depolymerisation. Thus, the actin polymerisation in leading edge could be regulated by 
Cdc42 or Rac through the activation of PAK. Altogether, activation of PAK appears to 
be an important key for various actin organisation pathways. The finding that PAK is 
involved in the dystroglycan dependent filopodia formation implies that dystroglycan, 
in addition to triggering the Cdc42-PAK-ezrin pathway, might be involved in a 
complicated network mediated by multifunctional PAK.
5.3.3.2 Role o f ezrin
In addition to interacting with membrane proteins, active ezrin has also been shown to 
bind and disassociate RhoGDI from GDP bound Rho GTPases (Takahashi et ah, 1997)
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(Fig 1.6A). In the cytoplasm, RhoGDI is found bound to the switch domains of Cdc42 
leading to the inhibition of both GDP dissociation and GTP hydrolysis (reviewed in 
Hoffman and Cerione 2001). Binding of ERM proteins with RhoGDI reduces the 
binding affinity of RhoGDI to Cdc42-GDP, resulting in dissociation of RhoGDI from 
Cdc42 and the recovery of GDP/GTP exchange ability of Cdc42 (Takahashi, et aL, 
1997). The molecular mechanism of ERM protein binding induced disassociation of 
RhoGDI from Cdc42 is still unknown. Since N-terminal FERM domain of ERM 
proteins has been shown to be sufficient to dissociate RhoGDI fi’om Rho GTPases 
(Takahashi, et aL, 1997), the conformational activation of ERM might be required for 
its binding to RhoGDI. Thus, by modulating the disassociation of RhoGDI from Cdc42, 
activation of ezrin appears to play a role in upregulating gi'oss Cdc42 activity (reviewed 
in Louvet-Vallee, 2000).
Activation of ezrin has also been shown to be regulated by RhoA (Mackay et aL, 1997; 
Shaw et aL, 1998), Rho kinase (Matsuti et aL, 1999), and protein kinase C (PKC) (Ng et 
aL, 2001; Piertromomaco et aL, 1998). Activation of RhoA in Swiss 3T3 cells induced 
the activation of ERM proteins followed by recruitment of ERM to plasma membrane 
structures (Mackay et aL, 1997; Shaw et aL, 1998). Activation of Rho kinase, a 
downstream effector of RhoA, was found to lead to the phosphorylation of ERM 
proteins at a carboxy-terminal threonine (Matsui et aL, 1999). Thus, Rho dependent 
signalling appear s to regulate the activation of ezrin and is involved in formation of the 
membrane protrusions, while activation of Rho-dependent signalling has also been 
described as inducing the formation of stress fibres and being inhibited by the activation 
of Cdc42.
PKC-a and PKC-0 have been shown to stimulate the conformational change and 
activation of ERM proteins as well (Ng et aL, 2001; Piertromomaco et aL, 1998). CD44 
is an integral cell membrane glycoprotein with a postulated role in matrix adhesion 
lymphocyte activation (reviewed in Haynes et al, 1991). Legg and colleagues have 
recently demonstrated that PKC stimulated the CD44-ezrin interaction as a consequence 
of Ser325 and Ser291 in the cytoplasmic tail of CD44 being phosphorylated (Legg et aL,
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2002).. This study showed that activation of PKC led to dephosphorylation of Ser325 
and phosphorylation of Ser 291 on CD44, resulting in the decrease of the binding 
affinity between ezrin and CD44. Additionally, they also suggested that the 
phosphorylation of CD44 cytoplasmic tail at Ser291, which is adjacent to its positively 
charged juxtamembrane region, might interfere with the char ge of this juxtamembrane 
region and reduce the binding affinity of CD44 to ezrin.
This interesting finding raised the possibility that the binding affinity of ERM proteins 
to their membrane targets could be regulated by their phosphorylation. P-dystroglycan 
contains several potential tyrosine phosphorylation sites, and the binding affinity of P- 
dystroglycan to WW domain has been shown to be regulated by a phosphorylation- 
dependent conformational change of its PPPY motif in the C-terminal end (James et ah, 
2000; Haung, et al, 2000; Ilsley et al, 2002). Thus, conformational changes triggered 
by tyrosine phosphorylation seem to play an important role for P-dystroglycan in 
regulating its affinity for its binding partners. In accordance with these, it is possible 
that the binding affinity of P-dystroglycan RKKRK domain to ezrin could be regulated 
in a phosphorylation-dependent manner, which might alter the charge or conformation 
of RKKRK domain and modulate the dystroglycan-ezrin-Cdc42 dependent formation of 
membrane protrusions.
5.3.4 Role of dystroglycan in adhesion and filopodia formation
In this work, a novel pathway of dystroglycan stimulated Cdc42-PAK-ezrin activation 
is suggested. The active ezrin targets to the RKKRK sequence, a positively charged 
juxtamembrane region in the P-dystroglycan cytoplasmic tail, required to induce the 
actin-based microvilli or filopodia formation. Thus, dystroglycan seems to stimulate a 
signalling cycle that activates Cdc42, PAK, and ezrin in turn, and transmits the signal 
back to dystroglycan. This signalling cycle can induce the filopodia formation through 
the activation of WASP/Aip2/3 and activation of ezrin (Fig 5.10).
As mentioned above, formation of filopodia is now considered to be initiated from the 
organisation and parallel bundling of a lamellipodial meshwork (Svitkina et at, 2003)
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Figure 5.10 Hypothesis of the regulation of dystroglycan-dependent filopodia 
formation
P -dystroglycan triggers a signalling cycle that, in turn, activates Cdc42, PAK, ezrin 
and triggering ezrin to interact with p-dystroglycan. In the signalling cycle, 
activation of Cdc42 triggered by dystroglycan causes formation of membrane 
protrusions through activation of WASP/Arp2/3 complex or through activation of 
ezrin. P -dysti’oglycan localised to the plasma membrane enhances the filopodia 
bundling by recruitment of ezrin-F-actin or by direct interaction and bundling of F- 
actin. Activation of PAK in the signalling cycle might inhibit actin depolymerisation 
by activation of LIM kinase, which phosphorylates cofilin. Activation of PAK might 
also regulate the activation of Cdc42 through PIX, which acts as a Cdc42GEF. 
Activation of PAK induces the activation of MLCK, which is responsible for 
enhancing the assembly of focal adhesion and actin stress fibre formation. 
Activation MLCK is induced by ERK as well. Therefore, dystroglycan inhibits ERK 
activation could reduced the activation of MLCK thereby inhibiting the focal 
adhesions assembly and stress fibre formation. Together, by this signalling cycle, 
dystroglycan can induce the formation of membrane protrusions, filopodia bundling 
and inhibit the focal adhesion formation and stress fibre formation.
140
Directly
binding to 
F-actin
(3-DG
Promote actin bundling 
and filopodia formation
ERK
Cdc42 Ezrin
F-actinStressfibre MLCK
PIX
PAK
LIM kinase
Depolymerisation 
of F-actin
(Fig 5,1). Activation of ezrin recruits F-actin to dystroglycan, implying that 
dystroglycan plays a role in actin organisation by regulating ezrin. Additionally, the 
finding that dystroglycan directly interacts with actin and promotes F-actin bundling 
also strongly implies that dystroglycan is a ti'ansmembrane receptor which mediates the 
bundling of actin during the formation of filopodia from the lamellipodia meshwork. 
Supporting this idea, it has been shown that activation of Cdc42 promotes the formation 
of a IRSp53: Mena complex, which induces the formation of filopodia (Krugmann et al, 
2001). IRSp53 is a SH3 domain-containing scaffold protein, which is conformationally 
activated by Cdc42 (Govind et a l, 2001). Mena is a member of Ena/VASP family 
which has been shown to localised at the tip of established filopodia structure 
(Krugmann et al, 2001). This finding revealed that the activation of Cdc42 might be 
involved in not only the nucléation and actin branching in lamellipodia extension, but 
also the organisation of filopodia formation. Dystroglycan, which regulates Cdc42 
activation, ezrin activation, and promotes F-actin bundling, might play a role in the 
organisation of the initiation or bundling of filopodia.
In this work, the PPPY motif in the C-terminal of |3-dystroglycan was initially suspected 
to be a mediator of the regulation for dystroglycan-dependent filopodia. Ezrin was later 
identified as a substrate for (3-dystroglycan interaction via the RKKRK motif and 
mediating dystroglycan-dependent filopodia formation (Spance et a l, 2003b). Thus, the 
dystroglycan dependent filopodia formation appealed to be regulated in a PPPY motif 
independent manner. In Src activated transform cells, dystroglycan PPPY motif has 
been shown to be phosphorylated at Y892 (Sotgia et a l, 2001). This Y892 
phosphorylation has been shown to lead to the reduction of the binding affinity between 
PPPY motif and WW domain, and the recruitment of SH2 containing protein including 
Fyn, Csk, Nek, and SHC (Sotgia et al, 2001). The role of these SH2 containing proteins 
in dystroglycan signalling is unknown. Since activation of Src causes the assembly of 
focal adhesion complex followed by activation of ERK cascade, and PPPY motif has be 
shown to bind Grb2, which is a also a mediator of ERK cascade (section 1.4), 
dystroglycan seemed to play a role in regulating focal adhesion formation through the 
phosphorylation of PPPY motif. However, a very recent study has shown that |3-
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dystroglycan phosphorylated at Y892 was localised to inti'acellular vesicles, revealing 
that dystroglycan with Y892 phosphorylation at PPPY motif does not target to focal 
adhesions (Sotgia et al, 2003), Thus, the regulation role of PPPY in focal adhesion 
assembly or ERK cascade activation is controversial.
In fibroblasts, focal adhesion assembly and actin stress fibre formation are 
consequences of Rho or Rho kinase activation (section 1.7). Activation of Rho has been 
shown to be inhibited by integrin-induced activation of P I90GAP mediated by 
activation of Src (Arthur and Burridge, 2001; Ren et a l, 1999) (Fig 1.7). Integrin 
engagement appeared to inhibit Rho activity in the protrusion formation stage (2 hour 
and more) and suppresses the downstream focal adhesion complex and actin stress fibre 
formation (Aithur and Buixidge, 2001; Ren et al, 1999). Activation of Cdc42 induced 
by integrin engagement has been found to be mediated by activation of Src and inhibits 
the activity of Rho (Hall, 1998). Therefore, during the filopodia formation stage, 
activation of Cdc42 can induce lamellipodia and filopodia formation and, at the same 
time, inhibit the activation of Rho and the downstream focal adhesion assembly and 
actin stress fibre formation. Thus, dystroglycan might indirectly play a role in 
suppressing Rho activation and inhibit the focal adhesion/stress fibre formation. The 
result shown in figure 5.7 supports this idea. However, activation of PAK, which is the 
Cdc42 downstream effector, has been determined as an activator of MLCK enhancing 
the formation of stress fibres (Sanders et al, 1999). It seems activation of Cdc42 can 
also be involved in inducing stiess fibre formation.
Since dystroglycan has been identified as being involved in the Cdc42 dependent 
filopodia formation, the inconsistent role of Cdc42 in both inducing stress fibres and 
filopodia formation might be regulated in a dystroglycan-dependent manner. Ferletta 
and colleagues have very recently demonstrated that in two types of epithelial cells, 
ERK activity, which is activated by engagement of integrin ocbA^l to laminin 10/11, is 
suppressed by the interaction of dystroglycan with laminin 10/11, suggesting an 
opposing role of integiin and dystroglycan in regulating ERK activity (Ferletta et al,
2003). Active ERK has been shown to function as an activator for MLCK to enhance
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the formation of focal adhesion and stress fibres (Klemke et a l, 1997). Therefore, 
dysti’oglycan, which is involved in the inhibition of ERK activity, may also reduce the 
activation of MLCK and inhibit the formation of focal adhesion and actin stress fibres 
formation. Thus, the stress fibre formation through MLCK might be enhanced by Cdc42 
and PAK activation and regulated by dystroglycan (Fig 5.10).
Altogether, dysti'oglycan is identified as a regulator for Cdc42 and downstieam 
membrane protrusion formation. A dystroglycan-dependent signalling cycle of P- 
dystroglycan-Cdc42-PAK~ezrin-P-dystroglycan was identified to regulate the formation 
of membrane protrusions. Activation of Cdc42 triggered by dystroglycan localised in 
the plasma membrane can either induce the membrane protrusions by activating 
WASP/Arp2/3 complex or organise filopodia bundling by recruiting ezrin-F actin or 
directly interacting with and bundling F-actin. This signalling cycle can also inhibit the 
focal adhesion assembly and sti'ess fibre formation thi'ough the regulation of MLCK. 
ERK activation of MLCK was initially proposed to be mediated by dystroglycan 
signalling that could enhance the formation of focal adhesion and stress fibre formation. 
However, the dystroglycan dependent signalling cycle has shown that the possible role 
of dystroglycan in adhesion is to inhibit the formation of focal adhesion and stress fibre 
and induce actin rich membrane protrusions.
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Chapter 6 
Summary
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Dystroglycan, which is a membrane laminin receptor containing a  and p subunits 
linking the extracellular matrix to the cytoskeleton, has been identified as playing a role 
in maintaining the stability of muscle cells. Dystroglycan is expressed in non-muscle 
cells associating with actin filaments via dysti’ophin/utrophin isoforms, and interacting 
with laminin.
(X-dystroglycan, which interacts with the extracellular laminin or LG domain containing 
ligands, has been identified to be necessary for cell adhesion dependent events such as 
morphogenesis, myelinogenesis and embryogenesis, indicating that dystroglycan plays 
a role in regulating cell adhesion signalling. Considering the signalling mediated by 
dystroglycan, it has been shown that P-dystroglycan interacts with Grb2 SH3 domain, 
caveolin, and the uti'ophin/dystrophin WW domain via its C-terminal PPPY motif. The 
binding of these appeared to be regulated in a PPPY motif phosphorylation dependent 
manner. Some SH2 containing proteins including Fyn, Csk, Nek, SHC, and v-Src have 
been shown to be recruited to the PPPY motif in response to the tyrosine 
phosphorylation in the PPPY motif. Therefore, dystroglycan PPPY motif might play a 
role in mediating the signalling which regulates adhesion and cytoskeleton organisation. 
Additionally, it has shown that dystroglycan was colocalised with the structural proteins 
in focal adhesions and active ERK has also been demonstrated to be localised to focal 
adhesions. Previous work showed that dystroglycan is colocalised with ERK at focal 
adhesion site. These all suggested that dystroglycan signalling might be involved in the 
regulation of focal adhesion and actin stress fibre formation.
To investigate the relationship between dystroglycan and ERK, the first approach was to 
visualise the localisation of ERK or dystroglycan. Fluorescent protein tagged ERK 
(YFP-ERK), and dystroglycan (a(3DG-GFP) expression plasmids were constructed and 
expressed in REF52 cells. YFP-ERK expressed in REF52 cells was determined to be a 
functional ERK that can be regulated by integrin-mediated or RTK-mediated signalling 
and inhibited by U0126. However, examining the localisation, YFP-ERK seemed not to 
be found in a typical focal adhesion structures. Additionally, ERK activity was not 
detected at the adhesion-like structures formed by YFP-ERK. Therefore, YFP-ERK
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construct might not be useful for the further study of investigating the relationship 
between dystroglycan and ERK.
The expression of dystroglycan-GFP consti'uct on the other hand led to dramatic actin 
reorganisation, resulting in filopodia formation in REF52. This interesting finding 
shifted the work into the study of the role of dystroglycan signalling in the regulation of 
actin filopodia. The functional domain of dystroglycan which is responsible for the 
dystroglycan filopodia formation signalling was determined to be the C-terminal 
cytoplasmic domain of (3-dystroglycan. The dystroglycan-dependent filopodia 
formation is induced by either fibronectin or laminin, and inhibited by poly L lysine, 
indicating that integrin-dependent signalling might be required for the dystroglycan 
dependent filopodia formation. Dystroglycan deletion mutants with defects in a- 
dystroglycan failed to induce the formation of filopodia, implying a- dystroglycan is 
required for the dystroglycan dependent filopodia formation. However, expressing an 
APp-DG construct, p-dystroglycan with its proper membrane localisation was 
sufficient to induce the formation of filopodia, suggesting that p-dystroglycan regulates 
the formation of filopodia in a a-dystroglycan independent manner. Since the 
dystroglycan functional domain deletion mutants lacking a-dysti'oglycan showed a 
nuclear or intracellular vesicle localisation, a-dystroglycan appeared to play an 
important role in the regulation of dystroglycan trafficking and targeting p-dystroglycan 
to the plasma membrane.
The dysti'oglycan-induced actin filopodia formation is very similar to a Cdc42-induced 
filopodia phenotype. By coexpressing constitutively activated or dominant negative 
constructs of Rho GTPases with dystroglycan or dystroglycan mutants, Cdc42 was 
identified as a mediator for dystroglycan dependent filopodia formation. The membrane 
localisation is necessary for P-dystroglycan in mediating Cdc42 dependent filopodia 
formation as well, indicating that p-dystroglycan-dependent Cdc42 activation might 
regulate the filopodia formation signalling taking place in the plasma membrane region. 
This idea is supported by the finding that ezrin is activated by Cdc42-induced activation
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of PAK. Active ezrin can recognise RKKRK motif of p-dystroglycan with proper 
plasma membrane localisation, and tai'get F-actin to dystroglycan. Thus a signalling 
cycle of dystroglycan-Cdc42-PAK-ezrin-dystroglcan was identified. This signalling 
cycle might be regulated in dystroglycan PPPY motif independent manner. Additionally, 
P-dystroglycan has been shown to directly associate with actin and promote the 
bundling of actin filaments. Thus, with active ezrin that targets F-actin to P- 
dystroglycan, according to the current model of filopodia formation, p-dystroglycan 
might play an important role in organisation and bundling filopodia from the actin 
dendritic network through the signalling cycle. Finally, in this work, ERK activated 
MLCK was initially presumed to mediate the dystroglycan signalling that could 
enhance the formation of focal adhesion and stress fibre formation. However, a recent 
study has shown that dystroglycan activation leads to the reduction of ERK activity. 
Therefore, instead of enhancing formation of focal adhesion and stress fibre formation, 
dystroglycan and dystroglycan-dependent signalling cycle appeal's to play a role in 
reducing the activity of ERK and MLCK thereby inhibiting focal adhesion and stress 
fibre formation.
Altogether, dystroglycan dependent signalling, which was initially predicted to regulate 
focal adhesion and actin stress fibre formation, has been identified to regulate formation 
of actin-rich membrane protrusions and filopodia formation. A novel signalling cycle of 
dysti'oglycan-Cdc42-PAK-ezrin-dystroglycan has been determined to be responsible for 
the dystroglycan-dependent filopodia formation. By triggering this signalling cycle, 
dysti'oglycan might be able to induce the formation of membrane protrusions and, at the 
same time, inhibit focal adhesion and stress fibre foi-mation.
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Appendix I Chemicals, reagents and Kits
The chemicals, reagents and kits used were obtained from following suppliers
Amersham-Pharmacia Biotech UK Ltd., Buckinghamshire, UK 
[32PJ-ATP
BDH Ltd., Lutterworth, UK 
NaCl, MgCla, Sodium deoxycholate, Naz HPO4, KHz PO4 , Phosphoric Acid
Fisher Scientific UK Ltd., Loughborough, Leicestershire, UK 
Glycine, EGTA, Sodium Dodecyl Sulphate (SDS), KCl, Hepes, NaF, MgClz, 
Boric Acid
Gibco BRL, Life Technologies Ltd., Paisley, UK
Lipofectamine™ rea;
Bovine Serum (FBS)
gent, Laminin, Fibronectin, epithelial gi'owth factor (EGF), Fetal
Iwaki, Scitech Dicision, Asahi, Japan 
25T, 75T and 175 T tissue culture flasks, 24 well tissue culture culture plates, 
100mm tissue culture dishes.
Promega UK Ltd., Southampton, UK 
U0126
Pierce, Perbio Science UK Ltd., Cheshire, UK 
MicroBCA
Qiagen, Crawley West Sussex, UK,
QIAprep miniprep kit, QIAprep midiprep kit, QIAquick gel extraction kit
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Roche Molecular Biocheicals/Boehringer-Mannheim, Germany 
Rapid DNA ligation kit
Schleicher & Schuell, Dassel, Germany 
Polyvinylidene Difluoride (PVDF) transfermembrane
Severn Biotech Ltd., Worcestershire, UK 
30% polyacrylamide solution
Sigma-Aldrich Company Ltd., Poole, Dorset, UK
Ethyl enedi amine Tetra-Acetic Acid (EDTA), Ethidium bromide, Ampicillin, 
Kanamycin, Protein A Sepharose, Heparin, Poly-L-lysine, Bovine Serum Albumin 
(BSA), Tris-base, Bromophenol blue, Triton X-100, Ethylene Gycol-bis Tetra-Acetic 
Acid (EGTA), Tween-20, 3-(Cyclohexylamino)-1-Propane Sulphonic Acid (CAPS), 
Sodium azide, Nitro Blue Tétrazolium (NBT), 5-bromo-4- chloro-3- indoly phosphate 
(BCIP), Teti'amethylethylenediamine (TEMED), Ammonium persulfate (APS), 
Rhodamine-Phalloidin.
Vector Laboratories Ltd., Peterborough, UK 
VECTASHIELD Mounting medium
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Appendix II Media and general buffers
2 X Y T  liquid medium
1.6% Tryptone (W/V), 1% Yeast exti'act (W/V), 0.5% NaCl (W/V) in IL distilled 
water
2 X Y T  solid medium
0.64% Tryptone (W/V), 0.4% Yeast extract (W/V), 0.2% NaCl (W/V), 0.8% agar 
(W/V) in 400 ml distilled water
Dulbecco's Modified Eagle Medium (DMEM)
Gibco BRL
OPTIMEM
Gibco BRL
TBE buffer (5X)
54g Tris base, 27.5g Boric acid, 50ml 0.2M EDTA in IL distilled water, pH = 8.0 
Agarose gel loading buffer
30% Glycerol (V/V) and 0.25% Bromophenol (W/V) Blue in 0.5 X TBE buffer 
2 X  SDS gel loading buffer
lOOmM Tris, 200mM DTT, 4% SDS, 0.2% Bromophenol Blue, 20% glycerol, 
pH -  6.8
Caps/methanol transblot buffer
lOmM CAPS [3-(Cyclohexylamino)-l-propansulfonsyre] in 20% methanol, pH=l 1 
TBST
20mM Tris-HCl, 0.15M NaCl, 0.5% Tween20, pH= 7.5 
AP buffer
lOOmM NaCl, 5mM MgCL, lOOmM Tris, pH= 9.5
Separating gel buffer
1.5mM Tris-base, 0.4% SDS, pH=8.8
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Stacking gel buffer
0.5mM Tris-base, 0.4% SDS, pH=6.8
lOxSDS gel running buffer
0.25 M Tris-base, 1.92 M Glycine, 10% SDS in 5L water 
IF A blocking buffer
1% FBS (VW) and 1% BSA (V/W) in PBS
Permeant buffer 
0.1% TritonX-100 in PBS
RIPA buffer
50mM Tris-HCl pH7.5, 150mM NaCl, linM EDTA, ImM EGTA, 1% Triton X-100, 
0.5% Sodium deoxycholate, 0.1% SDS, ImM Azide
PBS (lOX)
80g NaCl, 2g KCl, 11.5g Naz HPO4 • 7HzO, 2g KHz PO4 in IL distilled water 
MAPK lysis buffer
25mM Hepes, 0.3M NaCl, 1.5mM MgC12, 0.2mM EDTA, pH=7.4 
M APK Wash buffer
20mM Hepes, 50mM NaCl, 2.5mM MgC12, O.lmM EDTA, pH=7.4 
M APK kinase buffer
20mM Hepes, 0.5mM NaF, 7.5mM MgCI2, 0.2mM EDTA, pH-7.4
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Appendix III Plasmids and clones
(A) Plasm ids used in this work
Names Features Source
PRESYFP-Cl Mammalian expression vector with yellow 
fluorescent protein (YFP) tag sequence. Multiple 
cloning site allowed fusion to be made at C- 
terminus of YEP. CMV promoter, SV40 and fl 
ori, Kan^ and Neo .^
J. Pines 
(Chambridge)
PEGFP-N3 Mammalian expression vector with green 
fluorescent protein (GFP) tag sequence. Multiple 
cloning sites allowed fusion to be made at N- 
terminus of GFP. CMV promoter, SV40 and fl 
ori, Kan^ and Neo^.
Clontech
(B) Clones used in this work
Names Features Source/Reference
YFP-ERK P44 MAPK sequence cloned into EcoRI site of 
pRES-YFP vector.
This work
aPDG-GFP Full-length dystroglycan cloned into Sail and 
Smal sites of pEGFP vector.
This work
aPDGAcP-GFP Dystroglycan cytoplasmic deletion mutant 
sequence cloned at the Sail and Smal site of 
pEGFP vector.
This work
CP-GFP Cytoplasmic P-dystroglycan sequence cloned 
at the Sail and Smal site of pEGFP vector.
This work
aPDGAeP-GFP Dystroglycan extracellular P domain deletion 
mutant cloned at the Sail and Smal site of 
pEGFP vector.
This work
apDGAa-GFP Dystroglycan a subunit deletion mutant 
sequence cloned at the Sail and Smal site of 
pEGFP vector.
This work
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aDG-GFP a  -"dystroglycan sequence cloned at the Sail 
and Smal site of pEGFP vector.
This work
h a / P44 P44 MAPK sequenced cloned into EcoRI site 
ofpCDNAmeo. Kan''
Meloche et al, 
1992
mDG-1 Full-length of mouse dystroglycan cDNA 
sequence (DAG-1) cloned between EcoRI and 
BstXI sites in pCDNAII. Kan"
D.J. Blake 
(Oxford)
AP-pDG Full-length p-dystroglycan with an alkaline 
phosphatase sequence cloned into Hindlll and 
EcoRI site of PCAGGS vector. Amp".
Rentschler, S. et al, 
1999
N17Cdc42 Dominant negative Cdc42 sequence cloned 
into CMVneo-myc-1 at the BamHI and Nhel 
sites. Amp"
A.Hall
(London)
V12Cdc42 Constitutively activated Cdc42 sequence 
cloned into CMVneo-mycl at the BamHI and 
Nhel sites. Amp"
A.Hall
(London)
N17 Rac Dominant negative Rac sequence cloned into 
CMVneo-myc-1 at the BamHI and Nhel sites. 
Amp"
A.Hall
(London)
V12Rac Constitutively activated Rac sequence cloned 
into CMVneo-myc-1 at the BamHI and Nhel 
sites. Amp"
A.Hall
(London)
N19Rho Dominant negative Rho sequence cloned into 
CMVneo-myc-1 at the BamHI and Nhel sites. 
Amp"
A.Hall
(London)
V14Rho Constitutively activated Rho sequence cloned 
into CMVneo-myc-1 at the BamHI and Nhel 
sites. Amp"
A.Hall
(London)
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Appendix IV Cell lines
Cell s used in this work
Cells Features Source
REF52 Rat embryo fibroblast cell 
line
D. Helfman
COS7 Human epithelial cell line M. Frame (Glasgow)
Utrophin +/+ 
and
Utrophin-/-
Primary culture of mouse 
embryo fibroblasts
K. Davies
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Appendix V Antibodies
(A) Primary antibodies used in this work
Antibody names Direct against Dilution for Western blot 
and [IF]
Source / 
Reference
Total ERK* oo 
(NEB 9102)
Whole molecule 1:1000
[-]
New England 
Biolabs
Phospho- 
ERK (NEB 9105)
(j) °
Thr202/ Tyr204 1:1000
[1:100]
New England 
Biolabs
GFP 3 00 Whole molecule 1:1000
[-]
F. Barr 
(Glasgow)
Talin (j) ° Chiken talin, clone 8d4
[1:1000]
Sigma-
Aldrich
Poly-PDG * oo 
1710
P-dystroglycan 15 a-a 
peptide of extreme C- 
terminus
1:1000
[-]
Ilsley et al, 
2001
c-myc (|) ° Amino acids 408-439 
within the carboxy 
terminal domain of c- 
Myc of human origin
[1:100]
Santa Cruz
Rab6 *oo C-terminus of human 
utrophin (3204-3343)
1:1000
[-]
Winder, et 
al, 1995
^Rabbit 
(|) Mouse 
3 Sheep
° monoclonal antibodies 
oc polyclonal antibodies
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(B) Secondary antibodies used in this work
Antibody names Direct
against
Conjugate Raised in Dilution for 
Western blot 
and [IF]
Source
Anti-mouse IgG Y-chain AP Goat 1:10000
[-]
Sigma-
Aldrich
Anti-rabbit IgG Whole
molecule
AP Goat 1:10000
[-]
Sigma-
Aldrich
Anti-sheep IgG Whole
molecule
AP Donkey 1:10000
[-]
Sigma-
Aldrich
Anti-mouse IgG Whole
molecule
TR Horse
[1:1000]
Vector
Anti-mouse IgG Whole
molecule
FITC Horse
[1:1000]
Vector
AP: Alkaline phosphatase
TR: Texas-red
FITC: Fluorescein
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Appendix VIPCR Primers
O liglonucieotides used in this work
Oligos Function Sequence 5^-3’
aDG5 Full-length dystroglycan primer with 
Sail site
TTG GTC GAG ATG TCT GTG 
GAG AAG TGG GTA
PDG3 Full-length dystroglycan primer with 
Smal site
GGT TGG GGG GGG AGG 
GGG AAG ATA GGG AGG
Trans(35 Dystroglycan ot subunit and 
extracellulai’ P domain deletion mutant 
primer with Sail site
GGT TGG GGG GGG ATA 
GGA GAT GAT AGG AAT
cPDG5-Tyr p-dystroglycan cytoplasmic domain 
primer with Sail site
TTG GTG GAG TAT GGG 
AAG AAG AGG AAG GGG
epDG5 Full-length p-dystroglycan primer with 
Sail site
TTG TGG GAG GGG TGT 
ATG GTG TGT GAA TGG
ssa5 Dysti'oglycan signal sequence primer for 
a  dystroglycan deletion mutant. 10 
bases overlaps with 3’ end of p- 
dysti'oglycan
TGT TGG TGG ATT GGA 
GGA TAG AAG GGA GAG 
GGA GAG
ssep3 p-dysti'oglycan extracellular domain 
primer for a  dystroglycan deletion 
mutain; 10 bases overlaps with 5 ’ end of 
dystroglycan signal sequence
TGT ATG GTG TGT GAA 
TGG
ssaTM5 a-dystroglycan primer for extracellular 
P domain deletion mutant. 10 bases 
overlaps with 3’ end of P 
transmembrane domain
TGG GAT AAG GGT GTG 
GAG AGA GGG GGG AGT 
GAT
TM3 P~dysti'oglycan transmembrane domain 
primer for extracellular P domain 
deletion mutant. 10 bases overlaps with 
5 ’ end of a  dystroglycan
GTG GAG AGG GTT ATG 
GGA
aDG5X a-dystroglycan primer with Sail site GGT TGG GGG GGG GGG GGG ATG GAT GTT GTG
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Appendix VII PCR reaction conditions
Primers and PCR reaction conditions of dystroglycan functional domain deletion 
mutants
Mutants Primers Condition of PCR reaction
aPDG-GFP aDG5 1) 95°C 1 minute, 2) 95°C 1 minute, 3) 5 5 t  1 
minute, 4) 72°C 3minutes and 30 seconds.
2)- 4) repeat for 30 cyclesPDG3
(xPDGAcp-GFP aDG5 1) 95°C Iminute, 2) 95°C 1 minute, 3) 60“C 1 
minute, 4) 72°C 3 minutes.
2) -  4) repeat for 30 cyclesTransP5
Cp-GFP CPDG5-Tyr 1) 95“C Iminute, 2) 95°C 1 minute, 3) 65°C 1 
minute, 4) 72°C 2 minute
2)-4) repeat for 30 cyclespDG3
ocPDGAa-GFP PI aDG5*‘'’ First Round
PI 95°C Iminute, 95°C1 minute, 65°C 1 minute, 
72°C 2 minute .2-4 repeat for 30 cycles 
P2 95"C Iminute, 95°C 1 minute, 65"C 1 minute, 
72°C 2 minute 2-4 repeat for 30 cycles 
Second round
95°C Iminute, 95°C 1 minute, 65“C 1 minute, 
72°C 2 minute 2-4 repeat for 30 cycles
PI Ssa5*
P2 SseP3*
P2 .pDG3*®
aPDGAep-GFP PI ctDG5*® First Round
PI 95°C Iminute, 95°C 1 minute, 65“C 1 minute, 
72°C 2 minute .2-4 repeat for 30 cycles 
P2 95°C Iminute, 95°C 1 minute, 65°C 1 minute, 
72°C 2 minute 2-4 repeat for 30 cycles 
Second round
95°C Iminute, 95°C 1 minute, 65°C 1 minute, 
72“C 2 minute 2-4 repeat for 30 cycles
PI Pair 1 of primer 
P2 Pair 2 of primer
Primers for first round PCR 
0  Primers for second round PCR
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Appendix VIII Plasmid trasfection conditions
Transfection and cotransfectioii conditions used in this study
REF52 COS7
UTR+/+ and UTR-A 
Primary mouse 
embryo fibroblast
YFP-ERK * l.SxloV m l; 80%
2. 2 pg/ml
3. 5hr; then added 
equal volume of 
growth medium
- -
Dystroglycan 
and mutants*
1. 3x lOVml; 80% 
2.1.8pg/ml 
3. 5hr; then added 
equal volume of 
growth medium
1. 2 X lOVml; 95%
2. 1.8|Ug/ml
3. Overnight
1. 3x 10"/ml ; 80-90%
2. 1.5|ig/ml
3. 8hr; then added 
equal volume of 
growth medium
AP-
dystroglycan*
1. 3 X lOVml; 80%
2. 2.2 pg/ml
3. 5hr; then added 
equal volume of 
growth medium
- -
Cdc42 mutants* 1. 3xlOVml; 80%
2. 1.5 pg/ml
3. 5 hr; then added 
equal volume of 
growth medium
- -
Rac mutants * 1. 3 X lOVml; 80%
2. 1.5 pg/ml
3. 5hr; then added 
equal volume of 
growth medium
- -
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Rho mutants* 1. 3 X 10"/ml; 80%
2. 1.5 pg/ml
3. 5hr; then added 
equal volume of 
growth medium
- -
Dystroglycan or 
mutants with 
Cdc42 mutants
1.3x10"/ml; 80%
2. 0.9 jLig/ml+ 0.9|ig/ml
3. 51n; then added 
equal volume of 
growth medium
- -
Dystroglycan or 
mutants with 
Rac mutants
1. 3 x 10"/ml; 80%
2. 0.9 jug/ml+ 0.9frg/ml
3. 51ir; then added 
equal volume of 
growth medium
- -
Dystroglycan or 
mutants with 
Rho mutants
1. 3 X 10"/ml; 80%
2. 0.9 pg/ml+ 0.9jug/ml
3. 5Iu'; then added 
equal volume of 
growth medium
- —
1. Initially seeding number; percentage of cell confluent overnight
2. DNA concentration
3. Transfection reaction time and condition 
* Single DNA transfection
DNA cotransfection
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